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The work described in this thesis was carried out between March 1988 and 
September 1992 mainly in the laboratories of the Departments of Pharmacology and 
Haematology, University of Cape Town Medical School. Chapter 1 is divided into 
three parts. In Part I, the multidrug resistance phenomenon is reviewed - both in 
historical context of the problem and recent advances of molecular, cellular and 
pharmacological significance. Part II is an overview of the relevance of 
glycosylation. In addition, Parts I and II contain special areas of interest which, 
because of their close relationship with the principal text, are included in shaded 
boxes to provide adequate background for the research proposition outlined in Part 
III. The reader might find this presentation valuable to become familiar with the 
overall objective of the thesis. The research methodology and major experimental 
data accumulated during the course of the project are presented and discussed in 
Chapters 2 to 5. The most important results and their implications are summarized 
in Chapter 6. I have been diligent in keeping apace with the contemporary literature 
and exercised every effort to compare my findings with related results and 
information reported by other authors. However, the literature in this field is vast 
and ever-expanding, and I had to limit the current level of awareness in the thesis 
to April 1993. The manuscript was subjected to several critical revisions and I have 
taken care to remove any errors and redundancies. I am, however, accountable for 
the final version. I hope that this thesis will be of value to its readers and add to 
their appreciation of the relevance of glycoconjugate research in tumour biology. 
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The development of multiple drug resistance (MDR) by tumour cells presents a 
major impediment to effective cancer chemotherapy. Drug-resistant cells have 
raised levels of a plasma membrane glycoprotein, designated P-glycoprotein (P-gp ), 
of molecular weight (MW) 170 kilodaltons, relative to their drug-sensitive 
counterparts. P-glycoprotein functions as an active efflux pump and maintains a 
reduced level of drug inside the cell, possibly by a mechanism(s) involving 
decreased drug uptake and/or increased drug efflux. The association of MDR in the 
failure of tumours to respond favourably to a given regimen of anticancer drugs is 
the subject of intense research. Approaches for studying the underlying mechanisms 
of MDR raise hopes for preventing or overcoming the phenomenon. In this study, 
tunicamycin (TM), an inhibitor of glycoprotein synthesis and processing, has been 
evaluated for its potential to reverse the MDR phenotype. A correlation was sought 
·between the MDR phenotype (drug resistance· and toxicity, drug transport and 
retention) and the perturbation of cell-surface glycoproteins by T!vf. in vitro. 
The effects of TM on protein and glycoprotein synthesis were correlated 
with the responses of drug-sensitive (BG-1-P and KB-3-1) and drug-resistant (BG-
1/ ADR, KB-8-5-11 and UWOV2) human tumour cell lines, and of the murine 
fibroblast parental (NIH-3T3-parental) cell line and its drug-resistant transfectant 
(NIH-3T3-MDR) to various anticancer drugs alone or in combination with TM. 
The drug-sensitive cell lines (NIH-3T3-parental mouse fibroblasts, LR73 Chinese 
hamster cells, and KB-3-1 human epidermoid carcinoma) and their corresponding 
drug-resistant cell lines (NIH-3T3-MDR, LR73-1A and KB-8-5-11, respectively) as 
well as drug-resistant UWOV2 human ovarian carcinoma cells were also studied 
for .altered vincristi~e (VCR) transport and retention in response to TM 
pretreatment. In additiQn, leukaemia blast cells isolated from p'efipheral blood of 
patients with AML, and the human ovarian carcinoma cell line (UWOV2, 
established from a patient refractory to combination chemotherapy with 
actinomycin D, doxorubicin, cisplatin and VCR), were characterized for their 
expression of the MDR-associated 170 kDa P-gp by gel filtration, SDS-PAGE and 
immunocytochemical analysis using P-gp-specific ~onoclonal antibodies. 
Tunicamycin significantly increased the cytotoxicity of doxorubicin, 
epidoxorubicin, colchicine, VCR and cisplatin in MDR cells to a greater extent 




cytotoxicity of the various agents studied suggests a common mechanism of 
reversal of drug resistance by TM. In NIH-3T3-MDR, KB-8-5-11, and BG-1/ADR 
cells a drug sensitivity pattern developed in the presence of TM that corresponded 
to that in the parental line. On removal of TM from the culture media the cells 
regained their original pattern of drug resistance. 
Pretreatment of cells with TM, inhibits protein and glycoprotein synthesis 
in all the cell lines that were studied. In the NIH-3T3-MDR and KB-8-5-11 cell 
lines, glycoprotein synthesis was elevated compared with the drug-sensitive NIH-
3T3-P and KB-3-1 cell lines, respectively, but similar levels of glycoprotein 
synthesis were found in drug-resistant LR73-1A cells and the corresponding drug-
sensitive LR73 cells. Analysis of several glycosyltransferases in the various 
parental and MDR cell lines showed that activities of fucosyltransferase (FT) and 
N-acetylglucosaminyltransferase (NGT) are increased while the activities of 
sialyltransferase (ST) and galactosyltransferase (GT) are decreased in drug-resistant 
KB-8-5-11 cells compared with their parental controls. In NIH-3T3-MDR cells, the 
reactions catalyzed by FT, GT and NGT, but not by ST, occurred at significantly 
higher rates than those in the NIH-3T3-parental cells. The LR73-1A cells expressed 
elevated levels of FT whereas the levels of ST, GT and NGT remained constant 
compared with drug-sensitive LR73 controls. Similar ST, FT and NGT reaction 
rates were observed in the BG-11 ADR human ovarian carcinoma cell line and its 
parental control, BG-1-P. Tunicamycin pretreatment of cells produced fluctuations 
in reaction rates for the various glycosyltransferases in MDR and parental cells and 
no consistent trend of inhibition of enzyme activity was demonstrated. However, 
the inhibition by TM of FT-, GT- and NGT-catalyzed reactions was common to 
NIH-3T3-MDR and LR73-1A cells, although TM did not completely abolish the 
activities of the glycosyltransferases in these cells. Exposure of KB-8-5-11 cells and 
UWOV2 cells to TM did not inhibit any of the glycosyltransferases. These results 
demonstrate that glycoproteins are differentially expressed in various drug-sensitive 
and drug-resistant cell lines. 
Various drug-sensitive cell lines (NIH-3T3-parental, LR73 and KB-3-1) and 
their corresponding drug-resistant cell lines (NIH-3T3-MDR, LR73-1A and KB-8-
5-11, respectively) as well as drug-resistant UWOV2 cells were studied for altered 
VCR transport in response to TM pretreatment. The uptake of VCR was not 
affected in the various cell lines following prior exposure and co-incubation with 
TM; NIH-JT3-MDR cells accumulated less drug than their drug-sensitive parental 
cells. No differences in the levels of VCR accumulation could be demonstrated 
between KB-3-1 and KB-8-5-11 cells, as well as between LR73 cells and LR73-1A 
cells. Tunicamycin had no effect on the efflux of VCR from NIH-3T3-parental 
cells. Vincristine efflux was significantly reduced when mdr1-transfected NIH-3T3-
MDR cells were treated with TM. Tunicamycin increased the retention of VCR in 
KB-8-5-11 cells, in NIH-3T3-MDR and in UWOV2 cells, but not in NIH-3T3-
parental cells. In contrast, KB-3-1 cells expressed a decrease in VCR retention. A 
consistent association was found between treatment of MDR cell lines with TM and 
reduced VCR efflux with resultant increase in VCR retention. The results suggest 
that the enhancement of VCR retention in MDR cell lines by TM may occur as 
result of inhibition of VCR efflux. Drug-resistant cells appear to be affected to a 
greater extent by TM pretreatment than their drug-sensitive counterparts, possibly 
due to raised levels of P-gp in the former. In KB-8-5-11 cells, increasing 
concentrations of TM resulted in a concentration-related reduction in glycoprotein 
synthesis which did not correlate with inhibition of VCR efflux. Transient 
inhibition of both protein and glycoprotein synthesis during TM exposure may 
contribute to alterations in VCR efflux and retention observed in the MDR cell 
lines. The binding of [14C]doxorubicin and [3H]azidopine, a photoactive 
dihydropyridine calcium channel blocker known to bind P-gp, to UWOV2 ovarian 
carcinoma cells was studied in these cells. Binding of doxorubicin to UWOV2 cells 
was saturable in the concentration range 10-80 nM, whereas that of azidopine 
remained linear between 10 and 80 nM. In the presence of equimolar 
concentrations of doxorubicin, the binding of azidopine to UWOV2 cells was 
significantly inhibited in the concentration range of 30-80 nM. Tunicamycin 
increased the binding of both doxorubicin and azidopine to UWOV2 cells. In the 
presence of TM and equimolar concentrations of doxorubicin, however, the binding 
of azidopine was unchanged. The binding of both azidopine and doxorubicin to 
intact UWOV2 cells suggests that P-gp may be present on their cell surfaces. 
Leukaemia blast cells isolated from peripheral blood of patients with AML, 
and the UWOV2 cell line, were characterized for their expression of the MDR-
associated 170 kDa P-gp by gel filtration, SDS-PAGE and immunocytochemical 
analysis using P-gp-specific monoclonal antibodies. Plasma membrane 
glycoproteins prepared from patients L24 and LlOO eluted as distinct peaks in the 
regions between 450-158 kDa and 158-44 kDa. SDS-PAGE analysis of the 450-158 
kDa peak fractions revealed the presence of a 170-kDa band in samples prepared 
from both patients L24 and LlOO. SDS-PAGE of L24 and L100 plasma membranes 
also resolved a 170-kDa protein. In similar experiments, SDS-PAGE analysis of 
high MW (~150 kDa) peak fractions (eluted from Sephadex G150, Sephadex G-200 
or BioGel A-0.5M columns) and purified plasma membranes, showed a 170-kDa 
ix 
band in samples prepared from patients L19, L23, L28, L31, L45, L84, L94, L95, 
and L97, but not from samples prepared from patients L21, L26, L42 and L55. 
The expression of P-gp in peripheral blood leukaemia blast cells prepared from 
patients with AML was analysed by the P-glycoCHEK™ C219 
immunohistochemical detection kit. Two out of 15 samples prepared from patients 
with AML stained positively for P-gp. This was expected since the one patient 
(L24) was resistant to combination chemotherapy with etoposide, cytosine 
arabinoside and methotrexate, and the other patient (L100) presented with relapsed 
AML following chemotherapy with cytosine arabinoside, etoposide and 
daunorubicin. SDS-PAGE analysis of some samples from AML patients, who 
received either chemotherapy or no prior chemotherapy, showed the presence of a 
170-kDa membrane protein, but this could not be confirmed by 
immunocytochemical staining using the C219 monoclonal antibody reaction. No 
difference in staining patterns' could be discerned between samples prepared from 
treated and untreated patients in this group. Therefore, no clinical correlations with 
the presence of the 170-kDa protein could be made because P-gp was not 
identifiable in samples prepared from this group of patients. 
Separation of cell-surface glycoproteins derived from UWOV2 cells 
metabolically labelled with [3H]glucosamine on a column of BioGel A-0.5M, 
yielded high MW (240-158 kDa) peak fractions, consistent with the presence of a 
170-kDa glycoprotein. This was confirmed by Sephadex G-200 fractionation of 
[3H]glucosamine-labelled UWOV2 plasma membrane glycoproteins isolated after 
72h incubation in the absence (control) and presence (TM-treated) of 5 JLglml TM. 
High MW UWOV2 cell-surface glycoproteins eluted as a broad peak in the 200-
150 kDa range of the Sephadex G-200 chromatographic profile. This peak was 
reduced to approximately 53% of control in the presence of TM, indicating 
inhibition of glycoprotein synthesis. The presence of a 170-kDa glycoprotein in 
UWOV2 cells and its disappearance as a result of prolonged TM exposure were 
confirmed by SDS-PAGE analysis of purified plasma membrane samples. When 
UWOV2 plasma membranes were immunoprecipitated with P-gp-specific 
monoclonal antibodies MRK16 and C219, the 170-kDa band was again present, 
although contaminating bands were also noted. The results from this study show 
that UWOV2 ovarian carcinoma cells express a 170-kDa membrane glycoprotein 
and that this glycoprotein is synthesized at reduced rates following TM exposure. 
Thus, TM may be regarded as a resistance modifier in studies related to the 
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THE MOLECULAR, CELLULAR, AND 
PHARMACOLOGICAL BASIS OF 
MULTIDRUG RESISTANCE 
1. HISTORICAL OVERVIEW 
1 
For many years the importance of the original observation that a single viable 
murine leukaemia cell can give rise to a lethal leukaemic population in an 
appropriate strain of mice (Furth and Kahn, 1938) was overlooked. By the early 
1950s it was recognized that transplanted neoplasms (grafts) from any tissue origin 
will generate tumours in animals (Schabel, 1975). The knowledge that the survival 
of a malignant population may result in treatment failure led to the first-order or 
pseudo-first-order concept (log-kill hypothesis) of tumour cell elimination ~Skipper 
et al., 1964). According to this view, a given dose of drug will kill a constant 
fraction of cells, and not a specific number of cells, provided that they are exposed 
to similar growth conditions and the ratio of sensitive to resistant targets remains 
the same. 
In the 1940s, Gilman and Philips (1946) noted regression of lymphoma in a 
patient treated with nitrogen mustard. This historic breakthrough evoked 
considerable interest in the potential use of cytotoxic agents in the management of 
neoplasms, and so had begun the modern era of cancer chemotherapy. Later, 
antitumour activity of the folate antagonists was demonstrated in children with 
leukaemia (Faber et al., 1948). In 1942 methotrexate was synthesized and proved 
to be the first antimetabolite capable of curing an advanced malignancy (Hertz et 
al., 1961). This latter outcome secured a definite place for these agents in 
chemotherapeutic regimens. The 1950s had seen an exciting period of drug 
development- the original anthracyclines became available in the 1960s and, by the 
1970s, numerous substances were synthesized for chemotherapy (Weiss, 1992). 
These include alkylating agents, plant alkaloids, nitrosoureas, and hormones (Muss, 
1984). 
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Another landmark observation was that a combination of nitrogen mustard, 
vincristine, procarbazine and prednisone could cure a majority of patients with 
advanced Hodgkin's disease (De Vita and Serpick, 1967; De Vita et al., 1970). 
The importance of this approach was that drugs used together may be more 
effective than when they are used separately. This is referred to as collateral 
sensitivity (Szybalski and Bryson, 1952; Bech-Hansen et al., 1976). In contrast, it 
was found that consolidation chemotherapy often resulted in the selection of drug-
resistant cells that are also refractory to other regimens. This is defined as cross-
resistance (Dam~. 1972; Hutchison and Schmid, 1973; Cano-Gauci and Riordan, 
1991). The two terms rely heavily on the accurate evaluation of sensitivity to 
different treatment regimens, and can vary for any particular tumour cell-drug 
system, and should thus not be considered as "all-or-none" phenomena (Hill, 
1984). 
Spontaneous regression of tumours is rare, although there are a number of 
well-quoted instances (Everson and Cole, 1956; Sumner and Foraker, 1960; 
Everson, 1964). A complete remission will depend on whether the target cell 
population is collectively sensitive to the type of treatment. Anything less . than a 
total disappearance of the tumour implies a degree of resistance. Dramatic 
responses to chemotherapy are frequently followed by relapse due to one or more 
surviving cancer cells. In this regard, Skipper (1979) considered the research of 
Luria and Delbriick (1943) to be a significant contribution to oncology. No allusion 
to the cancer problem is made in their paper, yet it became increasingly apparent 
that refractory cells of many malignancies continually arise from random mutations 
- in a manner comparable to phage- and antibiotic-resistant bacteria (Demerec, 
1948; Skipper, 1979). Several reports describing similar findings have followed 
(Burchenal et al. 1950; Law and Boyle, 1950; Law, 1952). Drug resistance is now 
a widely known, yet poorly understood phen()menon. 
It is clear that neoplastic transformation and tumour non-responsiveness 
represent a formidable challenge to generate novel and effective treatment 
modalities. Over the last few years there has been an explosion of research into 
multiple drug resistance (MDR). This chapter is intended to explore and present 
recent advances in understanding the molecular and cellular mechanisms involved 
in the initiation, progression, regulation and manipulation of this protective 
response during cytotoxic attack (see Figure 1 for outline). For quick reference, 
areas of special interest that led to the research undertaken in this thesis are located 
in shaded text boxes in Parts I & II on pages 8-11, 24, 25, 29, 32, 42, 49 and 50. 
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Figure 1. Flow diagram for the molecular, cellular and pharmacological basis of the 
multidrug resistance phenotype and its modification reviewed in Part I, Chapter 1. 
2. CONCEPTS AND TERMINOLOGIES 
2.1. Origins of Drug Resistance 
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Central to the concern of how MDR can be overcome is the question of its 
aetiology, i. e., the transition of a cell or population of cells from a state of drug 
sensitivity to one of insensitivity. Resistance is a relative term, with high, 
intermediate, and low degrees, as defined by the investigator in terms of individual 
experience (Henderson, 1984). Important also is the notion that the refractory phase 
is not a property of an individual tumour cell or tissue, but the manifestation of 
some tumour-drug system. 
2.1.1. Innate and Acquired Drug Resistance 
The ability of a single tumour cell to survive a local concentration of a cytotoxic 
drug that would otherwise kill it may be an innate property or may have been 
acquired by a gradual or rapid adaptive response (Henderson, 1984). If a cell were 
to survive a given dose of a damaging agent and divide, probably in the face of a 
loss of many similar cells within the population of which it is part, a new clone of 
resistant cells would ensue. Subsequent generations may be further selected for 
reduced sensitivity or actively become transformed by expressing alternative 
biochemical pathways. 
2.1.2. Clinical Drug Resistance 
Cancer management over the past few decades has been altered radically by the 
design of different classes of anticancer drugs. Despite this advancement, few 
universally successful agents acting solely and preferentially on neoplastic cells 
have hitherto emerged. Given the. right conditions, no tumour cell is completely 
resistant to the effects of existing chemotherapeutic agents. In clinical practice, any 
consequence of drug treatment hinges upon its contrasting effects on normal and 
tumour tissue. An important factor is the degree of drug selectivity for the target 
cell and its subsequent influence upon it (Zubrod, 1978). 
It is the qualitative nature of this specificity that varies from drug to drug 
when used against different cancers that equates with resistance, i.e., the margins 
of therapeutic benefit may be narrow in terms the consequences of toxicity to 
normal tissues. It has been suggested that chemotherapy of tumours may result in 
the selection of drug-resistant cells in a heterogeneous cell population and the 
outgrowth of a refractory tumour (Georges et al., 1990b). Some human 
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malignancies such as multiple myeloma, breast cancer, ovarian carcinoma, 
childhood neuroblastoma and leukaemia may respond favourably to initial treatment 
only to be followed by relapse and eventual death of the patient. In contrast, 
adenocarcinomas of the kidney and colon, non-small-cell lung cancer and glial 
tumours are at the outset resistant to cytotoxic drugs (Becker et al., 1991; van 
Kalken et al., 1991; Shin et al., 1992). 
The failure of chemotherapy can be ascribed to a variety of . factors, 
including poor drug absorption, unfavourable pharmacokinetics and 
pharmacodynamics, insufficient tumour vascularization or hypoxia, and low pH. 
Although clinical drug resistance is not always detected satisfactorily (Ma et al., 
1987), recent developments, especially the identification of a molecular marker, P-
glycoprotein (Pgp) and its gene (mdr), implicated in unsuccessful treatment 
outcome, are apt to prove effective (Bell et al., 1985; Cazin et al., 1992; Herzog et 
al., 1992). Tumour cell lines selected in-vitro for resistance to anticancer drugs 
(Vinca alkaloids, anthracyclines, epipodophylotoxins, colchicine, actinomycin D) 
are useful for studying multidrug resistance (MDR) mechanisms. It has yet to be 
verified, however, whether the experimental resistance pattern observed in such 
model systems is a reflection of that experienced clinically. Therefore, 
pretherapeutic detection of MDR in individual patients may be of great value to 
determine whether the proposed therapy would be beneficial (Verrelle et al., 1991; 
Mohammad et al., 1992). 
P-glycoprotein and its mRNA were found to be frequently present in 
tumour specimens from some patients {Fojo et al., 1987; Gerlach et al., 1987; 
Tsuruo et al., 1987), but not in others (Goldstein et al., 1989; Ito et al., 1989; 
Pieters et al., 1991). The degree of Pgp expression following drug administration 
is often greater than before treatment was begun (Goldstein et al., 1989) and often 
correlates with "clinical" MDR (Gekeler et al., 1992; Herzog et al., 1993). Cancer 
chemotherapy does not appear to enhance the synthesis of this glycoprotein in 
normal cells (Geromin et al., 1992). Therefore, observations of its expression in 
both normal and malignant tissues, together with the identification of MDR forms 
in human cells that do not overproduce Pgp, suggest that clinical assumptions of 
this nature are likely to be complicated {de Vries and Pinedo, 1991; Kato et al., 
1991; Marie et al., 1992a). 
Notwithstanding that chemotherapy has been invaluable in the management 
of many human tumours, effecting long-term survival or cures of haematologic · 
malignancies, ovarian carcinoma and small-cell lung cancers, the overall success 
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rate against some tumours remains low (Murren and Hait, 1992). The development 
of newer anticancer agents to overcome this obstacle is a major goal of cancer 
chemotherapy. The potential of MDR cells in the study and prevention of drug 
resistance is now widely accepted (Dietel, 1991). Clinical trials emanating from 
these advances hold great promise for future treatment of refractory tumours (Lum 
et al., 1992; Philip et al., 1992; Yahanda et al., 1992). 
2.1.3. Experimental Drug Resistance 
Cell lines isolated from tumour-bearing mice following chronic exposure to 
anticancer drugs mimic to some extent the in vivo acquisition of cellular 
refractoriness under clinical conditions, although the precise relationship between 
the two modes is not well established. Drug resistance may be due to multiple 
genetic and biochemical changes, and a single mechanism may not be implicated in 
all tumours (Masters, 1990; Fairchild and Cowan, 1991; Toffoli et al., 1991). The 
heterogeneity in spontaneous tumours further complicates the issue and tends to 
oversimplify current explanations and assumptions (O'Brien and Cordon-Cardo, 
1991). Hence, each system has to be evaluated individually. Transfection 
experiments with cloned eDNA have unequivocally shown that Pgp mediates the 
MDR phenotype (Ueda et al., 1987; Gros et al., 1988; Schurr et al., 1989). The in 
vitro selection of multidrug-resistant cell lines involves exposure of cells in culture 
to anticancer drugs. Of the most widely used techniques are: 
• continuous exposure of cells to initial subtoxic levels of the drug followed by 
stepwise dose increments of the same drug, 
• brief exposure of the cells to an initial high concentration of the selecting agent 
and subsequent growth of the cells in the absence of selection pressure, 
• chemical mutagenesis which increases the probability of the emergence of a 
replicating drug-resistant clone. 
2.2. Tumour Cell Sensitivity to Drugs 
2.2.1. Resistance, Survival and Toxicity 
The effectiveness of many anticancer agents is increased by a corresponding 
escalation of their concentration or accumulation in target sites. As the dose is 
increased, so normal tissues may become more prone to potential side effects. 
Therefore, tolerance by the patient is influenced by both the dosage and duration of 
chemotherapy which, in turn, should be determined by a realistic appraisal of 
potential therapeutic benefit. Toxicity is a consequence of both tumour resistance to 
the anticancer drug and its lack of specificity for neoplastic cells. Thus, dosage 
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must be maximized to the point where tumour cell kill can be achieved without 
irreversible damage to normal tissues. Quality of life is accordingly regarded as the 
principal moderator of therapeutic intervention. In the face of full-blown resistance 
despite rapid tumour proliferation, as for example in terminal malignant melanoma, 
it is unjustifiable to persist with intensive chemotherapy which may be more 
deleterious to the patient than to the tumour. 
As other specific and selective treatment modalities are made available and 
drug resistance becomes more accurately predictable, toxicity may possibly be 
reduced to a minimum and quality of life improved throughout therapy (Benard et 
al., 1990; Kaye, 1991; Kellen, 1991). Novel molecular and pharmacological 
approaches such as drug carriers (microspheres and polymers), antibody-directed 
strategies using pro-drugs and enzymes, genetic manipulation of the immune 
system, the introduction of suicide genes into tumour cells, or the application of 
drug-resistance genes to protect normal cells during chemotherapy, are already 
entering clinical trials and are anticipated to benefit cancer patients. 
2.2.2. Cross-Resistance 
Some tumours respond favourably to initial chemotherapy only to be complicated 
subsequently by relapse, which is characterized by decreased sensitivity not only to 
the primary drug, but often to all secondary regimens (Hutchison and Schmid, 
1973; Whitehouse, 1984). This cross-resistance pattern to multiple drugs seems to 
be largely unaffected by further dose increases and may influence the outcome of 
treatment (Gerlach et al., 1986b; Benard et al., 1990). The specificity of a given 
cross-resistance profile is determined by the actual mechanism of resistance, e.g., 
the altered expression of plasma membrane components and decreased drug 
accumulation (Bech-Hansen et al., 1976). In addition, cross-resistance may arise 
from biochemical changes in the tumour cell population which occur independently 
of the original selection pressure. 
2.2.3. Collateral Sensitivity 
This term refers to a cell population that is insensitive to some drugs but is more 
prone than the parent population to the cytotoxic effects of others (Szybalski and 
Bryson, 1952; Henderson, 1984). Such predisposition may be the consequence of 
biochemical alterations that accompany the development of resistance. In this 
regard, Brockman (1970) suggested that the increased sensitivity to deazauridine 
observed in a cytosine arabinoside (Ara-C)-resistant L1210 cell line could be the 
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result of their inability to metabolize deoxycytidine (dCT) due to loss of 
deoxycytidine kinase (dCK) activity. Many tumours that are resistant to Ara-C and 
dCT, for example, have elevated activities of cytidine deaminase. The relatively 
inactive compound bromodeoxycytidine was therefore prepared with the idea that 
its deamination by this enzyme would lead to the formation of bromodeoxyuridine, 
an antimetabolite with superior potency (Henderson, 1984). Despite insufficient 
knowledge of its biochemical basis and associated unpredictable clinical response, 
the collateral sensitivity paradigm has proven useful .in the/ treatment o~ some· 
tumours, particularly acute leukaemia, but has not improved "disease-free" survival 
in solid tumours. 
3. MECHANISMS OF DRUG RESISTANCE 
Resistance to anticancer drugs is associated with multiple genetic, biochemical and 
pharmacological alterations in tumour cells (Assaraf et al., 1989; Kane et al., 
1990; Ban, .1992), some of which are reviewed below. 
3.1. Changes in Plasma Membrane Proteins 
3.1.1. P-Glycoprotein 
Drug-resistant cells express on their surfaces a high molecular weight 
(MW) glycoprotein (designated P-glycoprotein, or P170, or Pgp) which is absent in 
their drug-sensitive counterparts (Juliano and Ling, 1976; Peterson and Biedler, 
1978; Beck et al., 1979). The MW of Pgp, estimated by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), has been reported to be 150 
kilodalton (kDa) (Peterson and Biedler, 1978), 165 kDa (Juliano·and Ling, 1976), 
and between 170- and 190 kDa (Beck et al., 1979). These discrepancies in MW s , 
would imply that different glycoproteins may be involved in the expression of 
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resistance in the various cell lines studied. Instead, it has been suggested that such_ 
' 
differences may either reflect fluctuations in the extent of glycosylation of similar 
proteins or may be due to differences in experimental calibration of SDS gels 
(Beck, 1984). 
3.1.2. Epidermal Growth Factor Receptor 
Some MDR cells exhibit in vitro growth behaviour of non-transformed cells and 
become less tumourigenic (Biedler et al., 1975). This reverse transformation is 
thought to be due to altered cellular responses to growth factors and fluctuations in 
the level and function of their receptors. Furthermore, similarity in the MW and 
isoelectric point (pi) of Pgp (Peterson et al., 1983) and the EGF receptor (Cohen et 
al., 1982; Carlin.et al., 1983) has prompted investigations into the presence of the 
latter in MDR cells. Sequence analysis, however, established that these two 
proteins are distinct (Ullrich et al., 1984; Gros et al., 1986b). Despite observations 
of increased EGF receptor expression in resistant cells, no quantitative correlation 
between this increase and the degree of Pgp-mediated resistance could be 
demonstrated (Meyers et al., 1986; Scotto et al., 1986; Meyers et al~, 1988). 
Although elevated expression of this receptor may be associated with diminished 
oncogenic potential of MDR cell lines (Meyers et al., 1986), several reports favour 
the idea that MDR and tumourigenicity are independent events (Hill, B.T. et al., 
1988; Slovak et al., 1991). 
3.1.3. Other Membrane Proteins 
Several researchers have described enhanced synthesis of membrane proteins and 
glycoproteins not characterized as Pgp. Examples include: 
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• DOX-resistant HL-60 human leukaemia cells which synthesize glycoproteins of 
MWs 160- and 110 kDa (Bhalla et al., 1985), 150- and 120 kDa (Marsh et_al., 
1986) not detectable in sensitive cells (Center, 1987), 
• Surface membrane glycoproteins with MWs 130-, 155-, and 180- to 210 kDa 
have been characterized in vinblastine (VBL)-resistant human leukaemia cells 
(Danks et al., 1985), 
• Membrane proteins of MWs 100- and 160 kDa were found to be expressed in 
DOX-resistant P388 mouse leukaemia cells (Shanbaky et al., 1986), 
• Mouse cells transfected with high MW DNA from DTN-resistant Syrian 
hamster cells express a 140-150-kDa surface glycoprotein (Suarez et al., 1985), 
• DTN-resistant human myeloid leukaemia cells which synthesize three 
membrane glycoproteins of MWs 65-, 83-, and 180 kDa (Tsuruo et al., 1986). 
3.2. Lipid Structural Order and Membrane Fluidity 
/ 
Since the transport of molecules across the cell membrane is regulated by the 
physical state of the lipid bilayer, typically poor accumulation of drugs by MDR 
cells may be due to alterations in membrane lipids. Compositional analysis of 
plasma membranes of drug-sensitive and -resistant CHO cells showed no apparent 
variation in the relative amounts of cholesterol, cholesteryl esters, neutral 
glycerides, free fatty acids, or total phospholipids (Ling et al., 1977). In contrast, 
changes in the proportions of phospholipid classes were noted in murine (Ramu et 
al., 1984) and human (Wright et al., 1985) leukaemia cell lines. The statistical 
significance of these differences, however, appeared to be marginal. No differences 
in fatty acid arrangement of plasma membranes between sensitive and resistant cells 
have been reported. Montaudon et al. (1986) postulated that the increase in the 
level of polyunsaturated fatty acids in drug-resistant glioblastoma cells may appear 
occasionally in the MDR phenotype. Similarly, Rintoul et al. (1984) concluded that · 
alteration of cell membrane lipid structural order is not an essential component of 
adriamycin (ADR) resistance in Chinese hamster lung (CHL) cells. It is likely, 
however, that increased fluidity due to elevated levels of polyunsaturated fatty acids 
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may be able to contribute to the maintenance of reduced intracellular drug levels by 
' 
preventing diffusion of drugs through the bilayer. In addition, membranes from 
drug-resistant cells may contain domains of less complex lipids than those found in 
drug-sensitive cells, thereby contributing to diminished drug permeability in MDR. 
Of special interest is the observation that the biosynthesis of gangliosides is blocked 
at the level of haematosides (GM3) in actinomycin D (ActD)-resistant Chinese 
hamster cells (Peterson et al., 1979). Increased expression of polysialylated 
gangliosides (particularly the disialoganglioside, GDia) and decreased expression of 
the monosialoganglioside GM2 may be pivotal during the acquisition of MDR 
(Mazzoni et al., 1991). 
Verapamil, tamoxifen and dipyridamole have been found to induce 
increased synthesis of phosphatidyl choline in MDR cells. The relative resistance of ' 
these cells to permeabilization by digitonin and the observation that verapamil is 
able to counteract this effect suggests that verapamil may modify the membrane . 
lipid organization in these cells and modulate drug permeability (Ramu et al., 
1991). In addition, studies with vesicles of the bile canaliculus membrane (CMV) 
'in which Pgp has been localized to the apical side, have demonstrated that increases 
in membrane fluidity of CMV inhibited [3H]daunomycin and [3H]vinblastine 
accumulation (Sinicrope et al., 1992). Therefore, an alteration in the physical state 
of CMV is likely to be at least one important modulator of Pgp function. 
3.3. Alterations in Drug Transport 
3.3.1. Drug Transport in P-Glycoprotein-Mediated MDR 
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3.3.2. P-Glycoprotein and Drug Binding 
The cellular accumulation and retention of drugs may be associated with their 
binding to transport or carrier proteins. Much insight into this putative mechanism, 
has come from the demonstration that [3H]VBL binds more avidly to plasma 
membrane vesicles prepared from drug-resistant cells compared to those derived 
from drug-sensitive cells (Cornwell et al., 1986). In addition, unlabelled VBL, 
VCR, and DNR competed with the binding of [3H]VBL to crude membranes 
whereas colchicine (COL) and DTN were comparatively less competitive. It was 
not evident from these studies that different binding sites and affinities for the 
various drugs contributed to the observed disparities. 
Safa et al. (1986) showed that the protein which binds a photoaffinity 
analogue of VBL could be immunoprecipitated with polyclonal antibody against 
Pgp, and that approximately 90% of the label could be displaced with a 200-fold 
excess of VBL. Numerous other reports corroborated these findings and it is now 
widely accepted that Pgp binds at least to some drugs (Akiyama et al., 1988; Beck 
et al., 1988; Bruggemann et al., 1992). The binding of [3H]VCR to plasma 
membranes isolated from ADR-resistant human K562 cells occurs in an adenosine 
triphosphate (A TP)-dependent manner, and is blocked by non-hydrolyzable A TP 
analogues and inhibited by excess non-radiolabelled VBL, VCR, ActD, and ADR. 
These studies support the notion that A TP hydrolysis is a necessary component of 
drug binding to Pgp, and presumably also for subsequent efflux (Ambudkar et al., 
1992; Doige et al., 1992; Shimabuku et al., 1992). 
A significant observation is that many of the compounds that participate in 
the MDR phenotype share properties such as hydrophobicity (lipid solubility) and 
cationic charge at physiological pH (Zamora et al., 1987; Zamora et al., 1988; 
Ford et al., 1989). Such common characteristics could contribute to non-specific 
interactions with hydrophobic proteins such as Pgp that do not require drug-ligand 
interactions. By contrast, recent evidence has indicated that substrate-specific 
binding to Pgp does take place (Pearce et al., 1989; Ramu and Ramu, 1989; 
Spoelstra et al., 1991). 
3.3.3. P-Glycoprotein as Active Efflux Pump 
Several groups assert that Pgp contains nucleotide binding sites (Chen et al., 1986; 
Gerlach et al., 1986a; Gros et al., 1986a). P-glycoprotein has been· shown to bind 
photoaffinity analogues of ATP (Cornwell et al., 1987b) and to contain adenosine 
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triphosphatase (ATPase) activity (Hamada and Tsuruo, 1988). Experiments using 
Pgp-mAb-Protein A-Sepharose conjugates established that verapamil (VPL) and 
trifluoperazine (TFP), unlike VCR and DOX, enhanced such activity. Nucleoside 
triphosphates (NTPs), but not VBL, effectively decrease the affinity of Pgp for the 
nucleotide, indicating that distinct binding sites for NTPs and drugs may exist on 
the molecule. Doige et al. (1992) confirmed that certain drugs ~d 
chemosensitizers, including COL, progesterone, nifedipine, VPL and TFP enhance 
the catalytic function of the enzyme, and that Mg2+ and ATP are required for 
optimal activity. Doige and Sharom (1992) demonstrated that the uptake of 
[3H]COL and [3H]VBL into plasma membrane vesicles (PMV) from the MDR 
CHRC5 cell line, but not the AuxB1 drug-sensitive parent, was stimulated by the 
presence of A TP which is also a requirement for the efflux of VBL from PMV 
isolated from human MDR KB-V1 cells (Horio et al., 1988; Lelong et al., 1992). 
Furthermore, the observation that expression of the human MDR1 gene in cultured 
insect cells via a baculovirus vector generates a high activity vanadate-sensitive 
membrane ATPase that is markedly stimulated by compounds known to interact 
with the Pgp provides further evidence for the existence of an energy-requiring 
"drug exodus" system in MDR cells (Sarkadi et al., 1992). 
3.3.4. Mechanism of P-Glycoprotein-Mediated Drug Efflux 
According to the model depicted in Figure 2, lipophilic drugs enter the cells by 
passive diffusion through the lipid bilayer, bind Pgp on the cytoplasmic side of the 
plasma membrane and are pumped out of the cell utilizing the energy of A TP 
hydrolysis. This scenario suffers from a major drawback in that Pgp, to be effective 
in efflux, should have a higher affinity for the drug than its intracellular target. It is 
unlikely that the affinity of Pgp for any individual ligand would be very high, since 
it binds reversibly to a wide variety of structurally dissimilar drugs. Also, 
anticancer agents are primarily selected on the basis of their high specificity for 
intracellular targets, e.g., the efficacy ofDNR and Vinca alkaloids can be attributed 
to their strong affinity for tubulin. 
In an alternative efflux model, drug binding to Pgp is proposed to occur 
within the membrane phase (interior) instead of in the cytoplasmic domain (Gros et 
al., 1986a). An example in favour of this view is resistance to gramicidin D 
(GRAM), a membrane ionophore, which exerts its cytotoxic effect at the cell 
surface, without entering the cell (Bradley et al., 1989). Mutational inactivation of 
the nucleotide binding sites of Pgp abolishes resistance to GRAM, suggesting that 
resistance to this ionophore is also dependent upon ATP (Roninson, 1991a). 
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Figure 2. Simplified schematic model of the mechanism of action of P-
glycoprotein. A, P-glycoprotein uses A TP as energy source to transport the drug 
out of the cell; B, Verapamil (VPL) inhibits the active outward transport of the 
drug by competing for binding site(s) on the P-glycoprotein molecule. The result is 
a net intracellular accumulation and retention of the drug. (Adapted from Dickson 
and Gottesman, 1990). 
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Recently Higgins and Gottesman (1992) proposed that substrates for Pgp 
first partition into the inner lipid phase of the plasma membrane before being 
pumped to the extracellular side. The substrate may also be flipped from one face 
of the membrane to the other (transverse diffusion) by the multidrug transporter, 
cognate to the rotation of phospholipids by flippases (Devaux, 1991). 
Another model, first described by Beck (1987) is based on observations of 
an increase in the number of vacuoles and apparent localization of anthracyclines to 
cytoplasmic vesicles in MDR cells. P-glycoprotein is postulated to be anchored in 
both plasma and intracellular membranes so that drugs entering the cell are pumped 
into the lumen of intracytoplasmic membranes and subsequently discharged by 
exocytosis. This hypothesis agrees with immunohistochemical evidence that Pgp is 
present in both the plasma membrane and cytoplasm (Willingham et al., 1987), and 
may show primarily intracytoplasmic distribution in cells not selected for drug 
resistance in vitro (Scheper et al., 1988). 
3.4. Overexpression of Sorcin in MDR Cells 
Sorcin is a 22-kDa cytosolic calcium-binding protein excessively produced in many 
but not all MDR cells (Meyers and Biedler, 1981). Cells which synthesize this 
protein also manifest gene amplification (Meyers et al., 1985) which may be a 
fortuitous or random occurrence and/or the result of its proximity to the mdr gene 
(van der Bliek et al., 1986a; van der Bliek et al., 1986b; Jongsma et al., 1987). 
Sorcin consists of four "E-F hand" structures typical of calcium binding sites (van 
der Bliek et al., 1986a) and has striking homology with the light chain of calpain. 
Two of the calcium binding sites contain putative recognition sites for cAMP-
dependent protein kinase. The protein is phosphorylated in a cAMP-dependent 
manner (Meyers and Biedler, 1982; Biedler et al., 1983) and probably, like 
calpain, activates protein kinase C (PKC) which would explain the elevated activity 
of this enzyme in MDR cells (Fine et al., 1986). The abundance of sorcin in some 
drug-resistant cells may confer increased responsiveness to calcium channel 
blockers (Cano-Gauci and Riordan, 1987). Furthermore, the use of calcium 
antagonists in the prevention of drug resistance (see section 6.2.2.) may point to 
possible interplay of Pgp and sorcin. 
3.5. DNA Repair and Drug Resistance 
Increased repair of DNA confers resistance to anticancer compounds which exert 
their cytotoxic effects by intercalating with DNA (Fox and Roberts, 1987) and 
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causing single- or doublestrand breaks (Jamali et al., 1989; Bungo et al., 1990; 
Capolongo et al., 1990). These drugs include the alkylating agents: platinum 
compounds, nitrosoureas, ADR, DNR, bleomycin (BLEO), and related antibiotics. 
Different cell lines vary in their ability to replace DNA lesions and their repair 
capacity may be intrinsically related to cellular accumulation and sensitivity to 
antitumour agents (Jamali et al., 1989). The platinum complexes, e.g., cis-DDP 
(cis-dihlorodiaminoplatinum II), represent an important class of cytotoxic drugs 
generally capable of forming cross-links in DNA critical to their cytotoxicity 
(Bungo et al., 1990; Chu and Chang, 1990). Cis-DDP-resistant cell lines express 
increased levels of cellular factors that recognize damaged DNA, and concomitantly 
are more efficient in repair of such lesions. Furthermore, it has been suggested that 
acquired cellular non-responsiveness to cisplatin may be associated with increased 
gene-specific DNA repair of interstrand cross-links (Harris and Hochhauser, 1992; 
Zhen et al., 1992). 
It is generally believed that the mechanism of cisplatin refractoriness differs 
from that of MDR. Although cis-DDP-resistant cells also exhibit decreased uptake 
of platinum compounds (Chao, C.C. et al., 1992), Misawa et al. (1992) have 
clearly established that the reduced accumulation is not due to mdr1 gene 
expression. Cell lines selected for resistance to drugs in the MDR class (e.g., 
vinblastine, adriamycin, colchicine, vincristine and actinomycin D) usually express 
cross-resistance to other drugs in the same class (Kimiya et al., 1992), but not to 
DNA intercalating agents (e.g., methotrexate, cisplatin, nitrosoureas). Similarly, 
Futscher et al. (1992) reported that a DOX-resistant multiple myeloma cell line 
displayed a sensitivity pattern to the nitrosoureas (streptozotocin, STZ; 1,3-
bis[ chloroethyl]-1-nitrosourea, BCNU) identical to its drug-sensitive parental cell 
line. Their studies imply that cells resistant to "MDR-related" drugs are not 
resistant to nitrosoureas. In general, drugs which modify the MDR phenotype do 
not show a sensitizing effect to cisplatin (Morikage et al., 1991). 
By contrast, Yang et al. (1993) have recently indicated that Pgp-mediated 
MDR and cis-DDP refractory phenotypes may coexist in certain tumour types. 
Nevertheless, insensitivity to platinum-containing drugs and alkylating agents is 
multifactorial in that patients not only fail to respond to drugs from the same 
pharmacological classes as used in primary therapy, but they also do not respond to 
other available drugs or irradiation (Hamilton et al., 1990). Therefore, compounds 
which will induce DNA strand breaks and inhibit DNA repair could be of 
particular value in reversing such drug resistance mechanisms (Jamali et al., 1989; 
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Chen and Zeller, 1990; Zhen et al., 1992). (See also sections 3.6. and 6.3.2. for 
discussion on DNA damage by anthracyclines and epipodophyllotoxins.) 
3.6. DNA-Topoisomerase ll-mediated MDR (Atypical MDR) 
Atypical MDR (at-MDR) is characterized by decreased DNA topoisomerase ll 
(Topoll) activity (Beck et al., 1987; Danks et al., 1987; Danks et al., 1988), 
possibly due to reduced binding or hydrolysis •of A TP by the enzyme (Danks et al., 
1989; Hoban et al., 1992). Cells displaying this form of resistance are cross-
resistant to a variety of anticancer agents, except the Vinca alkaloids, DNR and 
ActD, and do not differ from parental sensitive cells in their uptake, accumulation 
and retention of drugs. They are also unaffected by VPL and chloroquine (CLQ), 
known modulators (cf section 6) of Pgp-MDR (Beck and Danks, 1991), but may 
exhibit a form of collateral sensitivity to anti-mitochondrial drugs (de J ong et al., 
1992). Some cell lines exhibit features of both Pgp- and at-MDR (Priebe et al., 
1991; Kamath et al., 1992). However, the large variability in Pgp expression and 
Topoll activity observed in, for instance, fresh ovarian tumour specimens (van der 
Zee et al., 1991), implies that clinical correlations of the concomitant expression of 
Pgp- and at-MDR in cell lines should be made with caution. 
3.7. Glutathione and GSH-S-Transferases 
The increased expression of Pgp is typical of a vast number of MDR cell lines. 
There are reports, however, of cell lines that exhibit resistance to anticancer drugs 
in the absence of Pgp (McGrath and Center, 1988; Nygren et al., 1991; Nakagawa 
et al., 1992). Alterations in the levels of glutathione (GSH), GSH-S-transferase 
(GST), GSH reductase, and GSH peroxidase have been observed in DOX-resistant 
ovarian carcinoma cells (Hamilton et al., 1985; Lewis et al., 1992), multidrug-
resistant human colon cancer cells (Chao, C.C. et al., 1992; Peters et al., 1992) 
and breast tumour cells (Batist et al., 1986; Akman et al., 1990; Whelan et al., 
1992), and elevation of non-protein sulfhydryls in myeloma cells (Bellamy et al., 
1989). The intrinsic GSH level and GST activity may affect anthracycline toxicity 
per se and not MDR in the human colon cancer cells (Chao, C. C. et al., 1992). 
4. MOLECULAR GENETICS OF MULTIDRUG RESISTANCE 
4.1. Gene Amplification and Inactivation in MDR 
Drug-resistant cells often display chromosomal aberrations, including 
homogeneously staining regions (HSRs) and double minute chromosomes (DMCs; 
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cytogenetic markers of gene amplification) (Chao et al., 1991; Roninson, 1992a; 
Schoenlein et al., 1992). Molecular characterization of amplified genes in 
numerous cell lines in vitro has contributed to the elucidation of the genetic basis ·of 
MDR. Roninson et al. (1984) correlated resistance to ADR and DNR, respectively, 
in Chinese hamster cell lines with amplification of common DNA sequences. It was 
deduced from this investigation that one or several genes in the region of the 
amplicon must be activated in MDR. A large DNA segment of the amplified 
sequence associated with MDR has subsequently been cloned and characterized, the 
basic transcription unit of the MDR domain being designated m.dr. Recent evidence 
suggests that coordinate induction of the m.dr and P-4501A gene families 
(Thorgeirsson et al., 1991) as well as sequential amplification of the dihydrofolate 
reductase (DHFR) and m.dr genes (Assaraf et al., 1989) may provide a collateral 
response to prevent lethal accumulation and effects of xenobiotics. 
4.2. Chromosomal Localization of mdr Genes 
Analysis of human tumour cell lines resistant to the anthracycline DOX, the Vinca 
alkaloid VBL, and the epipodophyllotoxin teniposide VM-26, revealed the 
involvement of chromosomes 1, 3, 6 and 7 in at least two of the six cell lines 
(Trent et al., 1987). The latter was the most consistently altered, with breaks along 
its entire length, but clustered along the mid-distal long arm (ca. 57% of all 
breaks). Despite the finding that breakpoints in several cell lines are cytologically 
coincident with the loci of the Pgp gene, many are not. If the interruptions along 
chromosome 7 are aligned with known growth-regulatory sequences, the region 
corresponds to the EGF receptor gene (Zuckier and Tritton, 1983). It is no.t clear 
whether the structural interchanges involving this chromosome are indeed 
associated with altered expression of the Pgp or EGF receptor genes. However, 
recent data on SW-1573 cells indicate that the acquisition of non-Pgp-mediated 
MDR involves a specific deletion or a translocation involving the short arm of 
chromosome 2, whereas rearrangement of the long arm of chromosome 7 is a 
critical event in the development of Pgp-mediated MDR (Nieuwint et al., 1992). 
4.3. Origin, Evolution, and Nomenclature of mdr Genes 
The striking sequence homology between the N-terminal and C-terminal domains of 
Pgp (Chen et al., 1986) warrants consideration that m.dr arose by internal 
duplication of its ancestor (Figure 3). Recently, Chen et al. (1990) determined the 
entire intron-exon sequence of the human MDRl gene. On the basis of their results 
they conceptualized an alternative genealogic scheme. According to this hypothesis, 
\ 
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Figure 3. Proposed scheme for the evolutionary relationship between P-
glycoproteins. Alternative names for P-glycoprotein are indicated in parenthesis. 
See section 4.6 for details. (Adapted from Roninson, 1991b). 
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primordial proteins corresponding to the left and right halves of Pgp were formed 
separately by fusion of common or related entities coding for the nucleotide-binding 
domain with genes for different transmembrane proteins. Subsequent convergence 
of these two independently evolved genes resulted in the formation of Pgp. The 
availability of mdr eDNA clones has facilitated analysis of complete amino acid 
sequences of the mammalian, protozoan and yeast gene products which share 
evolutionary links with a diverse group of membrane transport proteins in bacteria 
and invertebrates (Roninson, 1991b). 
4.4. MDR Expression in Plasmodium falciparum 
Resistance of Plasmodium falciparum to CLQ and successive antimalarial drugs is 
also associated with increased drug efflux (Krogstad et al., 1987). Interestingly, 
two genes closely related to mammalian mdr, were isolated from P. falciparum 
(Foote et al., 1989; Wilson et al., 1989). One of these, pjmdr1, was amplified in 
two out of five CLQ-resistant strains (Foote et al., 1989) and in one mefloquine-
resistant derivative (Wilson et al., 1989). Plasmodium falciparum and mammalian 
Pgps show a high degree of sequence homology in both halves of the protein, hence 
the probability that its emergence preceded the divergence of protozoan and 
metazoan eukaryotes (Roninson, 1991b). 
4.5. Yeast mdr Expression 
Several studies have described an mdr gene in the yeast Saccharomyces cerevisiae 
(McGrath and Varshavsky, 1989; Raymond et al, 1992) that codes for a protein 
consisting of 1290 amino acid residues, 57% of which are highly conserved with 
human MDR1-encoded Pgp, and resembles another yeast gene, STE6, associated 
with secretion of a-factor pheromone, a modified dodecapeptide that carries a 
highly hydrophobic farnesyl group attached to its C-terminal cysteine (Cys) residue 
(Anderegg et al., 1988). The secretion of a-factor follows the classical signal 
sequence-dependent protein secretory pathway, implicating yeast Pgp as a 
component of a novel protein efflux system. The results of their study exemplify a 
normal function for Pgp. 
Recent evidence indicates that pleiotropic resistance in yeasts mimics MDR 
in higher eukaryotes (Nevzglyadova et al., 1992). By analogy with a-factor 
secretion, McGrath and Varshavsky (1989) concluded that at least some of the 
mammalian Pgps may function in transmembrane transport of specific proteins or 
peptides and that hydrophobic post-translational modifications such as myristylation 
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may serve to target these proteins to the cell surface and Pgp. Interleukin-1 (IL-l), 
for example, whose processing and secretion is similar to the biogenesis of the 
pheromone, has been proposed as a potential substrate for mammalian Pgps. 
4.6. Human and Rodent mdr Genes 
Analyses of hybridization patterns and sequencing of eDNA and genomic clones 
revealed that human cells contain two and rodent (mouse and hamster) cells three 
mdr genes (Croop et al., 1989; Hsu et al., 1989; Ng et al., 1989). MDRl is 
directly associated with drug resistance in humans; the function of MDR2, also 
referred to as mdr3, remains undetermined. Chin et al. (1989) also detected these 
in green monkey DNA. Two genes appear to be actively involved in drug 
resistance in rodent cells (Gros et al., 1991a; Gros et al., 1991b). One is 
designated pgp1 in hamsters and mdr3 in mice and the other, pgp2 in hamsters and 
mdr1 in mice; the sequences of both match closely that of human MDRl (Croop et 
al., 1989; Ng et al., 1989). The third member, termed pgp3 in hamsters and mdr2 
in mice, is homologous to human MDR2 and and also lacks association with MDR. 
The alignment of amino acid sequences of mammalian Pgps is almost 
identical, particularly in the region of the nucleotide binding domains. This reflects 
a strong selection pressure for the evolution and conservation of these sites 
(Endicott et al., 1987; van der Bliek et al., 1988; Hsu et al., 1989). The proposed 
evolutionary relationship between Pgps is illustrated in Figure 3. According to this 
scheme, mdr1 has undergone duplication in the rodent lineage after the divergence 
of primates and rodents, or before the mammalian branching with subsequent loss 
of one of the two mdr1 genes in the primate lineage. Roninson (1991b) contends 
that the latter possibility seems less likely, since the rodent mdr1a and mdr1b 
products have identical amino acid residues where they differ from the human gene 
product. 
4. 7. The P-Glycoprotein Multigene Family 
The existence of multiple non-allelic Pgp genes has been postulated by several 
researchers (Riordan et al., 1985; de Bruijn et al., 1986; Roninson et al., 1986) 
and adds to the complexity of the MDR phenotype. Information regarding the 
nomenclature and actual number of these genes is not easily established since newer 
units are invariably being identified and added to an already indistinct list (Borst 
and van der Bliek, 1991; Kirschner et al., 1992). The utilization of molecular 
biology techniques, in combination with mAbs against Pgp (Chen et al., 1986; 
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Hamada and Tsuruo, 1986a; Gros et al., 1988), has extended our knowledge of the 
genetics of MDR (Barrand and Twentyman, 1992). Complete eDNA sequences for 
two human and two murine Pgps (Chen et al., 1986) and partial sequences for 
Chinese hamster genes (Endicott et al., 1987; Roninson et al., 1984; Gros, et al., 
1986b) have been documented. 
Sequence analysis of eDNA encoding mdr has revealed that the epitope 
recognized by mAb C219 is present in almost all Pgps, and thus provides a 
universal probe for its detection. Monoclonal antibody C494, for example, binds 
preferentially to the pgp1 product in human and hamster cells, whereas the mAb 
C32 is specific for hamster pgp1 and pgp2 products (Kartner et al., 1985). The 
requirement for a multigene family is not well established, but can be discerned 
especially from the perspective of the complexity and diversity in the MDR 
phenotype. It is possible that Pgp molecules differ in their efficiencies in 
transporting specific classes of anticancer drugs and, under stringent selection 
pressure, more efficient molecules may be selected (Endicott and Ling, 1989). 
5. STRUCTURE AND FuNCTION OF P-GLYCOPROTEIN 
5.1 Sequence Homology with Other Proteins 
The mdr1 gene is a member of the ATP binding cassette (ABC) superfamily of 
active transporters, including the cystic fibrosis transmembrane conductance 
regulator ( CFTR), the hlyB gene of bacteria, the yeast ajactor (STE6), and the 
histocompatibility antigen modifier (HAM) (Hyde et al., 1990; Berkower and 
Michaelis, 1991; Bremer et al., 1992). The cystic fibrosis gene product (Fuller and 
Benos, 1992; Higgins, 1992a; Higgins, 1992b) and Pgp are structurally related 
proteins and both are probably associated with chloride channel activities (Gill et 
al., 1992; Gollapudi et al., 1992a; Valverde et al., 1992), and may therefore have 
a physiological role of regulating epithelial cell volume (Trezise et al., 1992). 
In addition, the mdr1 efflux pump has been reported to function as an ATP 
channel (Abraham et al., 1993) which may be specific for ATP transport essential 
to the regulation of Pgp activity in a manner analogous to the regulation of CFTR 
by phosphorylated channels (Anderson et al., 1992). P-glycoprotein has remarkable 
homology with other proteins (see also sections 4.3 and 5.1), most notably the 
nucleotide-binding domains of several bacterial transport proteins (Chen et al., 
1986; Gerlach et al., 1986a; Gros et al., 1986a). The best-characterized proteins in 
this group function as energy-coupling subunits of multicomponent transport 
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systems, e.g., the uptake of various metabolites from the periplasm into the 
cytoplasm of bacterial cells (Ames, 1988; Ames, 1992; Ames and Lecar, 1992). 
The white and brown genes of Drosophila (Mount, 1987; Dreesen et al., 
1988) were the first eukaryotic proteins identified to be homologous to Pgp. These 
proteins are thought to be involved in the uptake of pteridene precursor into 
pigment eye cells. This led to speculation that Pgp might be involved in the active 
uptake of some unknown substances, as well as in the efflux of hydrophobic 
compounds (Roninson, 1991b). Wu et al. (1991) have characterized two 
Drosophila homologues of the mammalian mdr gene. These, located in 
chromosomal regions 49EF and 65A, encode proteins that share over 40% amino 
acid identity with the human and murine mdr products. Studies on disruptions in 
the homologue in section 49EF implicate this gene in conferring colchicine 
resistance to the organism. 
5.2. Transmembrane Topology 
The overall organization of all mammalian Pgps is essentialy identical. The human 
MDR1-encoded glycoprotein, as predicted from its eDNA sequence, consists of 
1280 amino acid residues constituting a molecular mass of 141 kDa (Chen et al., 
1986). It is possible that post-translational processing such as phosphorylation and 
glycosylation may alter the sequence of the mature molecule. The apparent MW of 
141 kDa agrees with that reported for the unglycosylated protein synthesized by 
glycosylation-deficient mutants of Chinese hamster cells (Ling et al., 1983). The 
predicted secondary configuration of the protein, based on analysis of its primary 
structure, suggests that the protein possesses 12 transmembrane helices and 2 
cytoplasmic nucleotide binding sites (Chen et al., 1986; Gerlach et al., 1986a; 
Gros et al., 1986a). A short mostly hydrophilic N-terminal sequence is followed by 
a long hydrophobic region and a long relatively hydrophilic C-terminal domain. In 
this tandem duplication structure, the former and latter halves show homology, 
especially in the C-terminal region. In addition, the protein has a putative sugar 
binding site. P-glycoprotein belongs to a class of polytopic or multispanning 
integral membrane proteins containing signal sequences, which are located 
internally rather than at the N-terminus (Friedlander and Blobel, 1985). The 
hydrophobic moment plot (Eisenberg et al., 1984) of the membrane-spanning 
domains places all of them within or very near the area containing the majority of 
transmembrane segments from known channel-forming proteins. 
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Recent evidence strongly suggests that Pgp has ·a quaternary structure in the 
membrane and may exist as dimers compared with other active transport systems, 
such as the sarcoplasmic reticulum Ca2+ -ATPase and the H+ ,K+ -ATPase which 
form oligomeric structures in membranes (Boscoboinik et al., 1990). At present, 
little is known about the direct relationship between the molecular mechanism o( 
the energy-dependent arug efflux pump and its topology in the plasma membrane: 
Georges et al. (1993) have proposed two models based on epitope mapping studies 
with mAb MRK-16. In the first model, the 12 a.-helical transmembrane domains 
are closely packed in a circle to form a monomeric efflux channel with max_imum 
pore diameter. In the second model, 4 transmembrane helices are , packed in 
proximity to form a pore and more than one'Pgp molecule may be included to form 
multimeric (clusters) pores. It is not evident, however, which of the two (monomer 
or multimer) is best representative of a functional drug-efflux pump. 
5.3. Post-Translational Modification 
5.3.1. Glycosylation 
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5.3.2. Phosphorylation 
The observation that Pgp is phosphorylated in vivo (Hamada et al., 1987; Mellado 
and Horwitz, 1987; Richert et al., 1988) has stimulated interest in the regulatory 
function which such a process may have in MDR (Sibley et al., 1987; Bates et al., 
1992). The addition of phosphate groups is thought to occur by a calcium-
dependent mechanism, suggesting the involvement of protein kinase C (PKC) or a 
calcium-calmodulin-dependent kinase. Calcium channel blockers and calmodulin 
antagonists (cf section 6.2.2.) enhance the phosphorylation of Pgp (Hamada et al., 
1987). Protein kinase C activity is known to be modulated by tumour-promoting 
agents such as phorbol esters (Castagna et al., 1982). In support of this view, Pgp 
has been shown to be a substrate for calcium-dependent PKC in the presence of 
phorbol esters (Hamada et al., 1987). 
In addition, Gollapudi et al. (1992b) reported that prolonged exposure of 
P388/ ADR cells to phorbol myristate acetate (PMA) down-regulated total PKC 
activity with an associated correction of daunorubicin accumulation in these cells. 
Since the level of expression of Pgp in PMA-treated cells was similar to that in 
untreated cells, their data support the proposed role of PKC in modulating Pgp 
activity by phosphorylation-dephosphorylation (Chambers et al., 1992; Hait and 
Aftab, 1992; Blobe et al., 1993). In contrast, protein kinase A (PKA), which is 
cAMP dependent, has also been shown to mediate the phosphorylation of Pgp 
(Meyers, 1989) and sorcin (see section 3.4), a calcium-binding protein that is 
overexpressed concomitantly with Pgp in some MDR cells (Koch et al., 1986; van 
der Bliek et al., 1986a). These discrepant findings have led to the notion that 
perhaps any or all of the known protein kinase systems may operate in different 
aspects of the MDR phenotype (O'Brian et al., 1989; Abraham et al., 1990; Chin 
et al., 1992a). However, conflicting reports cast doubt on whether the MDR 
phenomenon is wholly related to the calcium, calmodulin and the cAMP 
physiologic repertoire (Nair et al., 1986; Cole et al., 1989; Anderson et al., 1991). 
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5.4. Expression in Normal and Tumour Tissue 
P-glycoprotein-specific eDNA probes and monoclonal antibodies (e.g., C219, 
MRK16, JSB-1, HYB211, HYB612) have provided useful tools for the 
identification of Pgp in normal and tumour tissues (Kartner et al., 1985; Hamada 
and Tsuruo, 1986a; Scheper et al., 1988). The glycoprotein has been detected in 
several normal human tissues (Thiebaut et al., 1987; Hitchins et al., 1988; Pileri et 
al., 1991). In the liver, mAb MRK16 localizes to the luminal surfaces of the 
hepatocytes lining the biliary canalicular space and the small biliary ductules. P-
glycoprotein is diffusely present on the surfaces of most cells of the adrenal cortex 
and, in the kidney, it is distributed on the apical surface brush border of the 
proximal tubular cells (Lieberman et al., 1989). In the gastrointestinal tract,· it is 
prominent on the apical (mucosal) surface of the jejenum and colon, but not on that 
of the oesophagus or stomach. Highly confined areas of Pgp expression are 
detectable in the small collecting ducts of the pancreas. Other interesting locations 
include specialized capillary endothelial cells of the brain and testis (Cordon-Cardo 
et al., 1989; Thiebaut et al., 1989), placental tissue (Sugiwara et al., 1988), and 
normal lymphocytes (Coon et al., 1991b). 
Significant levels of Pgp may be present in breast cancer before exposure to 
drugs and may be of prognostic value in patients with locally advanced disease 
(Wishart et al., 1990; Sanflippo et al., 1991; Verrelle et al., 1991). In metastatic 
human musculoskeletal tumours and those which did not respond to combination 
chemotherapy, an increased expression of the MDR gene was detected whereas no 
evidence of appearance of this gene was found in the benign tumours (Nagata et 
al., 1992). The elevated levels of Pgp in remission phase associated with early and 
resistant relapse in multiple myeloma is indicative of a significant relationship 
between failure of chemotherapy in patients and an increase in expression of the 
mdr1 gene (Musto et al., 1991a; Linsenmeyer et al., 1992). The presence of the 
same gene in human glial tumours suggests that the multidrug transporter may 
contribute to the clinical non-responsiveness of these tumours to chemotherapy 
(Becker et al., 1991). 
Although the glycoprotein is infrequently detected in untreated lymphomas, 
it is often well-defined in clinically drug-resistant disease with a close correlation 
between the level of expression and the clinical course of disease (Dan et al., 1991; 
Miller et al., 1991; Pileri et al., 1991). The proportion of strongly MDR-positive 
cells is very common in acute non-lymphoblastic leukaemia (ANLL), albeit higher 
in relapse than at diagnosis, and failure of standard treatment is associated with a 
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progressive increase of Pgp levels (Michieli et al., 1992). Numerous other reports 
have confirmed the notion that the positive identification of Pgp in tumours may be 
closely associated with clinical drug resistance in some cases but not in others. 
These include: 
• ovarian and gynaecological cancers (Finstad et al., 1990; Rubin et al., 1990), 
• leukaemias (Marie et al., 1991; Pirker et al., 1991; Campos et al., 1992), 
• tumours of the brain and central nervous system (Chan et al., 1991; Henson et 
al., 1992; Tishler et al., 1992), 
• non-small-cell lung cancer (Scagliotti et al., 1991; Shin et al., 1992), 
• colorectal carcinomas (Toffoli et al., 1992), and 
• adrenocortical carcinomas (Flynn et al., 1992). 
5.5. Functional Correlates of P-Glycoprotein 
Observations of evolutionary conserved sequences of Pgp, together with their 
identification in normal and tumour tissue, have led to an interest in the physiologic 
functions which this membrane glycoprotein might have in normal embryonic and 
adult tissues, and the contrasting pathologic functions in neoplastic tissues. The 
localization of Pgp in normal tissues such as liver, colon, kidney and adrenal gland 
(Fojo et al., 1987; Cordon-Cardo et al., 1989), as well as in endothelial cells of the 
blood-brain barrier (Thiebaut et al., 1989; Hegmann et al., 1992; Tatsuta et al., 
1992), implies a functional role for the protein in normal physiologic transport 
processes. 
The presence of Pgp on the luminal surfaces of excretory organs 
exemplifies its postulated function as an energy-dependent drug efflux pump. It is 
probable that the mdr multigene family has evolved to protect animals against 
hydrophobic xenobiotics and microbial toxins, many of which are present in plants 
and contaminated food. The liver is known to respond to xenobiotics by expressing 
a host of cellular oncogenes and detoxifying enzymes. The location of the 
multi drug transporter in the liver and kidney, therefore, provides excellent 
pharmacologic defence against the accumulation and retention of potentially 
harmful substances. Many of the drugs to which MDR cell lines are resistant, 
including DNR, Vinca alkaloids, and DOX, are thought to be excreted by the liver 
into bile and by the kidney into urine (Bender and Chabner, 1982; Meyers, 1982). 
Thus, Pgp can be viewed as an energy-transducing transmembrane excretory pump 
that exudes hydrophobic amphipathic drugs, which have diffused into the proximal 
tubular cells of the kidney, or the pericanalicular hepatocytes, into the urine 
(Charuk and Reithmeier, 1992), or the bile (Gottesman et al., 1991). According to 
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this view, it is possible that drugs that are excreted into bile could be reabsorbed in 
the jejenum or colon, but such reabsorption is prevented largely by the activity of 
.the glycoprotein on their mucosal surfaces. 
The liver is an active modifier of circulating metabolites and also produces 
bile salts (which are amphipathic, hydrophobic compounds) that may be natural 
substrates for the active transporter. The widely used immunosuppressive drug, 
cyclosporine A (CsA), is a substrate for Pgp (Goldberg et al., 1988; Ryffel et al., 
1991). Since nephrotoxicity is the major limitation in the use of CsA, the presence 
of an efflux pump in the apical membrane of the renal proximal tubule may have 
clinical implications for cyclosporine toxicity. In rat small intestinal brush border 
membrane vesicles Pgp may be responsible for the transport of substrates into the 
lumen of the small intestine (Hsing et al., 1992) and perhaps provides protection 
against potentially damaging exogenous lipohilic cations (Gros et al., 1992). This 
may contribute to the rarity of small intestinal cancer in humans and animals (Hsing 
et al., 1992). 
The role of Pgp in the adrenal gland is not completely understood, but is 
speculated to include steroid transport. In support of this view, progesterone has 
been shown to inhibit photoaffinity labelling of Pgp by [3H]azidopine and to 
reverse the MDR phenotype (Yang et al., 1989). These studies are corroborated by 
observations that progesterone can bind the pharmacophore in MDR human 
leukaemia lymphoblasts (Qian and Beck, · 1990) and, under physiological 
conditions, may play a role in the excretion of the hormone from certain cells. 
Likewise, cortisol, aldosterone and corticosterone have been postulated as 
substrates for the protein (Ueda et al ., 1992; Wolf et al., 1992). Also, the 
interaction of organic chemicals with Pgp in the adrenal gland and kidney points to 
its physiological function of excreting certain classes of carbon compounds 
(Ichikawa et al., 1991b). On the luminal surface of pancreatic exocrine ductules it 
is postulated to prevent concentration of toxic metabolites produced in the pancreas 
or the reabsorption of pancreatic acinar cell secretions. 
The localization of Pgp in specialized capillary endothelial cells of the brain 
and testis has raised the interesting possibility that it might be functional in the 
blood-brain and -testis barrier. The natural product drugs which are substrates for 
the MDR transport system are principally excluded from these organs. By analogy, 
its presence in placental ti~sue (Sugiwara et al., 1988) and in the human fetus (van 
Kalken et al., 1992) has been suggested to aid in the protection against harmful 
substances and might, in addition, serve as an active transporter for nutrients vital 
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to the fetus. In the mouse,' the mdr gene 'is expressed in secretory glands of the 
gravid uterus, implying an involvement in hormone secretion during pregnancy 
(Arceci et al., 1988). 
In considering the causative role of,the glycoconjugate in the development 
of resistant tumours on the one hand, and its protective role in normal tissues such 
as the blood-brain barrier, liver, kidney and placenta on the other, future strategies 
for developing chemotherapeutic regimens, will have to anticipate possible host 
toxicities that may result from interfering with physiological Pgp-protective 
functions. 
6. MODIFICATION AND CHEMOSENSITIZATION OF MDR 
6.1. Implications of Collateral Sensitivity and Cross-Resistance 
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Correlations of patterns of cross-resistance and enhanced sensitivity with 
various tumour types may provide valuable information needed in initial treatment 
or equally successful secondary therapy of advanced recurrent or untreated disease 
(Futscher et al., 1992; Shinoda et al., 1992; Warrington, 1992). 
6.2. Chemosensitizers and Resistance Modifiers 
Much impetus of collateral sensitivity has come from the identification of 
substances termed chemosensitizers or resistance modifiers that can partially or 
completely reverse MDR (Georges et al., 1990b; Pearce et al., 1990; Hait and 
Aftab, 1992). Compounds with such activity include drug analogues, calcium 
channel blockers, lysosomotropic agents, calmodulin antagonists, cyclosporins, 
monoclonal antibodies, dihydropyridine analogues, pyrazoloacridines, 
thioxanthenes, and many other agents. The possible significance of selected agents 
will be considered in turn. 
6.2.1. Immunosuppressive and Non-Immunosuppressive Agents ~. 
Cyclosporin A is a potent resistance modifier in a number of human and rodent 
MDR cells (Foxwell et al., 1989; Gaveriaux et al., 1989; Nooter et al., 1990). 
Although CsA has specific Pgp binding activity but less membrane perturbing 
effects, inhibition of protein kinase C may also be involved in its sensitizing action. 
However, this immunosuppressant is toxic to organs, and thus raises concern 
regarding its clinical use. Nevertheless, a number of its immuno- and non-
immunosuppressive analogues are less harmful, possess similar or more potent 
chemosensitizing activity than the parent molecule (Arceci et al., 1992; Friche et 
al., 1992; Mizuno et al.,. 1992), and clinical studies of their MDR modulating 
effects seem highly relevant. Cyclosporine and some of these agents alone or in 
combination with other drugs have already been used successfully in clinical trials 
(Lum et al., 1992; Sonneveld et al., 1992a; Yahanda et al., 1992). 
6.2.2. Calcium Channel Blockers and Calmodulin Antagonists 
Calcium channel blockers such as VPL and calmodulin inhibitors such as TFP 
enhance intracellular accumulation of VCR and ADR in cells resistant to these 
drugs (Tsuruo et al., 1981; Tsuruo et al., 1982). Several reports followed which 
confirmed the potentiation of cytotoxicity of various drugs by calcium antagonists 
(Rogan et al., 1984; Bruno and Slate, 1990; Mickisch et al., 1991a), as well as by 
calmodulin inhibitors (Ganapathi et al., 1991a; Ganapathi et al., 1991b; Philip et 
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al., 1992). The mechanism of action of the calcium channel blockers evidently 
involves their direct binding to Pgp in competition with other drugs for Pgp-
mediated efflux (Cornwell et al., 1987a; Safa et al., 1987; Horio et al., 1991). The 
inhibition of VCR binding to Pgp by VPL apparently does not require cellular 
calcium ion fluxes (Naito and Tsuruo, 1989). In contrast, Vasilev et al. (1987) 
postulated that the higher efflux rate of cisplatin in cis-DDP-resistant L1210 cells 
may be due to changes in cellular calcium levels. Verapamil has been demonstrated 
also to enhance the action of drugs which cause DNA strand breaks or inhibit the 
repair of damaged DNA (Yalowich and Ross, 1984; Harker et al., 1986; Yalowich 
et al., 1987). 
Observations that some MDR cells overproduce cytosolic calcium-binding 
proteins (sorcin or V19 or CP22) indicate that calcium may have a role to play in 
MDR and its modulation (Meyers and Biedler, 1981; Meyers et al., 1985; Koch et 
al., 1986). The mechanism of action of calmodulin inhibitors in the reversal of 
MDR is less well understood. They may interact with hydrophobic regions of the 
molecule that are exposed on the surface following conformational changes caused 
by calcium binding (Zimmer and Hofmann, 1987). By analogy, these agents may 
bind to the hydrophobic domains on the Pgp molecule and affect the MDR 
phenotype. 
6.2.3. Drug Analogues, Metabolites and -Delivery Systems 
The design of drugs, their analogues and metabolites for overcoming MDR is being 
pursued actively (Ford and Hait, 1990; Pearce et al., 1990; Klopman et al., 1992). 
Numerous reports have described the synthesis, chemical characterization and use 
of efficient MDR reversers alone or in combination with other agents (Table 1). 
Interestingly, several of these compounds (e.g., quinidine, quinine, tamoxifen, TFP 
and VPL) share structural features such as lipophilic aromatic rings and hydrophilic 
N-alkyl groups (Pommerenke et al., 1990). In some instances drugs (e.g., ADR) 
may modulate both the function and expression of Pgp, thus raising the issue of 
their administration and scheduling to achieve optimal therapeutic effect (Kato et 
al., 1992). In addition, the ability of liposomes (Thierry et al., 1992; Warren et 
al., 1992), liposome-encapsulated DOX (Sadasivan et al., 1991; Mickisch et al., 
1992c; Rahman et al., 1992) and biodegradable polymers loaded with DOX 
(Cuvier et al., 1992), to bypass the efflux mechanism responsible for MDR so that 
accumulation of drugs in resistant cells is restored to levels approximating those in 
sensitive cells, may provide another effective approach to chemosensitization. 
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Table 1. Drugs and Related Compounds Used in the Reversal of Multidrug 
Resistance 
REVERSING AGENT REFERENCES 
DOX derivatives Ripamonti et al., 1992 
Quinine and its analogues Genne et al., 1992 
Solary et al., 1992 
Quinidines Wishart et al., 1992 
Quinolines Sato et al., 1991 
Wakusawa et al., 1992 
Progesterone and related compounds Fleming et al., 1992 
Tamoxifen Millward et al., 1992 
Stuart et al., 1992 
Trumpet al., 1992 
Phenothiazines and N-substituted Ramu and Ramu, 1992 
phenoxazines Thimmaiah et al., 
1992 
Indole derivatives Kadam et al., 1992 
Toremifene and several of its Wiebe et al., 1992 
metabolites 
Triazine derivatives Cros et al., ·1992 
Dhainaut et al., 1992 
Polyether antibiotics Kawada et al., 1992 
Metabolites of niguldipine, Hofmann et al., 1992 
nitrendipine and verapamil 
Amiloride analogues Epand et al., 1991 
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6.2.5. Lysosomotropic Agents 
These agents have recently been reported to reverse MDR in human cancer cells 
(Shiraishi et al., 1986; Zamora and Beck, 1986). The lysosome-endosome 
secretory system has been implicated in the enhanced efflux of drugs observed in 
MDR cells (Beck, 1987; Sehested et al., 1987). It has further been speculated that 
Pgp may function in the trans-Golgi network vesicles rather than in the lysosomal 
compartment or at the level of the plasma membrane (Klohs and Steinkampf, 1988). 
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P-glycoprotein presumably pumps drugs into secretory vesicles derived from the 
Golgi apparatus where they become entrapped and extruded from the cell by fusion 
of the vesicle with the plasma membrane. 
Klohs and Steinkampf ( 1988) presented evidence that lysosomotropic agents 
(Triton WR-1339 and CLQ), and secretory inhibitors (monensin, cytochalasin B, 
and VBL) are effective in limiting DNR and DOX efflux from MDR P388 
leukaemia cells and potentiating their cytotoxicity. They exert their effects by 
alkalinizing the normally acidic intralysosomal compartment (Ohkuma and Poole, 
1978; Poole and Ohkuma, 1981). Neither methylamine nor ammonium chloride, 
both of which raise endosomal and lysosomal pH, could be demonstrated to inhibit 
drug efflux from MDR cells (Zamora et al., 1987; Klohs and Steinkampf, 1988). ' 
These discrepancies make the acidic vesicles of the trans-Golgi network, 
which are destined for secretion, prime candidates for the energy-dependent 
removal of drugs from MDR cells. Such a mechanism implies that after drugs have 
entered the cells they can be sequestered in the Golgi vesicles either by Pgp, which 
would bind and actively transport them into these vesicles, or by passive diffusion. 
Once inside the vesicular compartment, the drugs become protonated and entrapped 
in the acidic environment. This process of vesicular drug accumulation is analogous 
the concentration of catecholamines in storage granules of the adrenal medulla and 
might even explain the elevated expression of Pgp in this tissue (Fojo et al., 1987). 
P-glycoprotein may be related to the monamine transporter of the chromaffin 
granules. After drug concentration, these vesicles migrate to and fuse with the 
plasma membrane to shed their contents by exocytosis (Klohs and Steinkampf, 
1988). 
6.2.6. Polyclonal and Monoclonal Antibodies 
A vast number of polyclonal- (pAbs) and monoclonal antibodies (mAbs) have been 
used appropriately in defining the biology of tumour cells and in various aspects of 
cancer management (Schlom, 1986; Oettgen, 1990). Antibodies are being used as 
targeting vehicles for toxins, chemotherapeutic agents or their activating enzymes, 
cell-surface receptors, as well as inflammatory activators at the site of their 
interaction with tumour cell-surface antigens (Richardson et al., 1989; Ding et al., 
1990). Their potential application in the circumvention of MDR is now widely 
recognized. Several mAbs have been raised against Pgp (Danks et al., 1985; 
Kartner et al., 1985; Scheper et al., 1988) and are useful for detecting the 
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glycoprotein in human tumour specimens (Finstad et al., 1990; Efferth et al., 
1992; Mattern and Volm, 1992). 
Recombinant fragments (Marquardt et al., 1990; Tanaka et al., 1990) 
should also be useful to raise antibodies to Pgp in order to define the function of 
the various domains in MDR. Georges et al. (1991) have demonstrated that mAbs 
C219, C494, and C32 directed against short linear regions of the Pgp molecule 
inhibit its ATP binding capacity in vitro. They also presented evidence that both 
predicted domains bind A TP, that co-operativity exists between the two sites and 
that antibodies differentially inhibit the binding capacity of Pgp to the calcium 
channel blocker, azidopine. These observations couple specific perturbations of the 
molecule with ATP and drug binding. Monoclonal antibody-drug conjugates have 
been used successfully to augment the cytotoxicity of the conjugated drug (Pimm et 
al., 1990). 
Studies with mAbs MRK16 and MRK17, suggest that Pgp is involved in 
drug transport and proliferation of MDR cells (Tsuruo et al., 1989; Hamada and 
Tsuruo, 1991). Both mAbs exhibit growth-inhibitory effects on MDR cells and may 
be clinically useful to circumvent multidrug resistance (Beck, 1991a; Pearson et 
al., 1991; Heike et al., 1992). However, the obstacle of undesirable antibody-
induced toxic effects, arising either from Pgp expression in normal tissues or from 
host-immune responses, first needs to be addressed. An important advance to this 
end has been the selective elimination of MDR positive (MDR +) cells in vitro with 
MRK16 conjugated to the ribosome-inactivating protein saporin 6 (Dinota et al., 
1990). This has also been performed on MDR + and MDR negative (MDR-) cell 
lines, normal human bone marrow-derived haemopoietic precursors, and MDR + 
cells mixed with normal bone marrow to simulate a therapeutic bone marrow 
purging. The results implied that it may be possible to eradicate MDR + cells 
without affecting the in vitro proliferation of haemopoietic precursors (Dinota et 
al., 1990). 
Similarly, a combination of VP-16 and CsA was shown to be effective in 
purging MDR leukaemia cells from transplanted bone marrow in a murine model 
(Kuhl et al., 1992). Oher reports describe the successful purging of MDR cells 
(Aihara et al., 1991; Chao, N.J. et al., 1992) and the ability of MRK16 coupled to 
Pseudorrwnas exotoxin to effectively kill bone marrow cells in MDR-transgenic 
mice (Mickisch et al., 1992b; Mickisch et al., 1993). Correspondingly, a mouse-
human chimeric mAb, MH162, against Pgp was found to be more effective than 
MRK16 in lysis of MDR tumour cells by blood mononuclear cells, suggesting that 
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such mAbs may also be beneficial for in vivo destruction of MDR tumours 
(Ariyoshi et al., 1992; Nishioka et al., 1992). 
6.3. Enzyme Targeting 
Various enzymic mechanisms that confer cellular protection against anticancer 
drugs have been reported (Giai et al., 1991), some of these will be described 
briefly according to their proposed function in 1MDR. 
6.3.1. Glutathione S-Transferases 
The cytosolic glutathione S-transferases (GSTs) constitute a family of dimeric 
xenobiotic-detoxifying isozymes which are associated with resistance to anticancer 
drugs, e.g., alkylating agents (Hall et al., 1989; Miyazaki et al., 1990; Puchalski 
and Fahl, 1990). The mechanisms by which GSTs confer resistance to alkylating 
agents have not been elucidated, but it is hoped that combination chemotherapy 
with specific inhibitors of GST may improve the therapeutic effectiveness of 
alkylating agents (Hallet al., 1989). 
6.3.2. DNA Topoisomerases 
The regulation of DNA topology is obligatory for replication, transcription, 
recombination and repair. Topoisomerases are nuclear enzymes which catalyze the 
isomerization of DNA by breaking and rejoining DNA strands transiently (Wang, 
1985; Glisson and Ross, 1987; Preston and White, 1990). The cytotoxicity and 
DNA damage induced by anthracyclines (e.g., DOX and DNR), DNA intercalating 
agents and epipodophy llotoxins (e.g., etoposide and teniposide) appear to be 
mediated by Topoll (Utsugi et al., 1990; Utsumi et al., 1990; Sullivan and Ross, 
1991). Recent studies have implicated alterations in activity and function of this 
enzyme as an alternative mechanism of MDR (Deffie et al., 1989; De Isabella et 
al., 1991; Zwelling et al., 1991). 
Although Topoll is a principal determinant of cell sensitivity to DNA 
poisons, other changes involved in the regulation of enzyme function and/or in the 
cellular processing of drug-induced DNA damage may be critical in determining 
disparate cell responses to antitumour agents (Beck, 1990; Lefevre et al., 1991; 
Baguley et al., 1992). The precise nature of these alterations in MDR has yet to be 
established. However, several studies have demonstrated that the design of well-
defined DNA intercalators and drugs is both feasible and potentially useful to 
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overcome at-MDR (Baguely et al., 1990; Morrow and Cowan, 1990; Zwelling et 
al., 1991). 
6.3.3. Protein Kinases 
The relationship between protein kinases and MDR is an area of intense interest. 
The phosphorylation of Pgp is thought to involve multiple kinases, including, 
cAMP-dependent PKA, calcium-sensitive PKC, and calcium-calmodulin-dependent 
kinases (Hamada et al., 1987; Chambers et al., 1990; Hait and Aftab, 1992). These 
kinases may have an effect on Pgp-mediated drug efflux, e.g., substances which 
stimulate the activity of PKC decrease the cellular accumulation of anticancer drugs 
such as Vinca alkaloids (Ido et al., 1986) whereas inhibitors of the enzyme enhance 
drug accumulation and reverse resistance (O'Brian et al., 1989; Sato et al., 1990; 
Gollapudi et al., 1992b). In addition, chemotherapeutic agents commonly 
producing drug resistance have been shown to inhibit PKC (Palyoor et al., 1987). 
However, it has been reported that the kinase can be decreased and increased in 
certain MDR cells and in other cells may be unrelated to MDR (Schwartz et al., 
1991). This may therefore complicate its targeting in strategies to overcome MDR. 
Observations of the modulation of basal MDR by PKA suggest that such 
intervention, too, has potential therapeutic implications (Abraham et al., 1990). 
6.4. Genetic Strategies 
Genetic approaches to the treatment of cancer promise to revolutinize patient care. 
There has been significant advances in recent years concerning the regulation of the 
cell cycle, the role of oncogenes in the maintenance of genomic stability, induction 
of terminal differentiation, signal transduction and growth regulation as well as the 
mechanisms by which cytotoxic drugs kill cells. Some of these advances together 
with molecular analysis of the structure-function relationship of Pgp in MDR 
should reveal new targets for cancer chemotherapy. Novel appoaches, based on 
gene therapy of cancer by manipulating the immune system, introducing suicide 
genes into tumours, or using drug-resistant genes to protect normal cells during 
chemotherapy have already entered clinical trials. Several genetic strategies have 
been explored in reversing MDR, some of which are detailed below. 
6.4.1. Site-Directed Mutagenesis 
P-glycoprotein, encoded by the mdr multigene family, consists of 12 
transmembrane domains and at least two nucleotide binding sites. Azzaria et al. 
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(1989) have demonstrated that the introduction of direct mutations into the 
predicted nucleotide binding sites of the mdr1 gene abolishes its ability to confer 
resistance. Simlar efforts to inactivate either or both of the nucleotide binding 
domains by site-directed mutagenesis have confirmed that these sites are essential 
for the Pgp-multidrug transporter in human epidermoid KB carcinoma cells (Kioka 
et al., 1989; Dickson and Gottesman, 1990). In addition, a mutational substitution 
of a Val residue for a Gly residue at amino acid position 185 (in the first 
cytoplasmic loop, near the third transmembrane sequence, TM3) alters the 
specificity of the pump, apparently by affecting drug transport but not initial 
binding. 
Major functional differences between MDR1 and MDR2 Pgps reside in a 
small segment of the first intracytoplasmic loop; the MDR2 gene product does not 
appear to be a functional drug efflux pump (Buschman and Gros, 1991; Currier et 
al., 1992). Analysis of the effect of replacing Asn183 of MDR1 with Ser which 
occurs in MDR2 as well as substitution of Ser at position 183 in combination with 
Val at position 185 in Pgp resulted in a relative increase in resistance to ActD, 
VBL and DOX in transfected NIH-3T3 cells. This is indicative of the importance 
of the first intracytoplasmic loop in determining function and relative drug 
specificity (Currier et al., 1992). 
These findings are in accordance with observations that single amino acid 
substitutions, Ser~Phe in transmembrane domain 11 (TMll) of mdr1 (amino acid 
position 941) and mdr3 (amino acid position 939), markedly alter the activity and 
substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps (Gros et al., 
1991a). The latter study has identified TMll as a critical structural and functional 
determinant of the mdr1 and mdr3 gene products. The requirement for both TM3 
and TMll in MDR is further in agreement with the notion that the activity of a 
transacting positive regulatory factor which may exist constitutively in various 
tissues might be modulated by anticancer drugs (Kohno et al., 1989). It also seems 
likely that the mdr gene is differentially expressed in response to the degree of 
cytotoxic exposure. Recently, Devine et al. (1992) have implicated the sixth 
transmembrane domain of Pgp in the mechanism of drug recognition and efflux. 
Moreover, their results revealed a close functional homology between Pgp and the 
cystic fibrosis transmembrane regulator in which the sixth transmembrane domain 
has likewise been shown to influence substrate specificity. 
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6.4.2. Antisense Oligonucleotides 
Another genetic approach, utilizing the ability of nuclease-resistant antisense 
oligonucleotides to suppress Pgp gene expression preferentially, has been described 
by Vasanthakumar and Ahmed (1989). These authors showed that antisense 
oligonucleoside methylphosphonates elicited sequence-specific, concentration-
related inhibition of Pgp synthesis and also increased the toxicity of DNR in human 
K562 erythroleukaemia cells. Since the entire length of the mdr1 is delineated, a 
complementary base sequence would be advantageous in selectively targeting a 
desired mRNA segment and in arresting the synthesis of Pgp. Such studies may 
have implications for the genetic control ofMDR (Rivoltini et al., 1990). 
6.4.3. Transgenic Mice 
This biotechnology is becoming increasingly sophisticated so that genes can be 
targeted for replacement by a mutated version of the same gene (McGrane et al., 
1992; Mickisch et al. 1991d). The system is aimed at evaluating the efficacy, 
potency and toxicity associated with chemotherapy and chemosensitization of MDR 
cells in animals (Mickisch et al. 1991b; Mickisch et al. 1991c; Pastan et al., 1991). 
The transplantation of bone marrow cells from transgenic mice expressing the 
human MDR1 gene confers long-term protection against the myelosuppressive 
consequences of chemotherapy in mice (Mickisch et al. 1992a). This selective 
advantage conferred by expression of the MDR1 eDNA provides a strategy for the 
use of MDR1 gene in cancer chemotherapy and for the introduction of unselected 
genes into sensitive tissues such as normal bone marrow. 
6.5. Differentiation Inducers and Oncogenes 
Valuable insight into the maturation-dependent response of certain forms of cancer, 
including MDR tumours, to antineoplastic agents has been gained by the use of 
differentiation inducers (Bates et al., 1989; Mickley et al., 1989; Michaeli, et al., 
1990). The potential therapeutic advantage of differentiation inducers is based on 
their ability to convert unresponsive non-differentiated neoplastic cells to their non-
proliferating (i.e., terminally differentiated) mature counterparts (Shwartz et al., 
1983; Estervig et al., 1989; Hassan and Rees, 1990). 
Certain human MDR cell lines are unaltered in their state of differentiation 
compared with parental cells (Bhalla et al. 1985; Beck et al., 1986; Beran and 
Anderson, 1987) and they grow equally well as their drug-sensitive parental lines 
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in nude mice (Mirski et al., 1987; Hill et al., 1988a; Hill et al., 1988b). However, 
Ades et al. (1992) have demonstrated that the differentiation agent hexamethylene 
bisacetamide and transforming growth factor beta-1 (TGF-P1) acted synergistically 
on a multidrug-resistant human hepatocellular carcinoma cell line and resulted in a 
cell death rate of 80%. Their data support the notion of programmed cell death and 
suggest that drug-resistant tumour cells may be susceptible to a combination of 
cytokines and differentiation inducers. Okabe-Kado et al. (1991) have shown that 
the MDR phenotype can be reversed partially by treatment of K562/VCR cells with 
erythroid differentiation factor (EDF). It is presumed that EDF causes down-
regulation of Pgp in K562/VCR cells. Thus, differentiation-induction therapy may 
prove beneficial in patients who are unresponsive to conventional cytotoxic 
chemotherapy. 
Cellular differentiation is a multistep process (Chen et al., 1982), involving 
PKC, proto-oncogenes (including c-myc, c-myb, cjos, and p53), and expression of 
genes for differentiated phenotypes (Marks et al., 1987; Richon et al., 1989; 
Bhushan et al., 1992). The promoter of the human MDR1 gene is a target for both 
the c-Ha-ras-1 oncogene and the p53 tumour suppressor gene products (Chin et al., 
1992b). This implies that the MDR1 gene may be developmentally regulated and 
might also be activated during tumour progression associated with mutations in the 
ras and p53 oncogenes (Fearon and Vogelstein, 1990; Chin et al., 1992b). Recent 
data indicate that increased expression of cjos and c-erb proteins is a constant 
feature of several MDR cell lines and may play a role in the development of MDR 
(Efferth and Volm, 1992). These oncogenes may be explored as molecular targets 
for MDR reversal. 
PART II: 
1. INTRODUCTION 
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GLYCOSYLATION OF MEMBRANE 
PROTEINS 
The term glycoconjugate is used to describe molecules in which carbohydrate 
moieties (mono-, oligo-, or polysaccharides) are covalently linked to proteins or 
lipids. Glycolipids are lipids (e.g., diacylglycerol, sphingosine, ceramide or 
dolichol) to which oligosaccharides are attached. Oligosaccharides are coupled via 
N-and/or 0-glycosidic bonds to polypeptides and may represent up to 70% of their 
overall molecular weight (Beeley, 1985). Cell membranes of eukaryotic cells 
usually have a carbohydrate content of between 2 and 10% contributed by the sugar 
residues of their constituent glycolipids and glycoproteins. The oligosaccharide 
moieties of glycoproteins are discrete, stereo-specific and highly conserved 
structures. Four different monosaccharides can be combined to form over 36,000 
different tetrasaccharides. In addition, glycoproteins differ from other 
glycoconjugates, such as proteoglycans, glycosaminoglycans, mucoproteins and 
peptidoglycans, in having multiple branched, relatively short oligosaccharide chains 
with a greater aggregation of monosaccharides and without repeating disaccharide 
units (Shreeve, 1974). 
The core protein of glycoproteins is generally more prominent than it is, 
for example, in proteoglycans where amino acids are linked to carbohydrate chains 
composed of variable branches of repeating structural units (Abbreviated 
terminology of oligosaccharide chains, IUB-IUPAC recommendations, 1982). 
Furthermore, an outer sequence, sialic acid (neuraminic acid, NeuAc; or N-Acetyl 
neuraminic acid, NeuNAc) or fucose (Fuc)~galactose (Gal)~N-Acetyl D-
glucosamine (GlcNAc), linked to an inner core of "'3 mannose (Man) and 2 
GlcNAc residues, is common to many glycoproteins (Shreeve, 1974). Another· 
important class of glycoconjugate is glycosylphosphatidyl inositol (GPI) lipid 
anchors (Low et al., 1986; Low, 1987; Ferguson et al., 1988) which link cell 
surface glycoproteins to membrane lipids through an oligosaccharide bridge. Thus, 
proteins may be glycosylated with N-and 0-linked oligosaccharides (N-glycans and 
0-glycans, respectively), as well as a GPI membrane anchor (Abe~jon and 
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organisms ranging from bacteria to mammals (Ginsburg and Neufeld, 1969). This 
universality, together with the structural diversity of the carbohydrate moieties of 
glycoconjugates, has stimulated much interest in their biochemical and cellular 
functions (Rademacher et al., 1988). Indeed, glycoproteins have been implicated in 
a broad spectrum of processes (Table 1). 
Table 1. Functional Significance of Glycoconjugates in Biological Systems 
FUNCTIONS REFERENCES 
Embryonic development Loveless et al., 1990; 
Varki et al., 1991 
Cell adhesion and ligand- Brandley et al., 1990; 
receptor interaction Springer, 1990; Roche, 
1991 
Biosynthetic disorders Kornfeld, 1986; Fukuda 
et al., 1987 
Lymphocyte homing and Yednock et al., 1987; 
migration Stoolman, 1989 
Parasite-host binding Friedman et al., 1985; 
Lev et al., 1986 
Oncogenesis Leathem et al., 1987; 
Paietta et al. , 1987; 
Santer, et al., 1989 
Tumour metastasis Humphries et al., 1986; 
Dennis et al., 1987; 
Benedetto et al., 1989 
Resistance to proteolytic Loh and Gainer, 1978 
degradation 
Natural cytotoxicity Mueller et al., 1990 
Multiple drug resistance Endicott and Ling, 1989 
2. N-GLYCOSYLATION OF PROTEINS 
Glycosylation of proteins is a prevalent post-translational modification process 
detected in all eukaryotes (Abeijon and Hirschberg, 1992; Haltiwanger et al., 
1992). Glycoproteins are classified into two broad categories: N-glycosylated 
proteins and 0-glycosylated proteins. The bond in the former is via the amide 
nitrogen of an asparagine (Asn) residue of the protein, whereas that of the latter 
occurs via the hydroxyl of serine (Ser), threonine (Thr), hydroxylysine, or 
hydroxyproline. The structures of several hundreds of N-linked oligosaccharides 
associated with many glycoproteins share a number of characteristics, including the 
pentasaccharide core, Man3GlcNAc2, which forms the attachment point between 
the oligosaccharide and the Asn residue of the protein. This core then undergoes 
modification into diverse branches, viz., high/oligomannose-type, complex-type and 
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hybrid-type structures (Hirschberg and Snider, 1987; Roth, 1987). The biosynthetic 
pathway of N-linked glycoproteins is schematically illustrated in Figures 1 and 2. 
3. INRIBITORS OF N-LINKED OLIGOSACCHARIDE PROCESSING 
4. APPLICATION OF TuNICAMYCIN IN GLYCOBIOLOGY 
The chemistry of the tunicamycins (TMs) has been reviewed by Elbein (1981). The 
TMs . are a group of nucleoside antibiotics produced by Streptomyces 

















Figure 1. Initial steps in the assembly of N-linked oligosaccharide chains: transfer to protein and trimming to high-mannose 
structures. Arrows represent enzyme-catalyzed reactions. Lines perpendicular to arrows indicate inhibition sites of glycosylation 
inhibitors. Dol-PP, dolichol pyrophosphate; Asn, asparagine. Modified from Kornfeld and Kornfeld (1985) and Glycosylation 
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Figure 2. Processing of high-mannose structures to complex structures. Arrows represent enzyme-catalyzed reactions. Lines 
perpendicular to arrows indicate inhibition sites of glycosylation inhibitors. Asn, asparagine. Modified from Kornfeld and Kornfeld 





















First step in synthesis of lipid-linked 
oligosaccharide i.e., forma-tion of 
GlcNAc-P-P-Dol from UDP-GlcNAc and 
Dol-P. In presence of TM, newly 
synthesized proteins carry no Asn-linked 
oligosaccharides. 
Forms complex with Dol-P-P and 
prevents its dephosphorylation, i.e., 
formation of Dol-P from Dol-P-P. 
Formation of Dol-linked monosaccharides 
Formation of Glc-P-Dol 
Formation of GlcNAc2-P-P-Dol, of Man-
P-Dol and of GlcNAc-P-P-Dol 
Comments on Use 
Used with intact cells at 0.1-10 
~-tg/ml) or in cell-free systems at 
(0.5-5 ~-tg/ml). 
Inhibitor probably does not cross 
cell membrane. 
Cell-free systems, 500 ~-tg/ml 
Cell-free system, 5-10 ~-tg/ml 
Cell-free system, 50 ~-tg/ml 
References 
Schwarz and Datema, 1982; 
Elbein, 1987 
W edgewood and Strominger, 
1980; Elbein, 1987 
Schwarz and Datema, 1982; 
Elbein, 1987 
Schwarz and Datema, 1982; 
Elbein, 1987 























Table 2. (Continued) 
Inhibitor Reactions Inhibited 




Release by glucosidase I and II of Glc 
residues from Glc3Man9GlcNAc2; also 
inhibits synthesis of Glc3M~GlcNAc2-
P-P-Dol; cells incubated in presence of 
dNM synthesize ..1- amounts of complex 
oligosaccharides and t amounts of high 
mannose structures; Subsequent transport 
and secretion of glycoproteins have been 
shown to be impaired in some cases. 
Potent inhibitor of Golgi a-mannosidase I 
which normally removes several Man 
residues from the precursor. The 
principal product formed in the presence 
of dMAN is Man9GlcNAc2Asn, a high 
mannose structure; dMAN blocks 
formation of complex and hybrid 
oligosaccharide structures. 
Comments on Use 
Used with intact cells at 1-5 mM 
and as glucosidase inhibitor (100-
500 JLM). 
dMAN at 50 JLM is sufficient to 
inhibit rat liver Golgi a-
mannosidase I in vitro without 
significantly affecting other a-
mannosidases; Used at 1-5 mM in 
culture media, to prevent 
conversion of high mannose 




Grosset al., 1983; Bischoff 
and Kornfeld, 1984; Elbein 

























Table 2. (Continued) 
Inhibitor Reactions Inhibited 




Inhibits only glucosidase I which refeases 
terminal Glc from Glc3Ma~GlcNAc2 ; 
the inhibition causes accumulation of Glc-
containing oligosaccharides of secreted 
and membrane glycoproteins; has no 
apparent effect on protein synthesis; 
Recent studies have shown that CsP 
interferes with HIV infectivity. 
Inhibits Golgi a-mannosidase II, i.e. 
formation of GlcNAc2Man5 is blocked. 
Processing to hybrid-type oligosaccharide 
structures containing Fuc and NeuNAc 
can occur as well as high mannose and 
complex-type structures. 
Inhibits mammalian a-glucosidase II; 
Does not affect mammalian a-glucosidase 
I, Golgi a-mannosidase I or formation of 
Dol-P-P-oligosaccharide or its transfer to 
proteins. 
Comments on Use 
CsP at 100 ~-tgfml completely 
blocks mammalian glucosidase I; 
In intact cells 10-50 ~-tg/ml is 
used. 
Intact cells, 0.1-2 ~-tg/ml; Cell-
free systems, 0.1-10 ~-tM 
For inhibition of glycoprotein 
processing, 1-5 mM used in vivo 
and in vitro. As a glucosidase 
inhibitor, 0.2-2 mM is 
recommended. 
References 
Pan et al., 1983; Elbein, 
1987; Gruters et al., 1987; 
Fleet et al., 1988; Taylor et 
al., 1991 
Grosset al., 1983; Elbein et 
al., 1983; Schwarz and 
Datema, 1984; DeSantis et 
al., 1987; Elbein, 1987 
Datema et al., 1982; 






















(Continued) I :!:J 








Formation of Dol-linked monosaccharides 
by trapping Dol-P as dGlc-P-P-Dol; Also 
inhibits the initial assembly of lipid-
linked oligosaccharides by incorporation 
of dGlc instead of Glc or Man 
Formation of Man-P-Dol and Glc-P-Dol 
is blocked; -.l.UDP-Glc pool size. 
Synthesis of lipid-linked oligosaccharides 
Synthesis of lipid-linked oligosaccharides 
Comments on Use 
Intact cells 1-50 I-'M or 1-120 JLM 
GDP-dGlc or UDP-dGlc in cell-
free systems 
Intact cells 0.2-0.3 mM 
Intact cells 0.2-10 mM 
Intact cells 4-40 mM, inactive in 
cell-free systems. 
References 
Schwarz and Datema, 1982; 
Elbein, 1987 
Schwarz and Datema, 1982; 
Elbein, 1987 
Schwarz and Datema, 1982; 
Elbein, 1987 
Schwarz and Datema, 1982; 
Elbein, 1987 
See List of Abbreviations for abbreviations and nomenclature used. Adapted and condensed from: Beeley, 1985; Tools for Glycobiology, Oxford Glycosystems Catalogue, 1992, 
Oxford Glycosystems Ltd., UK; Reagents for Glycoconjugate Research, Inhibitors of Glycoprotein Synthesis, G~cohydrolases, Boehringer Mannheim Biochemica Information, 1987, 
Boehringer Mannheim GmbH, Germany; Inhibitors of Glycoprotein Processing, Genzyme Corp., Boston, USA. See also Reutter and Bauer (1985) for additional sugar analogues; t, 
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antibiotics, the main components being TMs V, VII and X, also referred to as A, 
B, C and D, respectively; The Merck Index, 1989), is composed of uracil, an 11-
carbon aminodialdose called tunicamine, GlcNAc that is attached to one of the 
anomeric carbons of tunicamine, and a fatty acid coupled to the amino group of 
tunicamine via an amide bond. The homologues vary in their fatty acid 
composition, saturation, chain length and branching. The molecular weights of the 
TMs range from about 814 to 872. Tunicamycin is easily soluble in 
dimethylsulphoxide (DMSO), dimethylformamide (DMF), and pyridine (> 10 
mg/ml). Solutions in DMSO and DMF are stable for 3-4 weeks if stored at -20°C. 
Tunicamycin is readily soluble in aqueous solutions at alkaline pH. Solutions are 
stable at neutral and alkaline pH, but not at acid pH (The Merck Index, 1989). TM 
is a higly toxic substance with an LD50 of 6.5 mg/kg (oral) and 1.8 mg/kg (i.p. or 
i.v.) in mice. 
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5. BIOCHEMICAL RELEVANCE OF GLYCOSYLATION 
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PART III: RESEARCH PROPOSAL 
Many of the difficulties encountered in the chemotherapy of human tumours can be 
attributed to the manifestations of drug resistance. P-glycoprotein is present in most 
drug-resistant cells and functions as an energy-dependent efflux pump that 
maintains subtoxic intracellular levels of a broad spectrum of chemotherapeutic 
agents. It is generally accepted that MDR cells accumulate less drug than their 
corresponding parental or drug-sensitive counterparts. Therefore, the extent of 
penetration into and accumulation and retention within tumour cells of certain 
anticancer compounds appears to be an important determinant of their cytotoxicity. 
Considering the relationship between its structure and function in the MDR 
phenotype, it may be that modification of Pgp can be applied usefully for 
chemosensitization purposes. P-glycoprotein is processed post-translationally by 
glycosylation, which may regulate its activity and result in disparities in cell 
responses to cytotoxic drugs. [Refer to shaded text boxes in Parts I and II, pages 8-
11, 24, 29, 32, 42, 49 and 50, for selected areas of interest that led to the research 
undertaken in this thesis.] 
In this study, tunicamycin, a specific inhibitor of N-glycosylation, will be 
evaluated for its potential to reverse the MDR phenotype in various cell lines. No 
attempt will be made to characterize the specific oligosaccharide alterations induced 
by antibiotic treatment in a single class of membrane glycoproteins, i.e., P-
glycoprotein. Rather, the inhibition of glycoprotein biosynthesis in general will be 
correlated with resistance and cytotoxicity, drug uptake, efflux and retention in 
vitro in cells transfected with the mdr gene. In addition, the partial characterization 
of Pgp expression in a continuous human ovarian carcinoma cell line (UWOV2) 
and peripheral blood leukaemia blasts obtained from patients will be undertaken. 
The UWOV2 cell line was isolated from an ovarian cystadenocarcinoma in a 
patient who had not responded to combined chemotherapy with actinomycin D, 
doxorubicin, vincristine and cisplatin. This cell line has not been characterized 
previously with regard to its expression of Pgp, and will be studied in association 
with the mdrl-transfected cell lines. 
Chapter 2 , 
CHAPTER 2 
EFFECTS OF TuNICAMYCIN ON GLYCOPROTEIN 
BIOSYNTHESIS IN VARIOUS DRUG-SENSITIVE AND 
DRUG-RESISTANT CELL LINES 
1. INTRODUCTION 
53 
A working hypothesis for acquired drug resistance at the biochemical level has 
been postulated, viz., enhanced glycoprotein synthesis and/or increased 
glycosyltransferase activity and decreased glycosidase activity (Bosman, 1971). 
Several reports have confirmed that cells selected in vitro for resistance to any of 
the natural product drugs (e.g., adriamycin, daunorubicin, actinomycin D, 
vincristine and vinblastine) display cross-resistance to the others, altered rates of 
glycoprotein synthesis, reduced glycoprotein degradation and a higher level of 
glycosyltransferase activity than in the parent or drug-sensitive counterparts 
(Biedler and Riehm, 1970; Bosman and Kessel, 1970). Exposure of certain drug-
sensitive cells to adriamycin modified their pattern of glycoprotein synthesis by 
enhancing the incorporation of radioactive fucose into plasma membrane 
glycoproteins (Kessel, 1979). However, the hyperglycosylation induced by 
adriamycin was not accompanied by a net gain in protein synthesis and this 
presumably involved amplified glycosylation of existing glycoproteins. Drug-
resistant cells displayed a significantly greater degree of fucosylation during the 
labelling period contrary to drug-sensitive cells, even in the absence of drug 
treatment. 
Studies with human multidrug-resistant KB carcinoma cells have shown that 
P-glycoprotein (Pgp) is synthesized as a 140-kDa precursor that is converted to a 
170-kDa glycoprotein. Tunicamycin, an inhibitor of N-glycosylation, prevents the 
conversion of the precursor to the mature forin (Richert et al., 1988). By contrast, 
Yoshimura et al. (1989) have presented evidence that human multidrug-resistant 
KB-C2 cells synthesize a 125-kDa Pgp that is modified to a 140-150-kDa protein, 
and that treatment with tunicamycin produces a 120-kDa species that is not further 
processed. These data, together with observations of molecular mass variations of 
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Pgps in normal human tissues such as liver, kidney, adrenal gland, 
capillary endothelium of the brain and testis, indicate that Asn-linked glycosylation 
represents a major modification of Pgp and that a variety of N-glycans may be 
present in normal tissue and tumour Pgps (Ichikawa et al., 1991a). Futhermore, 
Gervasoni et al. (1991) have established that in drug-sensitive human HL-60 
leukaemia cells a type of drug resistance, in the absence of Pgp expression, is 
partially inducible by inhibition of Asn-linked glycosylation of cell-surface 
proteins. 
Notwithstanding these observations, relatively few studies have directly,_ 
evaluated the role of glycosylation in the expression of MDR, which makes the 
characterization of the glycoprotein synthesis in MDR a challenging task. This 
chapter explores the effects of tunicamycin, an inhibitor of the earliest step of N-
linked glycosylation, on total protein and glycoprotein synthesis in various drug-
sensitive and drug-resistant cell lines. Tunicamycin was also tested for possible 
inhibition of the glycosyltransferase activities in these cells; The studies described 
in this chapter were necessary before further investigation of the_ possible 
consequences of TM treatment on the expression of the MDR phenotype in the cell 
lines described could be undertaken. 
2. MATERIALS AND METHODS 
2.1. Radioisotopes and Biochemicals 
Trypsin 1:250 (Difco Laboratories, Detroit, MI, USA), PBS Dulbecco 'A' 
[phosphate-buffered saline] (Oxoid, UK), tissue culture media (Gibco, UK), 
tunicamycin (Boehringer Mannheim, Germany), EDTA [ethylene-diamine 
tetraacetic acid Na2 salt] (Merck Chemicals, Germany), asialofetuin, ovalbumin and 
colchicine (Sigma Chemical Co., St. Louis, MO., USA), insulin monotard®(Novo 
Pharmaceuticals, South Africa), gentamicin sulphate (cidomycin®, Roussel 
Laboratories, South Africa), doxorubicin (adriamycin, generously supplied by 
Farmitalia Carlo Erba, Italy), radioactive precursor isotopes (Amersham, U.K.), 
and Bio-Rad™ protein assay dye reagent concentrate (Bio-Rad Laboratories Ltd., 
U.K.) were used in this study. All other reagents were of analytical grade and were 
obtained from either Merck Chemicals or Sigma Chemical Co. 
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2.2. Cell Lines and Culture Conditions 
The UWOV2 ovarian carcinoma cell line was provided by Professor W .R. 
Bezwoda (University of the Witwatersrand, South Africa). This cell line was 
derived from an ovarian cystadenocarcinoma in a patient who had not responded to 
combined chemotherapy with actinomycin D, vincristine, cisplatin and doxorubicin 
(Golombick et al., 1990), and therefore represents a cell line with in vivo-acquired 
drug resistance. The characterization of this cell line is descibed in Chapter 5. The 
BG-1 ovarian carcinoma eel~ line (Geisinger et al., 1989) was obtained from Dr 
C.A. Wallen (Bowman Gray School of Medicine, North Carolina,' USA). The BG-
1 I ADR cell line was selected for resistance to doxorubicin by stepwise exposure of 
BG-1 cells to the drug as described in Chapter 3. The KB-3-1 human epidermoid 
carcinoma cell line, and its MDR derivative, KB-8-5-11, which contains the 
amplified mdr1 gene encoding Pgp (Richert et al., 1985), were provided by 
Professor M.M. Gottesman (National Cancer Institute, Bethesda, MD, USA). The 
isolation and properties of the KB carcinoma cell lines have been described 
(Akiyama et al., 1985; Fojo et al., 1985). The NIH-3T3 murine fibroblasts and 
NIH-3T3-MDR cells, obtained by transfection of the NIH-3T3 cell line with the 
retroviral expression vector, pHaMDR1, containing a full-length complementary 
DNA from the human mdrl gene, (Shen et al., 1986a) were also provided by 
Professor M.M. Gottesman. The LR73 drug-sensitive and LR73-1A drug-resistant 
Chinese hamster cells were a gift from Professor P. Gros (McGill University, 
Montreal, Canada). LR73-1A cells were obtained by transfection of drug-sensitive 
LR73 cells with expression constructs containing the mdrl eDNA and selection of 
drug-resistant clones in adriamycin or colchicine (Schurr et al., 1989; Gros et al., 
1991b). 
Cell lines were maintained and propagated under the following conditions: 
UWOV2, in RPMI-1640 medium supplemented with 5% heat-inactivated fetal calf 
serum (HIFCS), penicillin G (100 U/ml) and streptomycin sulphate (100 J.Lg/ml) or 
gentamicin sulphate (50 J.Lg/ml); BG-1, in McCoy's SA medium supplemented with 
10% HIFCS, 100 U/ml insulin, 200 mM L-glutamine and antibiotics; KB-3-1 and 
NIH-3T3 parental cells, in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 10% HIFCS and antibiotics as above; KB-8-5-11 and NIH-3T3-
MDR cells, in DMEM as for parental cells with addition of 1 J,Lg/ml colchicine. 
LR73 and LR73-1A, in alpha minimum essential medium (a-MEM) containing 
ribo- and deoxyribonucleotide precursors, 10% HIFCS, 2mM L-glutamine and 
antibiotics. LR73-1A were grown in the presence of adriamycin or colchicine at 
/ 
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100 ng/ml. Incubator settings were calibrated to 37°C, 5% C02:air and 
85% relative humidity. Cells were routinely subcultured with trypsin-EDT A 
(0.25%-0.02%, w/v) in ca+2- and Mg+2-free PBS and maintained in the 
logarithmic phase of growth. Cell lines were periodically tested according to the 
method described by Chen (1977) and found to be free of mycoplasma 
contamination. 
2.3. Assay of Glycosyltransferases 
Glycosyltransferase activities in cell-free extracts prepared from various drug-
sensitive and -resistant cell lines were assessed follwing a 16h preincubation 
without (Control) or with (TM-treated) 5 fLg/ml tunicamycin by modification of the 
procedure previously reported by Liu et al. (1981). 
2.3.1. Preparation of Cell-Free Extracts 
Cell pellets were suspended at 107 cells/ml in cold lysis medium composed of 
Triton X-100/DMEM (0.1% v/v) and 1 mM glutaraldehyde to stabilize Golgi 
enzymes (particularly glycosyltransferases, Warley and Cook, 1976). The cell 
suspensions were frozen-thawed twice and cell-free extracts obtained by lysis for 10 
min. on ice. No intact cells remained after this treatment as judged by phase-
contrast microscopy. However, the lysates were centrifuged at 10 OOOg for 30s in a 
Beckman microfuge and the supernatants used as the crude enzyme preparation. 
Total protein in cell-free extracts was determined by the automated Bio-Rad™ dye-
binding assay described by Bradford (1976). 
2.3.2. Sialyltransferase Assay 
Sialyltransferase activity was measured by the transfer of [14C]sialic acid from 
CMP-[14C]sialic acid to an exogenous acceptor (asialofetuin) catalyzed by cell-free 
extracts. Assay mixtures in 1.5-ml microfuge tubes consisted of 10 J.Ll of 0.25 M 
sodium phosphate buffer, pH 7.0, containing 50 mM MgC12; 10 fLl of asialofetuin 
(50 mg/ml in the above buffer); 20 fLl of CMP-[14C]sialic acid (262 mCi/mmol, 
final specific activity 11.5 dpm/pmol); 50 fLl of the crude enzyme preparation (i.e., 
cell-free extract) and 28 fLl serum-free DMEM. Assay mixtures were incubated for 
2h at 37°C in a shaking waterbath. 
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2.3.3. Galactosyltransferase Assay 
Galactosyltransferase activity was assessed by measuring the transfer of 
[3H]galactose from UDP-[3H]galactose to exogenous desialylated fetuin. Reaction 
mixtures in 1.5-ml microfuge tubes consisted of 10 J.tl 0.75 M sodium cacodylate 
buffer, pH 7.0, containing 0.20 M MnC12; 10 J.tl fetuin free of sialic acid and 
galactose (50 mg/ml in the above buffer); 20 J.tl of UDP-[3H]galactose (20 
Ci/mmol; final specific activity 11.5 dpm/pmol); 50 J.tl of cell-free extract and 28 J.tl 
serum-free DMEM. Reaction mixtures were incubated for 2h as described for the 
sialyltransferase assay. 
2.3.4. Fucosyltransferase Assay 
The activity of fucosyltransferase was determined by measuring the transfer of 
[14C]fucose from GDP-[14C]fucose to exogenous asialofetuin (free of sialic acid 
and galactose) in cell-free extracts. Assay mixtures in 1.5-ml microfuge tubes 
consisted of 10 J.tl of 0.375 M Tris-HCl buffer, pH 7.0, containing 18.75 mM 
EDTA; 10 J.tl asialofetuin (50 mg/ml in the above buffer); 20 J.tl of GDP-
[14C]fucose (292 mCi/mmol, finaL specific activity 11.5 dpm/pmol); 50 J.tl of cell-
free extract and 28 JLI serum-free DMEM. Assay mixtures were incubated for 2h as 
described for the sialyltransferase assay. 
2.3.5. N-Acetylglucosaminyltransferase Assay 
N-Acetylglucosaminyltransferase activity was measured by the transfer of [6-
3H]GicNAc from UDP-[6-3H]GicNAc to an exogenous acceptor, viz., ovalbumin, 
in cell-free extracts. Reaction mixtures in 1.5-ml microfuge tubes consisted of 10 J.tl 
of 0.6 M sodium cacodylate buffer, pH 7 .0, containing 0.12 M MnC12 and 1.2 mM 
ATP; 10 J.tl ovalbumin (50 mg/ml in the above buffer); 20 J.tl of UDP-[6-
3H]GicNAc (60 mCi/mmol, final specific activity 11.5 dpm/pmol); 50 JL1 cell-free 
extract and 28 J.tl serum-free DMEM. Assay mixtures were incubated as described 
for the sialyltransferase assay. 
2.3.6. Harvesting of Assay Mixtures 
Glycosyltransferase assays were terminated by the addition of 1 ml ice-cold 10% 
trichloroacetic acid (TCA) to the reaction vessels and incubation for a further 10 
min. on ice. The precipitate containing the glycosylated acceptor protein was 
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poured onto glass microfibre filters (025mm, Schleicher & Schull or Millipore 
HAWP02500). The filters were washed three times with 1 ml ice-cold 10% TCA 
and once with 96% ethanol. The washed filters were air -dried, transferred to 10 ml 
Beckman Ready Protein™ scintillation cocktail in 20-ml glass vials and counted by 
liquid scintillation spectrometry. The radioactivity obtained in DPM was converted 
to pmoles and enzyme activity expressed as the number of pmoles of radiolabelled 
sugar transferred from nucleoside diphosphate sugar carrier to exogenous acceptor 
protein per hour. 
2.4. Precursor-Incorporation-Inhibition Studies 
Inhibition of protein and glycoprotein synthesis was studied by minor modification 
of the procedure described by lrimura et al. (1981). The effects of prior exposure 
to TM on the incorporation of labelled precursors [14C]leucine (50-60 mCi/mmol) 
or [35S]methionine ( > 1000Ci/mmol) and [3H]mannose (30-60 Ci/mmol) or 
[3H]glucosamine (20-40 Ci/mmol) into trichloroacetic acid-insoluble 
macromolecules (proteins and glycoproteins, respectively) were evaluated in the 
various cell lines as described in the results. Following an initial 16h exposure to 
TM (5 11g/ml), cells in the logarithmic phase of growth (usually 4x105 
cells/mllwell) in 24-well plates were incubated in the absence and presence of 5 
11glml or various concentrations of TM (0.005 to 5 11g/ml) and 5-10 11Ci/ml of 
[3H]mannose or [3H]glucosamine, 2.5 11Ci/ml [14C]leucine or 10 11Ci/ml 
[35S]methionine in medium devoid of leucine or methionine (DMEM or RPMI 
selectamine kit, Gibco) for various time intervals. 
After each incubation period, medium containing radioactive precursor was 
aspirated and the cells washed three times in ice-cold PBS and solubilized with 
0.5ml of 1% SDS/0.3M NaOH. One aliquot (0.1ml) was subjected to protein 
determination. To the other aliquot (0.4ml) was added 1 ml of ice-cold 10% 
trichloroacetic acid (TCA) and the mixture left on an ice bath for 20-30 min. TCA-
insoluble material (proteins or glycoproteins) was collected onto glass-fibre filters ( 
025mm, Schleicher & Schull). Filters were washed twice with 2ml of ice-cold 
10% TCA, twice with 3ml 96% ethanol and once with chloroform:methanol:water 
(10: 10:3, v/v) to remove glycolipids (Kuo and Lampen, 1976). Filters dried in air 
were placed in 20-ml scintillation vials to which 10ml scintillation fluid (Beckman 
Ready-Protein™) was added for radioactive counting. Counting efficiencies were 
33% for 3H and 66% for 14C. All samples were corrected for background 
radioactivity. 
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2.5. Protein Determination 
The total protein content in solubilized cells and cell-free extracts was estimated by 
utilizing the Bio-Rad™ protein dye-binding assay "kit based on the method described 
by Bradford (1976) with bovine serum albumin as standard. 
2.6. Statistical Method 
Differences between control and TM -treated cells as well as between drug-sensitive 
and drug-resistant cells were evaluated using the GraphPad™ INST AT© Student's 
t-test statistical program. The level of significance was set at p~0.05. Actual p 
values are presented. 
3. RESULTS 
3.1. Protein and Glycoprotein Synthesis 
The incorporation of [3H]mannose or [3H]glucosamine into glycoprotein and of 
[14C]leucine or [35S]methionine into protein was analysed in various drug-resistant 
(NIH-3T3-MDR, KB-8-5-11, LR73-1A and UWOV2) and drug-sensitive (NIH-
3T3-parental, KB-3-1 and LR73) cell lines in the absence (control) or presence of 
TM (TM-treated) at different time intervals following an initial 16-h preincubation 
with the antibiotic. Synthesis was standarized and expressed as the amount of DPM 
incorporated into trichloroacetic acid-insoluble fractions per total cell protein 
content. 
3.1.1. NIH-3T3-Parental and NIH-3T3-MDR Murine Fibroblasts 
The incorporation of glycoprotein precursor isotopes by both NIH-3T3-parental and 
NIH -3T3-MDR was significantly inhibited by TM at the time intervals indicated 
(Figure 1). The NIH-3T3-MDR cells showed a consistently greater rate of 
glycoprotein synthesis than their drug-sensitive counterparts (Figure 2). Similarly, 
total protein synthesis was significantly greater (except at the 4-h time interval, 
p=0.3752) in the NIH-3T3-MDR cell line compared with its parental cell line 
(Figure 3). Tunicamycin also inhibited protein synthesis in NIH-3T3-MDR cells, 
except at 4 hours of incubation (Figure 3). 
The antibiotic exerted varying time-dependent effects on NIH-3T3-parental 
cells, with inhibition of protein synthesis achieved at incubation times of 4h, 16h 
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Figure 1. Time-course of the effect of tunicamycin (5 JJ-g/ml) on the incorporation 
of radiolabelled mannose by NIH-3T3-parental and NIH-3T3-MDR cells in culture. 
Results are expressed as means ± S.E.M. of quadruplicate cultures. Asterisks 
indicate two-tailed p values for the differences between control and TM -treated 
cells as follows: *p <0.0001; **p=0.0003; ***p=0.003; ****p=0.038. 
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Figure 2. Time-course of total glycoprotein synthesis in NIH-3T3-MDR and NIH-
3T3-parental cells in culture. Data were replotted from Figure 1 and are expressed 
as means ± S.E.M. of quadruplicate cultures. Lowercase letters above error bars 
indicate two-tailed p values for the difference in glycoprotein synthesis between 
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Figure 3. Comparison of total protein synthesis in NIH-3T3-MDR and NIH-3T3-parental cells in the absence (control) or presence 
(TM-treated) of tunicamycin (5 1-1-g/ml). The effect of TM on total protein synthesis was measured by determining the incorporation of 
[14C]leucine into cellular protein. Data represent means ± S.E.M. (n=4). a-hindicate two-tailed p values for the difference between 
control and TM-treated cells as follows: ap:'S:O.OOOl; bp=0.0004; cp=0.0036; dp=0.0067; t:p=0.0074; fp=0.0827; gp=0.128; 
hp=0.4677. i-mnepict two-tailed p values for the difference in protein synthesis between MDR and parental cells as follows: 
ip=0.3752; jp=0.0019; kp=0.0002; 1p=0.0170; mp=0.0003. 








and 36h, but not at 8h and 16h (Figure 3). NIH-3T3-parental and NIH-3T3-MDR 
cells differed markedly in their susceptibility to suppression of protein synthesis by 
. TM at 8h, 16h and 36h, but not at 4h and 24h (Figure 4A). The percentage 
inhibition of mannosylglycoprotein synthesis induced by TM in both the NIH-3T3-
parental and NIH-3T3-MDR cell lines consistently exceeded 75-80% of the 
controls (Figure 4B). However, no differences in the degree of glycoprotein 
synthesis inhibition by TM could be demonstrated between NIH-3T3-parental cells 
and their MDR transfectants (Figure 4B). 
3.1.2. KB-3-1 and KB-8-5-11 Human Epidermoid Carcinoma Cells 
Multidrug-resistant KB-8-5-11 cells expressed higher rates of glycoprotein 
synthesis compared with parent KB-3-1 cells (Figure 5). In the absence of TM, at 
the end of selected time intervals, the level of radiolabelled mannose associated 
with trichloroacetic acid-insoluble material was significantly higher in KB-8-5-11 
drug-resistant cells than in KB-3-1 drug-sensitive cells. At all incubation times 
studied, exposure of both cell lines to TM resulted in a considerable decrease in the 
quantity of cell-associated [3H]mannose-labelled macromolecules (Figure 5). 
3.1.3. LR73 and LR73-1A Hamster Cells 
A time-course of the synthesis of mannosylglycoproteins in LR73 and LR73-1A 
cells in medium containing or lacking TM is shown in Figure 6. In the absence of 
TM no differences in either the level or rate of glycoprotein synthesis were noted 
between these two cell lines. In both the drug-sensitive and drug-resistant cell lines 
TM significantly reduced glycoprotein synthesis compared with untreated controls. 
3.1.4. UWOV2 Human Ovarian Carcinoma Cells 
In the presence of TM, a marked inhibition of both glycoprotein synthesis (Figures 
7 and 8B) and protein synthesis (Figure 8A) was observed in UWOV2 cells at 
every time period at which they were studied. The incorporation of [35S]methionine 
into cellular protein was greatly diminished at all incubation times, except at 4h. 
The concentration-dependent effect of TM on [3H]glucosamine incorporation by 
UWOV2 cells is shown in Figure 8. At concentrations less than 0.1/lg/ml, TM had 
no inhibitory activity, but at higher concentrations (0.5-50 11g/ml) the antibiotiC 
significantly reduced glycoprotein synthesis compared with the control. 
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Figure 4. Comparison of the inhibitory effects of tunicamycin (5 ~-tglml) on protein 
synthesis (A) and glycoprotein synthesis (B) in NIH-3T3-parental and NIH-3T3-
MDR cells. Values are means ± S.E.M. of quadruplicate cultures. Two-tailed p 
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Figure 5. Effect of tunicamycin (5 ~-tg/ml) on the synthesis of mannosylglycoproteins in KBS-5-11 and KB-3-1 cells measured by the 
incorporation of [3H]mannose into trichloroacetic acid-precipitated cellular protein. Data represent means ± S.E.M. (n=4). Lowercase 
letters above bars indicate two-tailed p values for the difference between control and TM-treated cells, and between KB-8-5-11 control 
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Figure 6. Effect of tunicamycin (5 fLg/ml) on the incorporation of radiolabelled 
mannose by LR73-1A and LR73 cells in culture. Results are expressed as means ± 
S.E.M. of quadruplicate cultures. a-elndicate two-tailed p values for the difference 
between control and TM-treated cells as follows: ap =0.0002; bp =0.0024; 
Cp=0.0006; dp<O.OOOl; Cp=0.0025. f-hRepresent two-tailed p values for the 
difference between LR73-1A control and LR73 control as follows: fp =0.1497; 
gp=0.6325; hp=0.0547. 
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Figure 7. Effect of tunicamycin (5 p.g/ml) on the incorporation of [3H]mannose by 
UWOV2 ovarian carcinoma cells in culture (A) and the corresponding level of 
inhibition of mannosylglycoproteins synthesis (B). Values are means ± S.E.M. of 
quadruplicate experiments. 
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Figure 8. Effects of tunicamycin (TM) on protein synthesis (A) and glycoprotein 
synthesis (B) in UWOV2 ovarian carcinoma cells in culture. Protein synthesis was 
monitored by measuring the incorporation of [35S]methionine into cellular protein 
at various time intervals in the absence (control) or presence (TM-treated) of the 
antibiotic. Glycoprotein synthesis as a function of TM concentration was evaluated 
by determining the amount of [3H]glucosamine incorporated into cellular protein 
after 16h of exposure to the antibiotic. Data represent means ± S.E.M. (n=4). 
Two-tailed p values for the difference between control and TM treated cells are 
presented within bars. 
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3.2. Glycosyltransferase Activities ' 
Glycosyltransferase activities measured in cell-free extracts prepared from various 
drug-sensitive and drug-resistant cell lines following a 16-h pre-incubation with 
(TM-treated) or without TM (control) are summarized in Table 1. 
3.2.1. KB-3-1 and KB-8-5-11 Human Epidermoid Carcinoma Cells 
Cell-free extracts from control multidrug-resistant KB-8-5-11 cells contained higher 
fucosyltransferase (FT) and N-acetylglucosaminyltransferase (NGT) activities, but 
considerably less sialyltransferase (ST) and galactosyltransferase (GT) activities 
than those from the corresponding untreated parental KB-3-1 cells. Tunicamycin 
significantly inhibited the activity of ST, but not that of FT, GT and NGT in KB-3-
1 cells. In KB-8-5-11 cells, TM pretreatment failed to inhibit the catalytic activity 
of any of the glycosyltransferases. 
3.2.2. NIH-3T3-Parental and Nffi-3T3-MDR Murine Fibroblasts 
When the levels of glycosyltransferases in cell-free extracts prepared from 
untreated NIH-3T3-parental and NIH-3T3-MDR cells were compared, the activities 
of FT, GT and NGT in NIH-3T3-MDR cells were increased approximately 1.5-fold 
above that of their parental cells. No differences in ST activities were detected 
between controls of the NIH-3T3-MDR cell line and its parental cell line. In both 
the parental and MDR cell lines, TM pretreatment significantly reduced the 
activities of all the glycosyltransferase enzymes investigated. 
3.2.3. LR73 and LR73-1A Hamster Cells 
Control LR73-1A cells contained equivalent levels of ST, GT and NGT activities, 
but a lower level of FT activity than their parental cells. In LR73 cells, TM did not 
alter the activities of ST, FT, and NGT, but markedly reduced the activity of GT in 
these cells. By comparison, the levels of FT, GT and NGT in LR73-1A cells were 
lowered by pretreatment with the antibiotic, whereas that of ST was not affected. 
3.2.4. BG-1-P and BG-1/ADR Human Ovarian Carcinoma Cells 
Analysis of glycosyltransferases in cell-free preparations from control BG-1-P and 
BG-1/ADR cells yielded similar ST, FT, and NGT activities. By contrast, 
Table 1. Comparison of Glycosyltransferase Activities in Various Drug-Sensitive and Drug-Resistant Cell Lines Following Exposure to Tunicamycin 
Glycosyltransferase Activity (pmol·J.tg protein-l.h-1) 
Sial y !transferase Fucosyltransferase Galactosy !transferase N-Acetylglucosaminy !transferase 
Cell Line Control TM treated Control TM treated Control TM treated Control TM treated 
KB-3-1 0.89±0.02 0.67±0.02a 0.14±0.004 0.14±0.01b 37.4±6.62 27.0± 1.22b 0.13±0.004 0.14±0.009b 
KB8-5-ll 0.74±0.o5n 0.57±0.05C 0.71±0.08° 0.50±0.10b 2.28±0.26P 2.52±0.20b 0.58±0.05q 0.63±0.04b 
NIH-3T3-P 4.48±0.57 2.71±0.1ld 1.38±0.01 1.23±0.03e 4.75±0.28 2.66±0.12f 27.1±2.28 18.0±0.72g 
NIH-3T3-MDR 6.08±0.64b 3.55±0.04h 2.06±0.02i 1.46±0.02i 7.08±0.o5a 3.96±0.13i 44.6±0.04ffi 35.8±0.16i 
LR73 5.32±0.88 3.96±2.27b 1.34±0.18 2.40± 1.16b 1.42±0.02 1.15±0.04-i 30.1±3.93 23.7±2.28b ~ 
LR731A 6.22±4.20b 3.25±0.22b 2.03±0.10r 1.67 ±O.o8k 1.59±0.16b 0.98±0.041 26.5±1.31b 16.4± t.o4i E. ..... [I> .. 
0.44±0.05 o.59±0.o5b 0.86±0.06 o.76±0.o5b 6.69±0.21 3.79±0.33ffi 0.59±0.05 o.68±0.o5b 
~ BG-1-P ~ 
C" 
;-
BG-1/ADR 0.62±0.11b 0.55±0.04b 0.64±0.08b 0.77±0.05b 9.02±0.o1i 5.12±0.03i o.54±0.o5b 0.60±0.08b .... 
UWOV2 0.29±0.06 0.26±0.02b 0.24±0.04 0.35±0.03b 1.15±0.10 0.99±0.03b 0.16±0.01 0.19±0.01b 
Values are means±S.E.M. (n=4). Superscripts represent Student's two-tailed p values for the differences between control and TM treated cells, and between parental and MDR cells as 
determined with the GraphPad INSTAT statistical program: ap=0.0002; bnot significant; cp=0.053; ~=0.022; ep=0.0032; fp=0.0005; gp0.0089; hp=0.0076; ~<0.0001; jp=0.0009; "'' 
~=0.0307; ~=0.010; mp=0.0003; ~=0.0318; 0 p=0.0004; Pp=0.0018; qp=0.0001; rp=0.0154. = 
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untreated BG-1/ ADR cells expressed an increased GT activity relative to their 
parental cells. In both BG-1-P and BG-1/ADR cells, the activities of ST, FT and 
NGT were unaffected by TM pretreatment, whereas GT was significantly reduced. 
3.2.5. UWOV2 Human Ovarian Carcinoma Cells 
In this cell line for which no corresponding drug-sensitive cell line exists, the 
activities of all the glycosyltransferases remained unchanged under the conditions 
of TM exposure. 
4. DISCUSSION 
Numerous studies with tumour and other cell types have. shown that the 
development of resistance to multiple chemotherapeutic drugs (MDR) correlates 
with amplified glycoprotein synthesis. In particular, the overexpression of a 170-
kDa membrane glycoprotein (Pgp) has consistently been associated with MDR 
(Endicott and Ling, 1989; Schinkel and Borst, 1991). Although there is ample 
evidence to implicate Pgp as the causative molecule in MDR, other reports point 
out that it may not be the only membrane protein or glycoprotein that is increased 
in MDR (Gros and Shustik, 1991; Krishnamachary and Center, 1992; Scheper et 
al., 1992). By contrast, reduced synthesis of specific surface proteins has also been 
observed in some MDR cells (Peterson et al., 1983). This adds further to the 
diversity of the MDR phenotype. 
The data indicate that glycoprotein synthesis in NIH-3T3-MDR and KB-8-
5-11 cells was increased above that of their parental cells. On the other hand, the 
LR73-1A drug-resistant cell line expressed equivalent levels of glycoprotein 
synthesis relative to its drug-sensitive control. Tunicamycin inhibited the synthesis 
of proteins and glycoproteins in the various cell lines studied. When 
glycosyltransferases in drug-resistant cells were compared with those in drug-
sensitive cells, no constant pattern of altered enzyme activity was observed .. 
Fucosyltransferase (FT) activity in KB-8-5-11, NIH-3T3-MDR and LR73-1A cells 
was consistently higher than in the corresponding drug-sensitive cells. Increased 
activity of N-acetylglucosaminyltransferase (NGT) was measured in the KB-8-5-11 
and NIH-3T3-MDR cell lines compared with the parental cell lines, whereas GT 
activity in NIH-3T3-MDR and BG-1/ADR cells exceeded that in their parental 
cells. Sialyltransferase (ST) acitivity remained constant in both the drug-sensitive 
and drug-resistant NIH-3T3 and the LR73 cell lines. In KB-8-5-11 cells, the 
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activities of ST and GT were reduced in relation to the parental cells. The BG-
1/ADR cells did not express altered ST, FT or NGT activities. In addition, the 
results presented in Table 1 point to differential inhibition of glycosyltransferase 
function by TM in the various cell lines. The lack of inhibition of 
glycosyltransferases by tunicamycin observed in KB-8-5-11 cells supports the claim 
that interference of N-linked oligosaccharide synthesis may not affect the surface 
{' 
expression of certain integral membrane proteins (Burke et al., 1984). This, ~ 
together with the finding that TM reduced the activity of all the 
glycosyltransferases in both NIH-3T3-parental and NIH-3T3-MDR cells, is further 
in agreement with reports of differences between drug-sensitive and drug-resistant 
cells due to changes in glycosylation patterns of plasma membrane glycoproteins 
(Beck and Cirtain, 1982; Marsh and Center, 1987; Ichikawa et al., 1991a). 
Differential glycosylation of Pgp has been shown to result in heterogeneous 
forms of MDR-associated glycoproteins in different cell lines (Greenberger et al., 
1988b; Greenberger et al., 1989; Meyers et al., 1989). It is not clear whether post-
translational processing of Pgp correlates with drug resistance (Center, 1983; 
Mukhopadhyay and Kuo, 1989). P-glycoprotein is expressed in VBL-resistant 
J7.V1-1 and a DNR-resistant J7.C1-100 cells as a 125-kDa nascent polypeptide that 
undergoes rapid (half-life, t112 ~20 min) N-glycosylation to a 135- or 140-kDa 
species (Greenberger et al., 1987). The 17. T1-50 cell line, selected for resistance to 
taxol, synthesizes two Pgp precursors of molecular sizes 120- and 125 kDa, both 
products of distinct genes (Greenberger et al., 1988a). In MDR KB cells (Richert et 
al., 1988) a single 140-kDa protein is modified to a mature 170-kDa glycoform. 
The function of the carbohydrate moieties of Pgp, which account for about 
18-24% of its molecular mass, has not been adequately evaluated in MDR. 
Previous suggestions that glycosylation may not be an obligatory component of the 
MDR phenotype (Beck and Cirtain, 1982; Ling et al., 1983) were not followed up 
by further research. Gervasoni et al. (1991) postulated that anthracycline resistance 
in HL-60 human promyelocytic leukaemia cells may be the result of 
hypoglycosylation of cell-surface glycoproteins. P-glycoprotein is, however, not 
overexpressed in these cells. It has also been shown to exist in an unglycosylated 
form in certain MDR cell lines (Germann et al., 1990). 
Structural analysis of the oligosaccharides produced by different cell lines 
in the absence or presence of TM was not the purpose of this study. Nevertheless, 
the results suggest that the degree of inhibition by TM of glycosyltransferases and 
of protein and glycoprotein synthesis in drug-sensitive and drug-resistant cells, 
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respectively, may depend on their specific complement of oligosaccharide 
structures. From these considerations it may be concluded that the effects of TM on 
glycoprotein synthesis in drug-sensitive and -resistant cells may be relevant in 
evaluating the role of Asn-linked glycosylation in multiple drug resistance. 
5. SUMMARY AND CONCLUSIONS 
Tunicamycin, an antibiotic which prevents N-glycosylation of proteins, has been 
evaluated for its effects on protein and glycoprotein synthesis in several drug-
sensitive (parental) and drug-resistant cell lines. Pretreatment of cells with the 
antibiotic, inhibits protein and glycoprotein synthesis in all the cell lines that have 
been studied. In the multidrug-resistant NIH-3T3-MDR murine fibroblast and KB-
8-5-11 human epidermoid carcinoma cell lines, glycoprotein synthesis was elevated 
compared with drug-sensitive (NIH-3T3-P and KB-3-1, respectively) controls, but 
no such elevation was found in drug-resistant Chinese hamster LR73-1A cells and 
their corresponding drug-sensitive LR73 cells. 
Analysis of several glycosyltransferases in the various parental and MDR 
cell lines showed that activities of fucosyltransferase (FT) and N-
acetylglucosaminyltransferase (NGT) are increased while the activities of 
sialyltransferase (ST) and galactosyltransferase (GT) are decreased in drug-resistant 
KB-8-5-11 cells compared with their parental controls. In NIH-3T3-MDR cells, the 
reactions catalyzed by FT, GT and NGT, but not by ST, occurred at significantly 
higher rates than those in the NIH-3T3-parental cells. The LR73-1A cells expressed 
raised levels of FT whereas the levels of ST, GT and NGT remained constant 
relative to drug-sensitive LR73 controls. Similar ST, FT and NGT reaction rates 
were observed in the BG-1/ADR human ovarian carcinoma cell line and its parental 
control (BG-1-P). 
Tunicamycin pretreatment of cells produced fluctuations in reaction rates 
for the various glycosyltransferases in MDR and parental cells and no consistent 
trend of inhibition of enzyme activity was detected. However, the suppression by 
TM of FT-, GT- and NGT-catalyzed reactions was common to NIH-3T3-MDR and 
LR73-1A cells, although TM did not completely abolish the activities of the 
glycosyltransferases in these cells. Exposure of KB-8-5-11 cells and UWOV2 
human ovarian carcinoma cells to tunicamycin did not alter any of the 
glycosyltransferases. These results demonstrate that glycoproteins are differentially 
expressed in various drug-sensitive and drug-resistant cell lines. 
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CHAPTER 3 
THE EFFECTS OF TuNICAMYCIN ON THE IN VITRO 
CYTOTOXICITY OF VARIOUS ANTICANCER DRUGS IN 
DRUG-SENSITIVE AND DRUG-RESISTANT CELL LINES 
1. INTRODUCTION 
The tumour cell surface has long been regarded as a target for chemotherapeutic 
intervention (D'Incalci et al., 1991; Daoud, 1992; Jandrig and Wunderlich, 1992). 
In particular, cell-surface glycoproteins are thought to mediate a number of normal 
and tumour-related processes such as tissue invasion and metastatic spread 
(Nicolson, 1984; el-Battari et al., 1986), cell attachment, growth and 
differentiation (Iwakura, 1987; Engstrom and Larsson, 1989; Kabakoff et al., 
1990), and multidrug resistance (Peterson and Biedler, 1978; Beck et al., 1979; 
Gervasoni et al., 1991). 
As with other glycoproteins, the multidrug resistance-associated P-
glycoprotein is subject to post-translational modification, such as N-glycosylation 
(Greenberger et al., 1989; Yoshimura et al., 1989; Ichikawa et al., 1991a). It is 
possible to interfere with different steps in the biosynthesis of N-linked 
glycoproteins by the use of specific inhibitors (Elbein, 1987; McDowell and 
Schwarz, 1988). The biological consequences of the alterations caused by 
glycosylation inhibitors are numerous, including enhanced susceptibility of proteins 
to proteases, improper protein processing and misfolding of polypeptide chains, 
loss of biological activity (McDowell and Schwarz, 1988) and sensitization of cells 
to cancerostatic protein toxins (Sandvig et al., 1986). Thus, sensitizing agents may 
prove valuable in enhancing the actions of immunotoxins and "anticancer agents. In 
this chapter we explored the effects of TM, an antibiotic which prevents protein N-
glycosylation and synthesis of glycoproteins (Elbein, 1987), on the reponses of 
several drug-sensitive and drug-resistant cell lines to various cytotoxic drugs. 
Cell Lines and Culture Conditions 75 
2. MATERIALS AND METHODS 
2.1. Drugs and Chemicals 
Doxorubicin (Adriamycin) and epidoxorubicin (Farmitalia Carlo Erba, Milan, 
Italy), cisplatin (Lennon), vincristine sulphate, colchicine, methylene blue, sarkosyl 
[sodium N-lauroyl sarcosine] and MTT 3-[4,5-dimethylthiazole-2-yl]-2,5-
diphenyltetrazolium bromide (Sigma Chemical Co., St. Louis, MO, USA), trypsin 
1:250 (Difco Laboratories, Detroit, MI, USA), PBS Dulbecco 'A' [phosphate-
buffered saline] (Oxoid, UK), tissue culture media (Gibco , UK), tunicamycin 
(Boehringer Mannheim, Germany), EDTA [ethylene-diamine tetraacetic acid N~ 
salt] and DMSO [dimethylsulphoxide] (Merck Chemicals, Germany) were usedjn 
this study. All reagents were of analytical grade. 
2.2. Cell Lines and Culture Conditions 
The UWOV2 ovarian carcinoma cell line was provided by Professor W.R. 
Bezwoda (University of the Witwatersrand, South Africa). This cell line was 
derived from an ovarian cystadenocarcinoma in a patient who had not responded to 
combined chemotherapy with actinomycin D (ActO), vincristine, cisplatin and 
doxorubicin (Golombick et al., 1990). The BG-1 ovarian carcinoma cell line 
(Geisinger et al., 1989) was received from Dr C.A. Wallen (Bowman Gray School 
of Medicine, North Carolina, USA). The KB-3-1, a human epidermoid carcinoma 
cell line, and its MDR: derivative, KB-8-5-11, which contains the amplified mdr1 
gene (Richert et al., 1985), were donated by Professor M.M. Gottesman (National 
Cancer Institute, Bethesda, MD, USA). The isolation and properties of the KB 
carcinoma cell lines have been described (Akiyama et al., 1985; Fojo et al., 1985). 
The NIH-3T3 murine fibroblasts and NIH-3T3-MDR cells, obtained by transfection 
of the NIH-3T3 cell line with the retroviral expression vector, pHaMDR1, 
containing a full-length complementary DNA from the human mdr1 gene, (Shen et 
al., 1986a; Shen et al., 1986b; Shen et al., 1986c) were supplied by Professor 
M.M. Gottesman. 
Cell lines were maintained and propagated under the following conditions: 
UWOV2, in RPMI-1640 medium supplemented with 5% heat-inactivated fetal calf 
serum (HIFCS), penicillin G (100 U/ml) and streptomycin sulphate (100 p.g/ml) or 
gentamicin sulphate (50 p.g/ml); BG-1, in McCoy's SA medium containing 10% 
HIFCS, 100 U/ml insulin, 200 mM L-glutamine and antibiotics; KB-3-1 and NIH-
3T3-parental cells, in Dulbecco's modified Eagle's medium (DMEM) composed of 
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10% HIFCS and antibiotics as above; KB-8-5-11 and NIH-3T3-MDR cells, in 
DMEM as for parental cells with addition of 1 JLg/ml colchicine. Incubator settings 
were calibrated to 3rC, 5% C02:air and 85% relative humidity. Cells were 
routinely subcultured with trypsin-EDTA (0.25%-0.02%, w/v) in ca+2- and 
Mg+2-free PBS and maintained in the logarithmic phase of growth. Cell lines were 
periodically tested according to the method of Chen (1977) and found to be free of 
mycoplasma contamination. 
2.3. Selection of BG-11 ADR Cells 
The BG-1/ ADR cells were selected by a modification of the procedure described by 
Jamali et al. (1989). BG-1-P cells were grown in increasing concentrations of 
doxorubicin over a period of 6 months until resistance to 0.2 JLg/ml was achieved. 
The cells were subsequently cultured in growth medium containing doxorubicin 
and reselected every 2-3 months in order to achieve maximum resistance. The 
resultant BG-1/ADR cells expressed a 59-fold increase in resistance to doxorubicin 
compared with the parental line. The cells also showed relative cross-resistance to 
colchicine and vincristine (1.4- and 10-fold, respectively). However, efforts in our 
laboratory to phenotype test BG-11 ADR cell line and to further characterize it with 
regard to Pgp expression and its lack of cross-resistance to colchicine were met 
with several obstacles, principal of which were the failure to propagate the cells to 
critical density from cryopreserved stocks and inability of the cells to attach to the 
culture substratum due to cytostasis. 
2.4. Pretreatment of Cells with Tunicamycin 
Tunicamycin stock solutions were prepared by dissolving the contents of a 10-mg 
vial' in 25 mM NaOH and then diluting to 0.8 mg/ml TM and 10 mM NaOH with 
pyrogen-free distilled-deionized water. The solution was sterilized by passing 
through a 0.22-JLm disposable filter (Millipore, Millex-GV) and was stored at -
20°C for a maximum period of 3 weeks. Immediately before each experiment, the 
TM solution was diluted to a final concentration of 5 JLg/ml in culture medium. 
This concentration was chosen because it had little effect on cell viability, which 
remained greater than 95% between 4h and 72h exposure, as assessed by the trypan 
blue dye exclusion method (Shier, 1985; Shier, 1988). Cell viability in the 
presence of TM at this concentration was also found by more rigorous cytotoxicity 
assays (Figure 1) to exceed 90% for all the cell types studied. Tunicamycin was 
tested for its ability to enhance the cytotoxicity of doxorubicin (DOX), 
epidoxorubicin (EPX), vincristine (VCR), colchicine (COL) and cisplatin (CPL). 
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Cells were pretreated with TM for 16h prior to their exposure to the different 
drugs. To control cultures were added an equal volume of 10 mM NaOH (vehicle), 
the final concentration (62.5 J.tM) of which was confirmed not to affect the pH of 
the culture medium. 
2.5. In Vitro Cytotoxicity Assays 
To determine the effect of TM on the cytotoxicity of DOX, EPX, COL, VCR and 
CPL, preconfluent cells from stock cultures were detached with trypsin-EDTA 
(0.25%-0.02%, w/v) in PBS, washed twice with PBS and resuspended in complete 
culture medium to obtain single-cell suspensions. Cells were counted in an 
electronic particle counter (Coulter, Hialeah, FL, USA). Standardization of cell 
numbers in individual wells of a 96-well microtitre plate was confirmed by a linear 
correlation (r=0.97) between cell number and absorbance up to a maximum 
density of 3.5-4.5 x 104 cells/well (Twentyman, 1988). Cells were seeded at a 
density of 3 x 103 cells/well in a total volume of 200 J.tl as follows: After 
trypsinization, cells were rinsed twice with PBS, resuspended in 10 ml complete 
culture medium and repeatedly pipetted to ensure a homogeneous mixture during 
dispensing of 100-J.tl aliquot/well. The cells were then allowed to attach and grow 
for 48-72h. 
Cytotoxic drugs were dissolved in PBS and sterilized through 0.22-J.tm 
disposable filters. The drugs were diluted in culture medium free of phenol red 
(Modified Eagle's medium- or RPMI-1640-selectamine kit) to avoid interference 
with spectrophotometric assays (Denizot and Lang, 1986). After the addition of 
drugs at various concentrations to octuplicate wells, cells were incubated in the 
presence or absence of TM for a further 72h, unless stated otherwise in the text. 
The cytotoxicity of drug in the TM-treated and TM-free cultures was determined 
by spectrophotometry. For the methylene blue (MeBlue) microassay, the cells were 
fixed and stained with 0.5% MeBlue in 50% ethanol for 30 min at room 
temperature. Excess stain was removed by blotting inverted plates onto adsorbent 
paper and immersing them in distilled water (3-4 sequential washes). Plates were 
blotted as described above and air-dried. Stained cells were solubilized overnight in 
1% sarkosyl in PBS containing 0.001% sodium azide, 100 J.tllwell. 
Absorbances were read by a microplate reader (Titertek Multiskan model 
MCC/340) at a sample wavelength of 620 nm and a reference wavelength of 405 
nm (Finlay et al., 1984). For the MTT (3-4,5-dimethylthiazol-2,5-
diphenyltetrazolium bromide) assay (Mosman, 1983), 20 J.tl of MTT (5 mg/ml in 
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sterile PBS) were added to each well and the plates were incubated for 5h at 37°C. 
Plates were then centrifuged at 400 x g for 5 min to pellet any floating cell 
aggregates. The supernatant was aspirated and the formazan crystals dissolved in 
DMSO (200 J.tl/well). The plates were then gently agitated for 10 min and the 
absorbance read at a sample wavelength of 540 nm and a reference wavelength of 
630 nm on a microplate reader as described above for the MeBlue assay. 
For both assays the IC50 of the dose-response curve was defined as the 
drug concentration required to reduce the final absorbance to 50% of the control 
value. Dose-response curves were corrected for the decrease in absorbance caused 
by TM per se, which was always less than 10% of the control value. The potency 
ratio for each drug in the presence of TM was determined from the following 
relationship (Twentyman et al., 1990): 
IC50 of drug in absence of TM 
Potency Ratio 
IC50 of drug in presence of TM 
2.6. Data Analysis 
Dose-response curves were evaluated by the method of Litchfield and Wilcoxon 
(1948) using a computer-assisted program (PHARM/PCS) to determine IC50 
concentrations (Tallarida and Murray, 1987). The values are representative of the 
means ± S.E.M. of 3 experiments (n=8 for each experiment). Statistical analysis 
was performed onthe variables in this study using the Student's two-tailed t-test. 
The level of significance was set at p::;;O. 05. The significance of the potency ratio 
was obtained by computing either the 95% or 99% confidence interval using 
Fieller's ratio-of-means test (Fieller, 1944), as simplified by Bliss (1956) or by 
estimating confidence limits of the potency ratios using the method of Litchfield 
and Wilcoxon (1948), using the PHARM/PCS computer program as described by 
Tallarida and Murray (1987). 
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3. RESULTS 
The effects of TM on the viability of various drug-sensitive and drug-resistant cell 
lines following 72h continuous exposure to the antibiotic were compared (Figure 
1). In all the cell types, TM did not affect cell viability in the concentration range 
0.001-10 11g/ml and survival was consistently greater than 90% or similar to 
control (i.e., cells not treated with TM). Higher concentrations of the antibiotic 
(30-100 11g/ml) were necessary to achieve greater than 20% reduction in cell 
survival as measured by the MTT cytotoxicity assay. This decrease in cell survival 
was clearly concentration dependent. The consequence of TM pretreatment of cells 
for 16-72h was not toxic and completely reversible with time after its removal from 
the culture medium. Similar results were obtained with the MeBlue cytotoxicity 
assay (not shown). Accordingly, a TM concentration of 5 11g/ml and conditions 
under which cell viability remained unaffected were chosen to test the outcome of 
antibiotic treatment on the sensitivity of drug-sensitive and drug-resistant cells to 
various anticancer drugs. 
The effect of TM at 24h, 48h and 72h, respectively, on the dose-response 
relation for DOX in NIH-3T3-MDR cells is shown in Figure 2. The survival of 
these cells at any particular concentration of DOX was significantly decreased in 
the presence of TM, except at DOX concentrations of 5 11g/ml at 48h and 72h 
exposure (in the latter there is an inversion of this effect at doses of DOX in excess 
of 5 11g/ml). An enhancement of DOX cytotoxicity by TM was also observed for 
BG-1/ADR cells after 24h, 48h and 72h (Figure 3). The sensitivity of BG-1/ADR 
cells to VCR was unaffected by TM after 24h, but was increased consistently after 
48h and 72h with doses greater than 0.05 11glml. Vincristine alone had little effect 
on the survival of BG-11 ADR cells as judged by the survival curves for 24h, 48h 
and 72h. The effects of TM were transient since the cells consistently regained 
their original state of resistance to DOX and VCR within 24h of removal of TM 
from the culture medium (data not shown). 
For both NIH-3T3-MDR and BG-1/ADR cells, TM markedly lowered th~ 
IC50 for DOX at each of the indicated times when determined by the MTT assay 
(Table 1). When assessed by the MeBlue cytotoxicity assay, a similar reduction in 
IC50 was observed only after 24h and 48h in the case of BG-11 ADR but not for 
NIH-3T3-MDR after 48h and 72h (Table 1). This discrepancy between the MTT 
and MeBlue assays can probably be ascribed to differences in slopes of the dose-
response curves. This was not investigated further. 
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Figure 1. The effects of tunicamycin on the viability of various cell lines following 
72h continuous exposure to the antibiotic. Cells were treated with increasing 
concentrations of tunicamycin and viability measured by the MTT cytotoxicity 
assay as described in "Materials and Methods". Values are means ± S.E.M. of 
octuplicate cultures. 
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Figure 2. The effect of TM on the dose-response relation for DOX in NIH-3T3-
MDR cells. Cells were exposed for the indicated times to DOX alone or to DOX in 
the presence of TM after preincubation with the antibiotic. Cell viability was 
determined by the MTT cytotoxicity assay. Values are means ± S.E.M. for 3 
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Figure 3. The effect of TM on drug cytotoxicity in BG-11 ADR ovarian carcinoma 
cells. Cells were exposed for the indicated times to drug alone or to drug in the 
presence of TM after preincubation with the antibiotic. Cell viability was 
determined by the MTT cytotoxicity assay. Values are means ± S.E.M. for 3 
experiments (n=8 for each experiment). 
Table 1. Comparison of the MTT and MeBlue Cytotoxicity Assays for Evaluating the Effects of TM on the Sensitivity of BG-11 ADR and 
NIH-3T3-MDR Cells to DOX In Vitro 
Mean IC50 ± S.E.M.(-TM) Mean IC50 ± S.E.M.( +TM) 
Tirne(h) Cell Line MTT MeBlue MTT · MeBlue 
BG-1/ADR 16.0±3.20 11.4± 1.50 4.80± 1.44C 0.70±0.142a 
24 
NIH-3T3-MDR 2.72±0.56 ND 0.25±0.06a ND 
BG-1/ADR 0.98±0.26 6.15± 1.02 0.03±0.01b 0.52±0.22a 
48 
NIH-3T3-MDR 2.51±0.60 1.67±0.80 0.20±0.003b 0.03±0.015d 1 
BG-1/ADR 0.59±0.10 2.07± 1.03 0.04±0.005a 0.01 ±0.006d 
72 
NIH-3T3-MDR 1.62±0.05 1.05±0.49 0.20±0.09a 0.02±0.0td 
Mean 1c50 values in p.g/ml; S.E.M. standard error of the mean for 3 experiments (n=8 for each experiment); _ND not determined; _a-csignificantly different from the value 













Survival curves for UWOV2 cells treated with different drugs in the 
presence or absence of TM are presented in Figure 4. Tunicamycin potentiated the 
cytotoxicity of DOX, VCR, COL, CPL, and EPX. Pretreatment of cells with TM 
effectively decreased the IC50 for DOX, VCR, COL and CPL, but not for EPX 
(Figure 5). 
Table 2 summarizes data on the time dependence of the effects of TM on 
the sensitivity of NIH-3T3-P and NIH-3T3-MDR cells to COL. Tunicamycin did 
not cause any change in the cytotoxicity of COL in both cell lines after 24 and 48h, 
but significantly augmented the cytotoxicity of the drug in NIH-3T3-MDR cells 
after 72h. The IC50 values for DOX separately or in combination with TM for each 
of the cell lines studied are presented in Table 3. Tunicamycin lowered the IC50 for 
DOX in NIH-3T3-parental and -MDR cells at 24h, 48h and 72h. In the presence of 
TM, the response of NIH-3T3-MDR cells to DOX after 48h and 72h approximated 
closely that of its parental line treated with the drug alone. This was also noted in 
the BG-1/ADR cells after 48h and 72h. In contrast, the KB-8-5-11 cells retained a 
DOX-sensitivity pattern that was significantly less than its parental line. 
The potency ratios for DOX were consistently higher in drug-resistant cells 
than in the corresponding parental cells (Table 4). This could not be tested in the 
case of UWOV2 cells for which no equivalent parental cell line exists. The effects 
of TM on the sensitivity of the same cell lines to other anticancer drugs are 
presented in Table 5. Sensitization of NIH-3T3-MDR cells to COL, VCR, EPX 
and CPL by TM was substantially greater compared with their parental cells. 
Tunicamycin failed to increase the sensitivity of NIH-3T3-parental cells to these 
drugs. Similarly, responsiveness was greater to COL and VCR in BG-1/ADR 
relative to its parental line, and to COL in KB-8-5-11 cells as opposed to their 
parental cells. Tunicamycin did not enhance the sensitivity of KB-3-1 cells to COL. 
I 
The enhancing effect of TM on the toxicity of CPL, a drug that is thought not to 
belong to the same pharmacological class of MDR-related drugs (see section 3.4, 
Chapterl), in UWOV2 and NIH-3T3-MDR cells implies a mechanism which does 
not at all involve Pgp. This was not resolved in this study. 
4. DISCUSSION 
Chemosensitizers may represent an important advance in overcoming MDR in 
cancer chemotherapy (Georges et al., 1990b; Pearce et al., 1990; Hait and Aftab, 
1992). However, the application of such agents in clinical medicine is limited by 
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Figure 4 .. The effects of TM on drug cytotoxicity in UWOV2 ovarian carcinoma 
cells. Cells were exposed to drug alone (open circles) or to drug in the presence of 
TM (solid circles). A, DOX; B, VCR; C, COL; D, CPL; E, EPX. Cell viability 
was determined by the MTT cytotoxicity assay. Values are means ± S.E.M. for 3 
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Figure 5. The effects of TM pretreatment on the IC50 of various drugs in 
UWOV2 ovarian carcinoma cells after 72h of exposure to the drug alone or in 
combination with the antibiotic. DOX, doxorubicin; EPX, epidoxorubicin; 
VCR, vincristine; COL, colchicine; CPL, cisplatin. Data represent the means 
± S.E.M. for 3 experiments (n=8 for each experiment). *p<O.OOl; 
**p < 0.005; ***not significant. 
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Table 2. Time-Dependence of the Effects of TM on the Sensitivity of NIH-3T3-Parental Cells and NIH-3T3-MDR Cells to COL Measured 
by the MTT Cytotoxicity Assay 







Mean IC501 (95% Confidence Intervai2) 
Control 
11.00 (7.06 to 17.16) 
32.12 (2.51 to 410.33) 
10.07 (1.49 to 68.07) 
26.53 (1.21 to 583.56) 
3.39 (2.14 to 5.37) 
31.81 (16.16 to 62.63) 
i 
TM-treated 
3.05 (0.46 to 20.33) 
6.22 (0.21 to 183.03) 
1.20 (0.16 to 9.03) 
1.85 (0.12 to 29.67) 
1.20 (0.09 to 16.38) 
0.51 (0.05 to 4.83) 
Potency Ratio (95% 
Confidence Interval) 
3.60 (0.51 to 25.26)a 
5.16 (0.08 to 356)a 
8.37 (0.52 to 134.6)a 
14.35 (1.23 to 914)a 
2.82 (0.19 to 40.1)a 
62.4 (5.96 to 652)b 












Table 3. The Effects of Tunicamycin on the Sensitivity* of Various Parental and Drug-Resistant Cell Lines to DOX 
Mean IC50 ± S.E.M.(J.tg/ml) 
24h 48h 72h 
Cell line Control TM-treated Control TM-treated Control TM-treated 
NIH-3T3-P 1.20±0.30 0.33±0.09d 0.31 ±0.05 0.13±0.01b 0.33±0.05 0.12±0.02b 
NIH-3T3-MDR 2.72±0.56 0.25±0.06a 2.51 ±0.60 0.20±0.003b 1.63±0.05 0.20±0.09a 
KB-3-1 ND ND NO ND 0.12±0.01 0.29±0.Q2f 
KB-8-5-11 NO ND NO ND 5.58±0.22 0.92±0.o5a 
BG-1-P 0.99±0.16 0.42±0.17e 0.22±0.02 0.04±0.0Q5d 0.01 ±0.003 o.o2±o.oo4f I 
BG-1/AOR 16.0±3.20 4.76± 1.44C 0.98±0.26 0.03±0.01h 0.59±0.10 0.04±0.005a I 
UWOV2 ND ND NO ND 2.24±0.52 0.03±0.004a I 
P, parental; MDR, multidrug-resistant; S.E.M., standard error of the mean for 3 experiments (n = 8 for each experiment; ND, not determined; _ a-esignificantly different from 












































Potency ratios were calculated from the data presented in Table 3.-*assessed by the MTT assay; _ND, not determined; _a99% CI; _b95% Cl; _cp<O.OOl; 



















2.82 (0.19 to 40.1)d 
62.4 (5.96 to 652)c 
0.44 (0.36 to 0.52)d 
366 (358 to 374)a 
0.96 (0.63 to 1.29)d 
149 (145.4 to 152.6)a 
1.82 (1.24 to 2.40)a 
Potency Ratio (95% Confidence Interval) 
Vincristine 
1.48 (1.43 to 5.07)d 
95.2 (17 .04 to 532)c 
ND 
ND 
16.4 (12.19 to 20.61)a 
541 (537 to 545)a 
25.0 (22.7 to 27.3)c 
Epidoxorubicin 
0.81 (0.16 to 4.20)d 





41.1 (40.05 to 42.15)d 
Cisplatin 
1.07 (0.35 to 3.25)d 
















-*Assessed by the MTT assay; _ND, not determined; _a-csignificantly different from cells treated with the drug alone:_ ~<0.001; _bp<O.Ot; _cp<0.05; _dnot significant. \ g 
Discussion 91 
their mechanisms of action and metabolic effects. The MDR phenotype 
characteristically manifests itself by overexpression of Pgp in a manner analogous 
to the expression of aberrant glycoproteins or glycolipids in transformed cells 
(Hakomori, 1985; Dennis and Laferte, 1987; Holzmann et al., 1988). Biochemical 
characterization of the role of N-glycosylation of Pgp should be useful in 
delineating the resistance mechanisms of MDR cell lines. 
The effects of TM have been studied in various biological systems, 
primarily with the aim of elucidating the role of the carbohydrate moieties in the 
cellular function of glycoproteins. It has been suggested that TM may be selectively 
more toxic to transformed cells than to non-transformed cells, and thus 
therapeutically useful as an antitumour agent effective against certain malignant 
cells while sparing normal cells (Olden et al., 1979b). In agreement with this view, 
Eren and Duksin (1985) have shown that a purified homologue of TM (B2-
tunicamycin) caused greater inhibition of sugar incorporation into glycoproteins in 
transformed cells than in wild-type ceJls. However, Brysk et al. (1986) observed a 
contrary pattern with two mouse epidermal cell lines; the malignant cells were 
more resistant to TM than their non-malignant counterparts, as measured by 
growth and viability. Such enhanced cytotoxicity may be due to differences in 
penetration of TM into cells, inhibition by TM of the synthesis of glycoproteins, of 
their insertion into the plasma membrane or their secretion, or of metabolic 
processes which may be essential for the altered phenotype (Duksin and Bornstein, 
1977; Eren and Duksin 1985). 
Recently, Engstrom and Larsson (1988) found that the TM-induced 
inhibitory effect on in vitro cell proliferation of transformed cell lines was cell 
cycle-specific since only cells in G 1 phase were blocked in their cell-cycle 
progression. Moreover, they found that TM suppressed the activity of 3-hydroxy-3-
methylglutaryl coenzyme-A reductase (HMG-CoA), which constitutes the rate-
limiting step in the biosynthesis of cholesterol and isoprenoid derivatives, by 
catalysing the reduction of HMG-CoA to mevalonate, and it has been suggested 
that it plays a role in the control of cell proliferation and in tumour transformation 
(Larsson and Engstrom, 1989). This raises the possibility that TM exerts its 
inhibitory effects on cell proliferation via the isoprene-synthetic pathway along 
with its effects on aspargine-linked glycosylation (Kabakoff et al., 1990; Langan 
and Slater, 1991). These pathways may have clinical ramifications for the 
expression of drug resistance which can occur during tumour development. We.did 
not correlate the enhancing effects of TM on the cytotoxicity of various drugs with 
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cell-cycle changes, but applied the criterion most often used in cytotoxicity assays, 
viz., the investigation of cells in exponential phase of the growth cycle. 
The results of this study indicate that TM augments the susceptibility to 
various anticancer agents in drug-resistant cell lines to a greater extent than in their 
respective parental cells. The extent of the potentiation of anticancer drug action by 
TM differed in the various cell lines that have been studied. We did not explore the 
nature of this differential sensitization, but the consistent pattern of increased drug 
cytotoxicity that was observed in all drug-resistant cell lines suggests a common 
mechanism of reversal of drug resistance. The differences between the cell lines 
can perhaps be attributed to variation in cross-resistance to the anticancer drugs 
which, in turn, is determined by dissimilarities in genetic regulation and 
biochemical mechanisms involved in the protection of cells against cytotoxic agents 
(Felsted et al., 1985; Capranico et al., 1989; Lehrman and Zeng, 1989). It is 
interesting also that resistance to TM in Chinese ovary cells is associated with gene 
amplification (Waldman et al., 1987; Scocca et al., 1988; Zhu et al., 1992) 
comparable to that occurring MDR cells (Chao et al., 1991; Roninson, 1992a; 
Stahl et al., 1992), which may be considered in studies related to TM. 
An important concern was whether any cumulative cytotoxicity of TM 
might have influenced the results described in this chapter. However, cytotoxicity 
solely attributable to TM was taken into account, and the dose-reponse curves were 
corrected accordingly. Tunicamycin at a concentration of 5 J.tg/ml did not 
significantly affect cell viability in the various cell lines. Protein and glycoprotein 
synthesis are perturbed to varying degrees by TM in different cell lines (Irimura et 
al., 1981; Elbein, 1987; Barathan et al., 1990). We found that TM, at a 
concentration of 5~-tg/ml, simultaneously impaired glycoprotein and protein 
synthesis in the cell lines studied, as assessed respectively by [3H]glucosamine or 
[3H]mannose and [35S]methionine or [14C]leucine incorporation (data not 
presented, see Chapter 2 for results). 
We did not compare the TM-induced increase in susceptibility of MDR 
cells to cytotoxic drugs with the effect of TM on the precise glycosylation of Pgp. 
We have assumed that the TM effect is based on the known action of the antibiotic 
on Pgp (Greenberger et al., 1987; Richert et al., 1988; Yoshimura et al., 1989). 
Tunicamycin has been shown to inhibit N-glycosylation of Pgp in drug-resistant 
cells, but this inhibition did not abolish resistance in these cells (Beck and Cirtain, 
1982). Similarly, a glycosylation mutant of drug-resistant CHRC5 cells has been 
reported to retain its drug-resistance attributes (Ling et al., 1983), suggesting that 
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the oligosaccharide chains of Pgp are probably not involved in the expression of 
drug resistance. These findings do not necessarily contradict our own results since 
we found that the effect of TM is reversible. Such discrepancies may also be 
explained by differences in the methods used. The fact that not all glycoproteins 
become unstable or non-functional in the unglycosylated form (Elbein, 1984; 
Elbein, 1987) suggests that Pgp may be synthesized at normal rates, although 
deficient in carbohydrate, but still sustain its biological activity in MDR (Chou and 
Kessel, 1981). Differential glycosylation of the mdr1 gene product (Greenberger et 
al., 1989) and the biosynthesis of heterogeneous forms of MDR-associated 
glycoproteins in various cell lines (Greenberger et al., 1988a; Greenberger et al., 
1988b; Meyers et al., 1989) indicate that complex genetic regulation may 
determine cell sensitivity to cytotoxic drugs. 
The principal finding reported in this chapter is that TM augments the 
cytotoxicity of different anticancer drugs in MDR cells. This enhancement of 
cytotoxicity may be due to a mechanism which probably involves impairment of 
(glyco)protein function. Tunicamycin treatment of NIH-3T3-MDR cells and 
UWOV2 cells resulted in a significant increase in the sensitivity of these cells to 
CPL. It is commonly held that CPL does not belong to drugs in the MDR class 
(e.g., VBL, DOX, COL, VCR and ActD) and that the mechanism of resistance to 
CPL differs from that of MDR (Futscher et al., 1992; Kimiya et al., 1992; Misawa 
et al., 1992). However, recent observations by Yang et al. (1993) ·that Pgp-
mediated MDR and CPL resistance phenotypes may coexist in cells with primary 
resistance to CPL complicate the issue. Therefore, an understanding of the precise 
relationship between the potentiating effect of TM on CPL toxicity must await 
clarification of the action TM on Pgp-mediated drug resistance. Our findings do 
not directly demonstrate that the modulating effects of TM on drug cytotoxicity are 
mediated by inhibition of Pgp, but they do establish that TM is a biological 
response modifier in MDR. Further research based on the knowledge that has been 
acquired in this study should allow the development of strategies to overcome 
MDR. 
5. SUMMARY AND CONCLUSIONS 
The responses of the drug-sensitive (BG-1-P and KB-3-1) and drug-resistant 
(UWOV2, BG-1/ADR, KB-8-5-11) human tumour cell lines, and of the murine 
fibroblast parental (NIH-3T3-parental) cell line and its drug-resistant transfectant 
(NIH-3T3-MDR) to various anticancer drugs in the presence or absence of 
tunicamycin (TM) have been investigated. Tunicamycin alone at a concentration of 
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5 JLglml did not exert any toxic effects on the different cell lines as measured by the 
MTT viability assay. However, pretreatment of cells with 5 JLglml TM for 16h and 
its combination with doxorubicin, epidoxorubicin, colchicine, vincristine and 
cisplatin significantly increased the cytotoxicity of these drugs in a time-dependent 
manner in drug-resistant cells to a greater extent than in the respective drug-
sensitive (parental) cells. This effect of TM on the cytotoxicity of the various 
agents studied suggests a common mechanism of reversal of drug resistance by this 
agent. In the NIH-3T3-MDR, KB-8-5-11, and BG-1/ADR cell lines drug sensitivity 
patterns developed in the presence of TM that corresponded to those in the parental 
cell lines. The effect of TM was reversible upon its removal from the culture media 
as the cells regained their original degree of drug resistance within 24h. 
Tunicamycin inhibited both protein and glycoprotein synthesis in the cell lines 
studied. The effect of the antibiotic on drug-resistant cells, in general, may be 
explained by this action. 
,_ 
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CHAPTER 4 
THE EFFECTS OF TuNICAMYCIN ON THE UPTAKE, 
EFFLUX AND RETENTION OF VINCRISTINE IN VARIOUS 
MULTIDRUG-RESISTANT CELL LINES 
1. INTRODUCTION 
Human tumour cell lines that have developed pleiotropic drug resistance often 
express increased levels of P-glycoprotein, a product of the mdr1 gene, compared 
with their drug-sensitive or related normal cells (Gerlach et al., 1986b; Endicott 
and Ling, 1989; .Schinkel and Borst, 1991). P-glycoprotein functions as an energy 
(ATP)-dependent drug efflux pump (Gerlach et al., 1986a; Hamada and Tsuruo, 
1988; Sarkadi et al., 1992) which protects cells against a broad spectrum of 
cytotoxic agents. The extent of penetration into and accumulation and retention 
within tumour cells of anticancer drugs is an important determinant of their 
cytotoxicity (Jamali et al., 1989; Nooter et al., 1990; Nakagawa et al., 1992), 
although this may not always be the case (Kato et al., 1991). Multidrug-resistant 
(MDR) cells accumulate less anticancer drug than their parental counterparts (Fojo 
et al., 1985; Lemontt et al., 1988; Keizer et al., 1989), presumably as a result of 
active efflux mediated by P-glycoprotein (Inaba et al., 1987; Spoelstra et al., 1991; 
Dordal et al., 1992). 
Major advances have been made in understanding the role of the plasma 
membrane in multidrug resistance, drug transport, development and disease 
(D'Incalci et al., 1991; Daoud, 1992; Jandrig and Wunderlich, 1992). P-
glycoprotein may be strategically positioned at the cell surface to mediate a 
complex array of interactions between the cell and its external and internal 
environments. P-glycoprotein is modified post-translationally by N-glycosylation 
(Ichikawa et al., 1991a). Oligosaccharides form an integral structural component of 
glycoproteins, and as such may affect many of their properties, such as cell-cell 
and cell-molecule recognition events (Varki, 1993). Moreover, proteolytic 
succeptibility, specific bioactivity, immunogenicity, half-life and physical 
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properties in general can all be influenced by glycosylation (Yamaguchi et al., 
1991; Dennis, 1992; Rudd, 1993). Glycoprotein processing inhibitors may 
therefore be valuable in establishing whether or not the actions of P-glycoprotein 
are regulated by glycosylation and if such modification can be applied usefully to 
overcome MDR. 
The aim of this study was to determine whether suppression of 
glycoprotein synthesis with tunicamycin, a specific inhibitor of protein N-
glycosylation (Elbein, 1987), would alter the capacity of various drug-sensitive and 
drug-resistant cells to transport and retain radiolabelled VCR. The effects of TM 
on doxorubicin and azidopine binding to intact UWOV2 cells was also investigated 
in an attempt to explain drug-resistance in these cells. In addition, azidopine, a 
photoactivated dihydropyridine calcium channel blocker known to interact with Pgp 
(Kamiwatari et al., 1989; Tarnai and Safa, 1991; Safa, 1992), was assayed for its 
ability to compete for doxorubicin binding to UWOV2 cells. 
2. MATERIALS AND METHODS 
2.1. Drugs and Chemicals 
Colchicine (Sigma Chemical Co., St. Louis, MO, USA), trypsin 1:250 (Difco 
Laboratories, Detroit, Ml, USA), phosphate-buffered saline [PBS] (Oxoid, UK), 
tissue culture media and antibiotics (Gibco, UK), tunicamycin [TM] (Boehringer 
Mannheim, Germany), ethylene-diamine tetra-acetic acid disodium salt [EDTA], 
trichloroacetic acid (Merck Chemicals, G~rmany), radiochemicals (Amersham, 
UK), were obtatained from the sources indicated in parentheses. All other 
chemicals were of analytical grade. 
2.2. Cell lines and Culture Conditions 
Multidrug-resistant KB-8-5-11 cells and drug-sensitive KB-3-1 human epidermoid 
carcinoma cells were obtained from Professor M.M. Gottesman, National Cancer 
Institute, Bethesda, MD, USA. The KB-8-5-11 cell line was selected as a 
colchicine-resistant subclone from the parent KB-3-1 cell line, and it contains the 
amplified mdr1 gene encoding Pgp (Akiyama, et al., 1985; Fojo, et al., 1985; 
Shen et al., 1986a; Shen et al., 1986b; Shen et al., 1986c; Choi, et al., 1988). 
NIH-3T3 murine fibroblasts and NIH-3T3-MDR cells (derived from NIH-
3T3-parental cells transfected with the retroviral expression vector, pHaMDR1, 
containing a full-length eDNA from the human mdr1 gene (Shen et al., 1986c; 
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Ueda, et al., 1987) were also provided by Professor M.M. Gottesman. The drug-
sensitive LR73 Chinese hamster cell line and its mdr1-transfectant, LR73-1A, were 
a gift from P. Gros (McGill University, Montreal, Canada). 
The human ovarian carcinoma cell line, UWOV2, was derived from an 
ovarian cystadenocarcinoma in a patient who had not responded to combined 
chemotherapy with actinomycin D, vincristine, cisplatin and doxorubicin 
(Golombick et al., 1990), and thus represents a cell line with drug resistance 
acquired in vivo. The UWOV2 cells were obtained from Professor W.R. Bezwoda 
(University of the Witwatersrand, South Africa). 
All cell lines were grown as adherent monolayers at 37°C in 5% C02:air, 
relative humidity close to saturation under the following conditions: UWOV2 cells, 
in RPMI-1640 medium supplemented with 5% heat-inactivated fetal bovine serum 
(HIFBS), penicillin (100 units/ml), streptomycin (100 J.tg/ml) and/or gentamicin (50 
f.lg/ml); KB-3-1 and NIH-3T3-parental cells, in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% HIFBS and antibiotics as above 
(complete DMEM); KB-5-8-11 and NIH-3T3-MDR cells, in complete DMEM with 
addition of 1 J.tg/ml colchicine; LR73 cells in a-MEM containing ribo- and 
deoxyribonucleotides, 10% HIFBS, 2 mM L-glutamine and antibiotics and LR73-
1A medium as for LR73, but supplemented with 100 ng/ml of adriamycin or 
colchicine. The cells were subcultured by brief exposure to trypsin-EDTA (0.25-
0.02%) in Ca2 +- and Mg2 + -free PBS and maintained in the exponential phase of 
growth. Cell lines were regularly tested using the method described by Chen 
(1977) and found to be free of mycoplasma contamination. 
2.3. Treatment of Cells with Tunicamycin 
~unicamycin (TM) was solubilized in 10 mM NaOH at a concentration of 2 mg/ml, 
sterilized by passing through a 0.22-J.tm disposable filter (Millipore, Millex-GV) 
and either used immediately or stored at -20°C for not more than 2 weeks. Before 
each experiment, the TM solution was diluted in culture medium. Cells were pre-
incubated at 37°C for 16h in medium containing TM (5 J.tg/ml, unless stated 
otherwise). Untreated cells (controls) received an equivalent amount of TM-
vehicle, viz., NaOH (final concentration 62.5 JLM, which did not affect the pH of 
the medium). TM was tested by the trypan blue dye-exclusion procedure described 
previously (Shier, 1985; Shier, 1988) and confirmed not to affect cell viability 
( > 95%) between 4h and 72h exposure. 
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2.4. Assay of Vincristine Uptake and Efflux 
To assay vincristine (VCR) uptake and efflux, cells were seeded at a density of 
5x104 cells/ml in 24-well plates and allowed to grow for 48h under standard 
conditions. Cells were pretreated with 5 11glml TM as described in section 3.3 
above. Parallel controls were set up. Total cellular accumulation of VCR was 
determined by exposing cells in quadruplicate wells to [G-3H]VCR sulphate (final 
specific activity 9.48 cpm/pmol in the case of UWOV2 cells, NIH-3T3-parental 
and NIH-3T3-MDR cells; and 7.74 cpm/fmol in the case of KB-3-1 and KB-8-5-11 
cells) in the continued absence or presence of TM in a final volume of 0.5 ml for 
various incubation times. 
At the end of each incubation period, cells were washed three times with 1 
ml ice-cold PBS and solubilized in 0.5 ml of 1% sodium dodecyl sulphate 
(SDS)/0.3M NaOH. One aliquot (0.4 ml) was neutralized by the addition of 0.2 ml 
of 2M acetic acid and mixed with 10 ml scintillation fluid (Beckman Ready-Solv 
EP™) and counted in a Beckman scintillation spectrometer. Intracellular drug at 
each time point was determined by subtracting the value for non-specific/surface-
bound drug obtained by incubation with 100 11M unlabelled VCR for lOs at 0-4 oc 
from the value for total drug. The other aliquot (0.1 ml) was assayed for total 
cellular protein. 
Vincristine efflux was measured by loading control and TM-pretreated cells 
with [3H]VCR for 60 min (0-time value for efflux) followed by washing preloaded 
cells three times with ice-cold PBS and subsequently incubating at 37oc in serum-
and antibiotic-free medium (2ml) for v'arious time intervals. The absence or 
presence of TM was maintained throughout the post-incubation periods. Cells were 
harvested as described for uptake studies. To measure VCR efflux rate, KB-8-5-11 
cells were seeded at a density of 2x106 cells/ml in quadruplicate 35-mm dishes. 
Cells were pre-incubated at 37°C for 16h in the absence or presence of TM 
(concentration range 0.005 - 5 11g/ml) in serum- and antibiotic-free medium. The 
cells were then washed free of medium and pre-exposed to VCR (final specific 
activity 667 dpm/pmol) in fresh serum- and antibiotic-free medium with or without 
TM for 60-min. 
The cells were then washed three times in cold PBS and exposed to drug-
free medium with or without TM. At 5-min intervals after the 60-min pre-exposure 
period, cells were washed three times with ice-cold PBS and solubilized in 1 ml 
1% SDS/0.3M NaOH. One aliquot (0.5ml) was mixed with 10 ml scintillation fluid 
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and counted. Another aliquot (0.1ml) was used for protein determination. A large 
volume ratio (i.e., preloading volume/postincubation volume of 4) was maintained 
during efflux measurements to minimize reutilization of extruded drug (Sirotnak et 
al., 1986). 
2.5. Binding of [3H]Azidopine and [14C]Doxorubicin to UWOV2 Cells 
The binding of [3H]azidopine to UWOV2 ovarian carcinoma cells was measured by 
a modification of the procedure described by Tarnai and Safa (1991). UWOV2 cells 
were seeded at a density of 5 X 104/ml in 24-well plates and allowed to reach 
confluence. The cell mono layers were cooled to 4 oc (by placing the plates on ice 
for 10 min) and washed four times with 1 ml cold phosphate-buffered saline (PBS), 
pH 7.4 (to remove serum glycoproteins) and maintained for 60 min at 4 oc with 
binding buffer (10 mM glucose, 3 mM ATP and 5 mM MgC12 in 10 mM Tris-HCl, 
pH 7 .4) containing various concentrations of [3H]azidopine or [14C]doxorubicin, or 
both. Following this incubation period, the cells were washed five times with cold 
PBS to remove unbound [3H]azidopine and [14C]doxorubicin. Cells were 
solubilized with 0.1 M NaOH and samples were counted to determine the amount 
of azidopine or doxorubicin bound to the cells, and aliquots were removed for 
protein determination. Specific binding was distinguished from non-specific 
binding to the cells and plastic wells by dilution with a large excess (100 JLM) of 
unlabelled drug. To examine whether doxorubicin competes for azidopine binding 
sites, UWOV2 cells were exposed to equimolar concentrations of both compounds 
and the specific binding of azidopine determined as described above. 
2.6. Protein Estimation 
Total cellular protein was determined by the automated Bio-Rad™ dye-binding 
microassay system described by Bradford (1976) using bovine serum albumin as a· 
standard. 
2.6. Data Analysis 
The p-values for the differences in the variables obtained in this study as well as 
for the comparison of VCR retention in the presence or absence of TM were 
calculated using the two-sided Student's t-test computer program in GraphPad™ 
INSTA T©. The increase in VCR retention induced by TM and the associated 95% 
confidence interval (95% CI) were determined by Fieller's ratio-of-means test 
(Fieller, 1944) as modified by Bliss (1956), using a computer-assisted program 
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(Tallarida and Murray, 1987). The rates of VCR efflux from KB-8-5-11 cells were 
determined from the slopes of the linear portion of efflux curves over the first 20 
minutes. 
3. RESULTS 
Uptake and efflux curves for the human epidermoid carcinoma KB-3-1 parental cell 
line and its multidrug-resistant derivative, KB-8-5-11, are shown in Figure 1. 
Uptake of VCR by KB-3-1 cells was unaffected by the presence of TM (Figure 
1A), but efflux was increased for the 60- 80- and 100-min post-incubation periods 
(Figure 1C). Tunicamycin failed to alter the uptake of VCR by KB-8-5-11 cells, 
except at 120 min when a significant decrease (p =0.0143) in intracellular VCR 
was noted in TM-treated cells (Figure lB). The rapid efflux of VCR was 
significantly impaired in KB-8-5-11 cells following pretreatment and co-incubation 
with TM (Figure 1D). 
The effects of TM on the uptake and efflux of VCR in cultures of NIH-
3T3-parental and NIH-3T3-MDR cells are shown in Figure 2. Pretreatment of 
NIH-3T3-parental cells with TM did not significantly modify their ability to 
accumulate VCR (Figure 2A). In NIH-3T3-MDR cells, TM treatment had no effect 
on the level of VCR accumulation (Figure 2B). NIH-3T3-MDR cells also 
accumulated less drug than their parental or drug-sensitve counterparts. In both cell 
lines, uptake displays a consistent biphasic course with a rapid initial component 
and a subsequent linear component (the drug-cell system reaches a steady state 
within 20-30 min). Efflux curves for NIH-3T3-parental and NIH-3T3-MDR cells 
are depicted in Figure 2C and Figure 2D, respectively. The efflux of VCR from 
NIH-3T3-parental cells was not affected by tunicamycin (Figure 2C). By contrast, 
VCR efflux was significantly reduced (p <0.05 at all post-incubation times) when 
mdr1-transfected NIH-3T3 cells (NIH-3T3-MDR) were treated with TM (Figure 
2D). It is noteworthy that the NIH-3T3-MDR cell line contained significantly less 
VCR after an initial 1-hour pre-exposure period when compared to its parental cell 
line (Figure 2C and Figure 2D). This observation further supports the idea that 
MDR, as expressed in NIH-3T3-MDR cells, is associated with decreased 
intracellular accumulation of drug. 
Exposure of drug-sensitive LR73 cells to TM significantly enhanced the 
accumulation of VCR at incubation periods of 15, 30, 75 and 90 min, but not at 45 
and 60 min (Figure 3A). In drug-resistant LR73-1A cells, TM augmented the 
intracellular accumulation of VCR at all the times that are indicated (Figure 3B). 
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Figure 1. Time course of vincristine uptake (A, B) and efflux (C, D) in drug-
sensitive KB-3-1 (A, C) and multidrug-resistant KB-8-5-11 cells (B, D) cultured in 
the absence or presence of tunicamycin following prior exposure to the antibiotic 
for 16h. Values are means ± S.E.M.(n=4). Where error bars do not overlap, 
Student's two-tailed p values are less than 0.05 (not shown). 
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Figure 2. Time course of vincristine uptake (A, B) and efflux (C, D) in NIH-3T3-
parental (A, C) and NIH-3T3-MDR cells (B, D) cultured in the absence or 
presence of tunicamycin following a 16h TM pretreatment. Details are described in 
the legend to Figure 1. Error bars are shown on the figure when larger than the 
plot symbols. 
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Figure 3. Effects of tunicamycin on vincristine accumulation in drug-sensitive 
LR73 (A) and drug-resistant LR73-1A (B) cells at various time intervals following 
an initial 16-h pretreatment with the antibiotic. Data represent the means ± 
S.E.M.(n=4). Student's two-tailed p values are indicated within bars. 
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As in the case of NIH-3T3-MDR cells, the LR73-1A cells accumulated 
significantly less VCR than the parental LR73 cells, but only at 75 and 90 min 
(Figure 4A). Following pretreatment with TM, LR73-1A cells accumulated VCR in 
amounts approximating those in untreated LR73 cells (Figures 4A and 4B). 
Tunicamycin had no effect on the uptake of VCR by UWOV2 ovarian carcinoma 
cells (Figures SA), but VCR efflux from these cells was significantly inhibited 
(p <0.05) at post-incubation times 60-180 min (Figures 5B). 
Figures 6 and 7 summarize data (obtained in separate experiments similar 
to those described for the efflux studies) on the retention of VCR in various drug-
sensitive and drug-resistant cell lines in response to TM treatment. TM increased 
the retention of VCR in KB-8-5-11 cells, in NIH-3T3-MDR cells (at post-drug-
loading periods of 40, 60 and 80 min), in LR73-1A cells at post-drug-loading 
periods of 40, 80 and 100 min (marginally significant), but not so at 20 and 60 min 
(Figure 6), and in UWOV2 cells at post-incubation times 60, 80 and 100 min 
(Figure 7), but not in NIH-3T3-parental and LR73 (Figure 6) cells. By contrast, 
KB-3-1 cells expressed a decreased VCR retention at. 40-, 60- and 80-min post-
incubation periods (Figure 6). Tunicamycin induced the greatest increase in VCR 
retention at all the times studied in KB-8-5-11 cells (2. 78- to 4.29-fold) compared 
with NIH-3T3-MDR and LR73-1A cells (Table 1). 
In order to determine whether the increased VCR retention induced by TM 
is associated with altered VCR efflux and inhibition of glycoprotein synthesis, KB-
8-5-11 cells were exposed to various concentrations of TM and the changes were 
measured. The effects of TM concentrations over the range 0.005 - 5 p,g/ml on 
glycoprotein synthesis as reflected by [3H]glucosamine incorporation as a 
percentage of the control and on the rate of VCR efflux from KB-8-5-11 cells are 
shown in Table 2. When these cells were treated with TM, a considerably reduced 
efflux rate was induced at all concentrations of TM compared with the controls. 
This decreased VCR efflux did not correlate with the inhibition of glycoprotein 
synthesis as measured by the incorporation of [3H]glucosamine. Tunicamycin at 
concentrations of 0.005 and 0.05 p,g/ml did not affect glycoprotein synthesis, but 
markedly inhibited VCR efflux. Although the inhibition of glycoprotein synthesis 
was increased to 43% and 81% at TM concentrations of 0.5 and 5 p,g/ml, 
respectively, the inhibition of VCR efflux remained constant at 70% for these TM 
concentrations. 
The MDR status of UWOV2 ovarian carcinoma cells was confirmed, in 
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Figure 4. Comparison of vincristine accumulation by LR73 and LR73-1A cells 
cultured in the absence (A) or presence (B) of tunicamycin. Values are means ± 
S.E.M.(n=4). Student's two-tailed p values are presented within bars. 
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Figure 5. Time course of vincristine uptake (A) and efflux (B) in human UWOV2 
ovarian carcinoma cells cultured in the absence or presence of tunicamycin 
following prior exposure to the antibiotic for 16h. Values are means ± 
S.E.M.(n=4). 
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Figure 6. Comparison of the effects of tunicamycin on the retention of vincristine 
in various drug-sensitive and drug-resistant cell lines at different time intervals 
after a 1-hr preloading period with the drug and subsequent exposure to drug-free 
medium. Values are means ± S.E.M.(n=4). Student's two-tailed p values are 
presented within bars. 
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Figure 7. Effects of tunicamycin on the retention of vincristine in drug-resistant 
UWOV2 human ovarian carcinoma cells at different time intervals after a 1-hr pre-
loading period with the drug and subsequent exposure to drug-free medium. Values 
are means ± S.E.M.(n=4). Student's two-tailed p values are presented within 
bars. 
Table 1. Fold Increase in Vincristine Retention in Various Multidrug-Resistant Cell Lines Following Exposure to Tunicamycin 
KB-8-5-11 NIH-3T3-MDR LR73-1A 
Time (min) Fold FR1 95% CI2 Fold FR 95% CI Fold FR 95% CI 
20 2.78 1.74 to 5.86 1.11 0.93 to 1.32 1.18 0.92 to 1.52 
40 3.63 2.55 to 6.06 1.64 1.42 to 1.93 1.78 0.83to 5.74 
60 4.29 3.19 to 6.46 1.88 1.70 to 2.08 1.63 1.14 to 2.47 
I 
80 3.40 2.16 to 7.14 2.04 1.52 to 2.91 1.90 1.28 to 3.15 I 
100 4.05 2.80 to 7.00 ND ND 2.23 1.27 to 5.65 I 
1 Fold increase in vincristine retention induced by tunicamycin. 2confidence interval. 1 ,2Calculated from fractional retention values presented in Figure 5 using Fieller' s ratio-
of- means test as described by Tallarida and Murray (1987). ND, not determined. 
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Table 2. Rate of Efflux of Vincristine from KB-8-5-11 and the Corresponding Level of Inhibition of Glycoprotein Synthesis After 16 Hours 














Values are means ± S.E.M. (n=4). _aDiffers significantly from control (p<O.OOOl). 
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Figure 8. Specific binding of [14C]doxorubicin (A) and [3H]azidopine (B) to 
cultured UWOV2 cells at 4 oc for 60 min in the absence (control) or presence (TM 
treated) of 5JLglm1 tunicamycin following an initial 16-h pre-incubation at 37oc 
with or without TM. Specific binding of doxorubicin and azidopine was calculated 
by subtracting non-specific binding data obtained in the presence of 100 11M each 
of doxorubicin and azidopine, respectively, from total binding. Each point 
represents the mean±S.E.M. (n=4). 
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dihydropyridine calcium channel blocker known to bind to Pgp, and 
[ 14C]doxorubicin to intact cells in culture at 4 ac in the absence (control) or 
presence (TM-treated) of TM following an initial 16h pre-incubation at 3rc with 
or without the antibiotic. The binding of doxorubicin to these cells was saturable in 
the concentration range of 30-80 nM (Figure 8A), whereas that of azidopine 
remained linear between 10 and 80 nM (Figure 8B). In the presence of equimolar 
concentrations (range 30-80 nM) of doxorubicin, the binding of azidopine to 
UWOV2 cells was significantly reduced (Figure 8B). This reduction of azidopine 
binding to UWOV2 cells in the presence of doxorubicin was abolished by treatment 
of cells with 5J,tg/ml TM (Figure 8B). Tunicamycin increased the binding of both 
doxorubicin (Figure 8A) and azidopine (Figure 8B) to UWOV2 cells. 
4. DISCUSSION 
The results show that TM enhances VCR retention in MDR cell lines by decreasing 
drug efflux. Drug-resistant cells appear to be more responsive to TM pretreatment, 
possibly due to the presence of Pgp. This observation is relevant in understanding 
the biochemical basis of MDR, since TM is thought to be selectively more toxic to 
transformed cells, and it could thus be useful in the design of anticancer agents for 
malignant cells while sparing non-transformed cells (Olden et al., 1979b; Eren and 
Duksin, 1985). KB-8-5-11, LR73-1A and NIH-3T3-MDR cells share a common 
mechanism of drug resistance, i.e., they all express amplified mdr1 genes which 
encode Pgp (Akiyama et al. 1985; Fojo et al., 1985; Choi et al., 1988). 
It is possible that TM induces lesions in the oligosaccharide moiety of Pgp 
in MDR cells and that this contributes to the increased VCR retention that is linked 
with decreased drug efflux. Tunicamycin may exert its effect by the inhibition of 
Pgp synthesis and/or by independent alteration in efflux pump activity. In KB-8-5-
11 cells, increasing concentrations of TM resulted in a concentration-related 
reduction in glycoprotein synthesis which did not correlate with inhibition of VCR 
efflux. Therefore, suppression of the efflux of this compound in these cells cannot 
be attributed to the inhibition of glycoprotein synthesis alone, since TM, even at 
low concentrations, can inhibit its efflux. This finding suggests that TM may act as 
a competitive inhibitor of VCR binding to Pgp for Pgp-mediated efflux, but this 
was not tested. Nevertheless, transient inhibition of both protein and glycoprotein 
synthesis during TM exposure may contribute to alterations in VCR efflux and 
retention observed in the MDR cell lines. 
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The UWOV2 cell line represents a cell line with in-vivo acquired MDR 
(Golombick et al., 1990). Bio-Gel A-0.5M gel filtration chromatographic and 
sodium dodecyl sulphate polyacrylamide gel electrophoretic profiles of UWOV2 
plasma membranes revealed the presence of a 170-kDa glycoprotein. The nature of 
this 170-kDa membrane glycoprotein has been analysed in our laboratory for 
immunoreactivity with Pgp-specific monoclonal antibodies (C219 and MRK16), 
and this is described in Chapter 5. In. addition, the finding that both doxorubicin 
and azidopine bind to intact UWOV2 cells points to the presence of Pgp on their 
cell surfaces. It was also shown that the specific binding of azidopine to UWOV2 
cells is inhibited (ca. 50%) by equimolar concentrations of doxorubicin. This is 
consistent with the notion that azidopine specifically binds to Pgp and that 
photolabelling with azidopine is inhibited by vinblastine, actinomycin D, 
doxorubicin and many MDR modulators and organic chemicals (Safa et al., 1987; 
Yang et al., 1989; Ichikawa et al., 1991b). However, the information obtained 
from our binding studies must be supplemented with structural characterization of 
Pgp and comparison with cells expressing Pgp and their respective wild-type cells. 
Thus, TM appears to modulate MDR by inhibition of enhanced drug efflux 
from MDR cells. TM inhibits both protein and glycoprotein synthesis and this may 
explain its action on efflux since the Pgp molecule has to be intact to be functional 
(Currier et al., 1989). Tunicamycin may modify the molecular conformation of Pgp 
synthesized de novo, and its ability to engage in intermolecular interactions such as 
drug recognition, binding and efflux. A possible explanation as to why TM did not 
affect uptake of VCR in our experimental system is a rapid exchangeable pool with 
a steady flux of VCR in both directions. Since VCR reutilization was minimized in 
efflux experiments, actual retention of drug could be studied. Our results are in 
agreement with previous assertions of Beck and Cirtain (1982) that TM does not 
enhance drug uptake in resistant cells. However, our results do establish that TM 
increases drug retention in resistant cells. 
In some MDR cell lines, the phosphorylation and glycosylation status of 
Pgp may or may not correlate with drug resistance (Center, 1983; Richert et al., 
1988; Mukhopadhyay and Kuo, 1989). We have not evaluated changes in MWs of 
MDR-associated glycoproteins upon TM treatment, but have assumed the known 
activity of the antibiotic on Pgp. (Greenberger et al., 1987; Greenberger et al., 
1988a; Ichikawa et al., 1991a), at least in NIH-3T3-MDR, LR73-1A and KB-8-5-
11 cells known to express Pgp. The function of the carbohydrate moieties of Pgp in 
MDR has not been evaluated adequately. Gervasoni et al. (1991) have proposed 
that anthracycline resistance in HL-60 human promyelocytic leukaemia cells may 
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be due to hypoglycosylation of cell-surface glycoproteins, albeit Pgp is not 
overexpressed in these cells. Several reports of differences between drug-sensitive 
and drug-resistant cells point to changes in glycosylation patterns of plasma 
membrane glycoproteins (Juliano and Stanley, 1975; Beck and Cirtain, 1982; 
Marsh and Center, 1987). Unglycosylated forms of Pgp have also been detected in 
certain MDR cell lines (Germann et al., 1990). The fact that not all glycoproteins 
become unstable or non-functional in the unglycosylated form (Elbein, 1984; 
Elbein, 1987) suggests that Pgp may be synthesized at normal rates, but deficient 
in carbohydrate and yet retain its biological activity in MDR (Chou and Kessel, 
1981). It is not clear, however, whether differential glycosylation of the mdr1 gene 
product (Greenberger et al., 1989) is required for MDR. 
The MDR phenotype is complex (Cornwell, 1991; Fairchild and Cowan, 
1991; Roninson, 1992b). Overexpression of distinct forms of Pgp may explain the 
observed diversity in the MDR phenotype (Hsu et al., 1989). Different cell lines 
may display various patterns of drug resistance or cell-type specific factors may 
modulate the resistance. The mdr1-transfected cell lines provide a convenient tool 
for studying Pgp-mediated phenomena. The results presented here may be useful to 
study the effects of glycosylation on the properties of Pgp and its interaction with 
cytotoxic drugs. In the broader sense, it is probable that glycosylation regulates 
drug efflux in drug-resistant cells through an as yet undetermined mechanism. 
Recently, inhibition of N-linked glycosylation by TM has been shown to affect 
organic cation transport across the brush border membrane of opossum kidney cells 
(Ott et al., 1992). This information, in association with the observation that Pgp 
binds certain organic chemicals in the adrenal gland and kidney, and presumably 
also functions in the excretion of these compounds (Ichikawa et al., 1991b), and 
the knowledge that Pgps from KB-C2 cells, kidney and adrenal gland exhibit 
different lectin binding capacities (Ichikawa et al., 1991a), may be applied 
effectively in strategies to overcome MDR. Moreover, TM interacts with lipophilic 
membrane components (Kuo and Lampen, 1976), which warrants consideration in 
such studies. However, the potential use of TM as an MDR modifier must await 
biochemical characterization of the precise relationship between the action of this 
antibiotic and Pgp together with an evaluation of its in vivo and in vitro cytotoxic 
spectrum (Vogel and McWilliam, 1987; Leaver, et al., 1988). 
5. SUMMARY AND CONCLUSIONS 
Various drug-sensitive cell lines (NIH-3T3-parental mouse fibroblasts, LR73 
Chinese hamster cells, and KB-3-1 human epidermoid carcinoma) and their 
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corresponding drug-resistant cell lines (NIH-3T3-MDR, LR73-1A and KB-8-5-11, 
respectively) as well as drug-resistant UWOV2 human ovarian carcinoma cells 
derived from an ovarian cystadenocarcinoma in a patient who had not responded to 
combined chemotherapy with actinomycin D, vincristine, cisplatin and 
doxorubicin, were studied for altered vincristine (VCR) transport in response to 
pretreatment with tunicamycin (TM), an inhibitor of protein N-glycosylation. 
The uptake of VCR was not affected by prior exposure of cells to TM, 
except in LR73 and LR73-1A cells for which enhanced uptake was observed. A 
consistent association was found between treatment of drug-resistant cell lines with 
TM and reduced VCR efflux with resultant increased VCR retention. Thus, TM 
enhances VCR retention in MDR cell lines by inhibiting its efflux. Drug-resistant 
cells appear to be more responsive to TM pretreatment, possibly due to the 
presence of P-glycoprotein (Pgp). In KB-8-5-11 cells, increasing concentrations of 
TM resulted in a concentration-related reduction in glycoprotein synthesis which 
did not correlate with inhibition of VCR efflux. It is reported that TM affects Vinca 
alkaloid transport in drug-resistant cells and that transient inhibition of both protein 
and glycoprotein synthesis during TM exposure (see Chapter 2) may contribute to 
observed alterations in VCR efflux and retention. 
The binding of [14C]doxorubicin and [3H]azidopine (a photoactive 
dihydropyridine calcium channel blocker known to interact with Pgp) to UWOV2 
ovarian carcinoma cells was studied in order to partially characterize MDR in these 
cells. Binding of doxorubicin to UWOV2 cells was saturable in the concentration 
range 10-80 nM, whereas binding of azidopine remained linear between 10 and 80 
nM. In the presence of equimolar concentrations of doxorubicin, the binding of 
azidopine to UWOV2 cells was significantly inhibited in the concentration range of 
30-80 nM. Tunicamycin augmented the binding of both doxorubicin and azidopine 
to UWOV2 cells. In the presence of TM and equimolar concentrations of 
doxorubicin the binding of azidopine was unchanged. The interaction of both 
azidopine and doxorubicin to intact UWOV2 cells implies that Pgp is present on 
their cell surfaces. However, the increased binding of these drugs to intact 
UWOV2 cells in the presence of TM also suggests that TM may exert its effects by 
modulating cell surface binding activity. Collectively, these results show that TM 
is a resistance modifier in MDR, and that structural analyses should be beneficial 
in understanding the precise relationship between the effects of this antibiotic and 
Pgp-mediated drug binding and efflux. This will further aid in the design of 
strategies to overcome drug resistance in malignant tumours. 
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CHAPTER 5 
PARTIAL CHARACTERIZATION OF HUMAN TuMOUR 
CELL SURFACE GLYCOPROTEINS, WITH SPECIAL 
REFERENCE TO UWOV2 OVARIAN CARCINOMA AND 
ACUTE LEUKAEMIA 
1. INTRODUCTION 
The aim of chemotherapy is the palliation and/or cure of of human cancers 
(Greenwald et al., 1990; Edgington et al., 1992). Tumours such as ovarian 
carcinoma, acute leukaemia, small-cell lung cancer and advanced breast cancer 
sometimes achieve high initial response rates and prolongation of survival after 
combination chemotherapy, only to be followed by relapse and death. The causes 
of failure of chemotherapy are multifactorial. The relapsed tumour phenotype, 
when it is associated with the development of drug resistance, is referred to as 
multiple drug resistance (MDR). The expression of MDR during chemotherapy, o~ 
after in-vitro exposure of tumour cells to chemotherapeutic drugs, is often not 
limited to the drugs to which the tumour cells have been exposed, but may include 
cross-resistance to other agents as well (Morrow and Cowan, 1988). Increased 
expression of a plasma membrane glycoprotein, Pgp, has been detected in certain 
human malignancies in response to chemotherapy (Chan et al., 1991; Sanfilippo et 
al., 1991; Murphy et al., 1992). The use of eDNA encoding Pgp and mAbs raised 
against Pgp in the diagnosis and therapy of patients in the refractory stage, as well 
as in studies of clinical resistance mechanisms, has been described (Gottesman and 
Pastan, 1989; van Kalken et al., 1991; Wallner et al., 1991). P-glycoprotein 
expression has been reported in breast cancer (Fuqua et al., 1987; Salmon et al., 
1989; Giai et al., 1991), colon cancer (Dalton et al., 1988), lung cancer (Scagliotti 
et al., 1991; Holzmayer et al., 1992; Shin et al., 1992), ovarian carcinoma (Rubin 
et al., 1990; Rutledge et al., 1990; Murphy et al., 1992), leukaemia (Campos et 
al., 1992; Michieli et al., 1992; Sonneveld et al., 1992b), myeloma and lymphoma 
(Musto et al., 1991a; Linsenmeyer et al., 1992; Ucci et al., 1992). However, there 
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is still uncertainty regarding the role of Pgp in tumour cells during the refractory 
stage of chemotherapy. 
The use of chemosensitizers or resistance modifiers in tumours that are 
unresponsive to anticancer drugs is likely to be paramount to the prevention of 
MDR and the improvement of treatment outcome (Gottesman and Pastan, 1989; 
van Kalken, 1991). Furthermore, the increased expression of Pgp in diverse 
tumour cell types may be a prognostic indicator for tumour response to 
chemotherapy (Ling et al., 1989; Rubin et al., 1990; Chan et al., 1991). Recent 
advances in cancer research indicate that clinically proven diagnostic tests and in 
vitro' cytotoxicity assays are becoming increasingly applicable in the optimization of 
treatment protocols, the prediction of therapeutic responsiveness and the 
identification of potential candidates for alternative approaches to chemotherapy 
(Greenwald et al., 1990). 
This chapter describes the partial characterization of the MDR-associated 
170 kDa glycoprotein in a continuous human ovarian tumour cell line ~ an:d 
peripheral blood leukaemia blasts obtained from patients. The UWOV2 cells were 
isolated from an ovarian cystadenocarcinoma in a patient who had not responded to 
combined chemotherapy with actinomycin D, doxorubicin, vincristine and cisplatin 
(Golombick et al., 1990). This cell line has not been studied previously with 
regard to its expression of Pgp, but was considered as a model to study in-vivo 
acquired (i.e., clinical) drug resistance along with the mdr1-transfected and in-
vitro-selected drug-resistant cell lines that were described in previous chapters. 
Evaluation of Pgp expression was performed in a randomly selected group of 
patients with acute leukaemia was by gel filtration, SDS-PAGE and by 
immunocytochemical detection methods using the P-glycoMab™ and P-glycoCHEK 
™ kits. 
2. MATERIALS AND METHODS 
2.1. Monoclonal Antibodies 
MRK16, a mAb to Pgp, was a gift from Dr. Takashi Tsuruo (Japanese Foundation 
for Cancer Research, Tokyo, Japan). MRK16 (immunoglobulin subclass lgG2a) 
was generated by immunizing mice with intact adriamycin-resistant K562 cells 
(Hamada and Tsuruo, 1986a; Hamada and Tsuruo, 1986b). Indirect 
immunofluorescence studies with adriamycin-resistant K562 cells have shown that 
MRK16 reacts with a determinant on their surface that corresponds to Pgp 
(Hamada and Tsuruo, 1991). Unlabelled C219, CHRC5 membrane standard 
Preparation of Human Peripheral Blood Leukaemia Cells 118 
(prepared from multidrug-resistant CHRC5 Chinese hamster ovary cells), P-
glycoCHEK™ control slides (consisting of a drug-sensitive human ~cute 
lymphoblastic leukaemia cell line, CCRF-CEM, as the negative staining control 
and its highly drug-resistant derivative, CEM-VLB100, as the positive Pgp staining 
control) and P-glycoMab™ (consisting of lyophilized C219 mAb and isotype-
matched negative antibody, biotinylated anti-mouse antibody, avidin and 
biotinylated horseradish peroxidase visualization system) were purchased from 
Centocor Diagnostics, Tongeren, Belgium. The C219, a murine mAb isotype 
lgG2A, was raised in mice immunized with multidrug-resistant Chinese hamster 
ovary and human leukaemia cell lines (Kartner et al., 1985). C219 binds to the 
cytoplasmic domain of Pgp. 
2.2. Radioisotopes and Biochemicals 
Lymphoprep™ (Nyegaard and Co., Oslo, Norway), trypsin 1:250 (Difco 
Laboratories, Detroit, Ml, USA), PBS Dulbecco 'A' [phosphate-buffered saline] 
(Oxoid, UK), tissue culture media and antibiotics (Gibco, UK), tunicamycin, 
Dactylium dendroides galactose oxidase, Vibrio cholerae neuraminidase 
(Boehringer Mannheim, Germany), D-[6-3H]glucosamine hydrochloride (20-40 
Ci/mmol), sodium boro[3H]hydride [NaB3H4, 5-10 Ci/mmol] (Amersham, U.K.), 
polyethylene glycol compound MW 15,000-20,000 [PEG 20,000], 
trifluoromethanesulfonic acid [TFMS], 3,3'-diaminobenzidine tetrahydrochloride 
[DAB] and Protein A-Sepharose CL-4B (Sigma Chemical Co., St. Louis, MO., 
USA), Bio-Rad™ protein assay dye reagent concentrate (Bio-Rad Laboratories 
Ltd., U.K.) and protein MW standards and kits (Amersham, Bio-Rad Laboratories, 
Boehringer Mannheim and Sigma Chemical Co.) were used in this study. All other 
reagents were of analytical grade and were obtained from either Merck Chemicals 
or Sigma Chemical Co. 
2.3. Preparation of Human Peripheral Blood Leukaemia Cells 
Peripheral blood specimens were obtained from patients with acute leukaemia and 
collected into sterile heparinized tubes. Leukaemia blasts were isolated by minor 
modification of the method described by Boyum (1968). Peripheral blood was 
mixed with RPMI-1640 medium 1:2 (v/v) and layered on top of lymphocyte 
separation medium (Lymphoprep™, p=1.077-1.078) and centrifuged (650g, 30 
min at room temperature). Mononuclear cells were removed from the interface, 
washed three times in RPMI-1640 medium containing 1 mM L-glutamine, 1% 
MEM non-essential amino acids, 100 U/ml penicillin, 100 J.tg/ml streptomycin and 
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15% heat-inactivated fetal bovine serum (HIFBS), referred to as complete medium. 
Contaminating erythrocytes were eliminated from mononuclear cells by NH4Cl 
lysis (Boyum, 1984). Briefly, pelleted cells were resuspended in 10 mM Hepes 
buffer, pH 7.4, containing 0.83% NH4Cl and incubated for 10 min at 3rC. The 
cells were then centrifuged for 5 min at 650g and the supernatant fluid aspirated. 
This step was repeated three times. Mononuclear cells were suspended in complete 
medium and cultured at 3rC in 5%C02:air and relative humidity 85% for 24-72h 
to eliminate adherent monocytes. The leukaemia blasts in suspension were 
recovered and either used immediately or stored at -70°C in complete medium 
containing 10% dimethylsulphoxide (DMSO) as cryopreservative. 
2.4. Assay of Tumour Cell Viability 
The percentage viable cells in culture was assessed by the method of Shier (1988) 
using trypan blue. Uptake of trypan blue was evaluated after allowing cells to stand 
at room temperature for 5 min and viewing with a Nikon inverted microscope fitted 
with phase optics and a yellow filter. A minimum of 5 fields and 250 cells were 
scored. Only cells with a viability more than 95% were used. 
2.5. Metabolic Labelling of Tumour Cell Membrane Glycoproteins 
UWOV2 cells were grown in RPMI-1640 medium supplemented with 5% heat-
inactivated fetal bovine serum (HIFBS) and antibiotics. Leukaemia blast cells were 
cultured in complete RPMI-1640. For metabolic labelling, cells were incubated 
with complete RPMI-1640 containing 10 mM Hepes and 10 mM glucose for 72h at 
37°C in the presence of 10 ~-tCilml [3H]glucosamine with (TM-treated) or without 
(control) 5~-tg/ml TM. 
2.6. External Labelling of Cell-Surface Glycoproteins 
The surface galactose and N-acetylgalactose residues of cells were labelled by a 
modification of the technique described by Gahmberg and Hakomori (1973). Solid 
NaB3H4 (250 mCi) was dissolved in 10 mM NaOH to a concentration of 1 mCi/50 
~-tl, immediately frozen under liquid nitrogen and stored in aliquots (100 ~-tlftube) at 
-70oc until used. The contents of one tube at a time were diluted with 2 ml 10 mM 
NaOH and divided into 20 equal portions that were immediately frozen. Routinely, 
one of these tubes was used for labelling experiments. The isotope remained stable 
for at least 10 months when handled in this way. Cells were washed 3 times with 
Dulbecco's PBS, resuspended to a density of 108 cells/ml and incubated for 10 min 
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at 4 oc with 1 mM sodium metaperiodate. The reaction was quenched by adding 
400 pJ 100 mM glycerol in PBS and washing 3 times with PBS. Galactose oxidase 
(5.25 U/ml) or galactose oxidase (5.25 U/ml) and neuraminidase (25 U/ml) were 
added to ceiis resuspended to 1 os ceiis/ml and incubated for 30 min with gentle 
agitation at room temperature in the presence of 10 p,Ci/ml NaB3H4 . The labelled 
cells were washed four times with PBS and solubilized in 2% SDS in buffer A. 
Sample viscosity due to the release of DNA from cells was abolished by brief 
sonication (20s) and subsequent centrifugation at 104,000g for 60 min at room 
temperature and the supernatant (solubilized plasma membrane fraction) was 
analysed by gel filtration chromatography on Bio-Gel A-0.5M. 
2. 7. Preparation of Tumour Cell Membranes 
Tumour cell membranes were prepared by minor modifications of procedures 
described previously (Riordan and Ling, 1979; Ujhazy et al., 1990). All operations 
were carried out at 0-4 °C. Tumour cells (control and TM-treated) were suspended 
to a density of 108 cells/ml in cold hypotonic lysis buffer (10 mM Tris-HCl, pH 
7.4, 10 mM NaCl, 1.5 mM MgC12 1 mM DTT, 2 mM PMSF, 1% aprotinin) and 
incubated for 15 min in an ice-bath. The swollen cells were then disrupted with 20-
50 strokes in a tight-fitting Dounce homogenizer. Phase-contrast microscopy 
revealed "'15% intact cells and disruption was continued with 10 more strokes 
followed by 4 cycles (45-s bursts with a 30-s interval) of sonication. This treatment 
disrupted > 90% of the cells. Nuclei were removed by centrifugation of the ceil 
lysate at 400g for 10 min. The supernatant was then centrifuged at 4000g for 10 
min to eliminate mitochondria, and the supernatant so obtained subjected to high-
speed centrifugation (104,000g, 60 min). The pellet was retained and resuspended 
by sonication in preservation buffer (50 mM Tris-HCl, pH 8.0, containing 150 mM 
KCl, 150 mM NaCI, 25 mM MgC12, 250 mM sucrose, 1 mM EDTA, 10 mM 
NEM, 1 mM PMSF, 5 mM DTT, 5 mM 2-mercaptoethanol, 5 mM benzamidine-
HCl, and 5 p,g/ml each of pepstatin A, aprotinin and leupeptin) and stored in 1 ml 
aliquots at -70°C. This preparation yielded "'50 mg membrane wet weight that was 
suspended as 10 mg membrane /ml preservation buffer. 
2.8. Detergent Solubilization of Membrane-Associated Glycoproteins 
Plasma membranes ("'50 mg protein) derived from tumour cells incubated for 72h 
in the absence (control) or presence (TM-treated) of 5 p,g/ml TM was solubilized 
by boiling at 60°C for 5 min in 2% SDS in buffer A (50 mM Tris-HCl, pH 7.5, 
containing 7 mM 2-mercaptoethanol, 5 mM dithiothreitol (DTT), 1 mM 
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phenylmethylsulphonyl fluoride (PMSF), 10 mM N-ethylmaleimide (NEM), 20 
mM ethylene diaminetetraacetic acid (EDTA), 5 mM benzamidine-HCl, 10 JLg/ml 
leupeptin and 5 JLglml pepstatin). The solution ("'5 ml in Beckman Ultra-Clear™ 
tubes) was centrifuged for 60 min at 104,000g in a Beckman model SW 55 Ti 
swing-out rotor and model L8-80 ultracentrifuge at room temperature and the 
supernatant used in subsequent steps. An initial solubilization trial for UWOV2 
cell-associated glycoproteins involved the extraction of [3H]glucosamine-labelled 
material from cell lysates (prepared as described in section 3. 7) with increasing 
concentrations of SDS in buffer A and centrifugation at 104,000g for 60 min at 
room temperature. The 104,000g supernatant and pellet fractions were assayed for 
radioactivity by liquid scintillation spectrometry. 
2.9. Gel Filtration Chromatography 
Dry Sephadex G-150, G-200 and Bio-Gel A-0.5M beads were suspended in buffer 
B (50 mM Tris-HCl, pH 7.5, containing 0.1% SDS, 10 mM mercaptoethanol, 2 
mM EDTA, 2 mM PMSF and 10 mU/ml aprotinin) and allowed to swell at 90°C 
for 5h. The slurry was cooled to room temperature, washed twice in buffer B and 
poured into a column (1.5 X 85 em) using a packing reservoir. The packed column 
was washed with 5 column volumes of buffer B described above and calibrated 
with buffer C (buffer B containing a micro-spatula tip each of blue dextran 2000 
and phenol red to mark the void and the total volume, respectively). Solubilized 
tumour membranes (1 ml, ....,100 JLg protein) were applied on the top of the column. 
Elution was achieved with buffer B at room temperature. Fractions were 
standardized and aliquots counted by liquid scintillation spectrometry. Molecular 
weight calibration proteins were assayed by recording the absorbance at 280 nm. 
Peak fractions were pooled, dialyzed extensively against distilled water at 4 oc and 
lyophilized before SDS-PAGE analysis. Relative MWs were determined from a 
plot of log MW vs Kay where Kay is given by the following relationship: Kay = 
(Ve-V0)/(VcV0 ); Ve=elution volume, V0 =void volume (marked by elution 
position of blue dextran 2000) and Vt=total volume (marked by elution position of 
phenol red). 
2.10. Deglycosylation of UWOV2 Cell-Surface Glycoproteins 
Chemical deglycosylation of UWOV2 cell-surface glycoproteins was performed by 
the method described by Kalyan and Bahl (1981). Lyophilized samples containing 
between 10 and 30 JLg/ml plasma membrane glycoprotein were treated with 50 JL1 
trifluoromethane sulphonic acid (TFMS) in the presence of 25 JLl anisole as 
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scavenger. After digestion at room temperature, the reaction was stopped at various 
time intervals by adding 250 ~-tl pyridine diluted 1:4 (v/v) in distilled water and by 
cooling samples on ice for 15 min. Samples were then dialyzed for 48h against 
several changes of distilled water and concentrated by either reverse dialysis 
against PEG 20,000 or lyophilization, before neutralization and SDS-PAGE. 
2.11. lmmunoprecipitation of UWOV2 Cell-Surface Glycoproteins 
UWOV2 plasma membranes were immunoprecipitated according to the method 
described by Foxwell et al. (1989). Whole cells (108) or purified plasma 
membranes (100 1-tg protein) were solubilized in 200 ~-tl 50 mM Tris-HCl, pH 7 .4, 
containing 0.2% SDS, 1.25% Nonidet P-40 (NP-40), 150 mM NaCl and 2 mM 
PMSF, and centrifuged at 12,000g for 10 min at 4 °C. Solubilized samples 
(supernatants) were incubated for 16h at 4°C with either 10 1-tg C219 mAb or 25 
1-tg MRK-16 mAb, specific for Pgp. Control samples were treated with normal 
mouse serum. Protein A-Sepharose CL-4B (20%, v/v in the above buffer) was 
added to the precipitates and incubated at 4 oc for a further 120 min. The protein 
A-Sepharose-mAb complexes were washed 5 times with 50 mM Tris-HCl, pH 7 .4, 
containing 0.1% NP-40, 0.03% SDS, 150 mM NaCI, 1 mg/ml BSA, 2 mM PMSF 
and once with Tris-buffered saline (TBS, 50 mM Tris-HCl, pH 7 .4, containing 150 
mM NaCI), before processing for SDS-PAGE. 
2.12. Immunocytochemical Detection of P-Glycoprotein 
Immunohistochemical detection of MDR-associated Pgp with P-glycoCHEK™ was 
performed as recommended by the manufacturer. UWOV2 cells and acute 
leukaemia blast cells were centrifuged at 150g for 5 min onto slides and either 
stored at -20°C as acetone-fixed slides or used immediately as cytospin slide 
preparations. The following criteria were considered necessary for a valid test, 
which if not met, made the results of m~known specimens suspect: positive staining 
with P-glycoCHEK™ (brown or dark brown) in more than 40% of positive cells on 
the control slide, staining should be localized typically on the cell membrane, and 
in immunoperoxidase· reactions in the cytoplasm as well, giving a heterogeneous 
and often polarized pattern, minimal or no staining (purple) of negative cells with 
glycoCHEK C219™, and minimal or no staining with negative control antibody in 
either cell preparations. Cytospin slides were incubated with 100 ~-tl of 5% normal 
horse serum in PBS/1% BSA for 10 min at 4 °C. Normal serum was removed and 
replenished with 100 ~-tl 10 mg/ml P-glycoCHEK C219™ in normal horse serum 
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and incubated for 60 min on ice. The slides were then rinsed 3 times (duration of 5 
min each) in cold PBS and excess liquid on the slides was blotted off before 
application of 100 ~-tl biotinylated anti-mouse lgG solution (5 ~-tl biotinylated IgG 
plus 2.5 ml 5% normal horse serum) for 30 min. The slides were again rinsed in 
PBS as described above and exposed to 100 ~-tl of avidin-biotinylated horseradish 
peroxidase conjugate for 60 min. Following another rinse in PBS, slides were 
covered for 10 min with DAB (3,3'-diaminobenzidine tetrahydrochloride, prepared 
by dissolving 10 mg DAB 0.1 M Tris-HCl, pH7.2 and adding 3 ~-tl 30% H20 2 
prior to filtering) as chromogen substrate. After removal of the chromogen 
solution, the slides were rinsed once in PBS, counterstained with Mayer's 
haematoxylin for 45-60s and mounted in aqueous mounting media. Peroxidase 
activity was visualized according to the manufacturer's instructions and expressed 
either as positive or negative according to the above criteria. 
2.13. SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was performed on a Bio-Rad model MiniProteanTM mini-gel apparatus 
or a Hoeffer model SE-600 vertical slab gel apparatus using the discontinuous 
buffer system described by Laemmli (1970). Slab gels (1-1.5 mm thick) consisted 
of a linear 5-15% acrylamide gradient supporting gel and a 3.5% stacking gel. 
Samples, equalized for protein and radioactivity, were prepared for electrophoresis 
by boiling for 5 min in an equal volume of sample treatment buffer consisting of 
0.125 M Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 10% 13-mercaptoethanol and 
0.002% bromophenol blue. Electrophoresis (usually 30 mV, constant current, 12-
16h) was continued until the tracking dye reached the bottom of the gel. Gels were 
stained with Coomassie brilliant blue R-250, dried on a Bio-Rad model 583 gel 
dryer, and photographed. Molecular weights of samples were estimated by 
comparing the relative mobilities with those of standard proteins. 
2.14. Densitometry of SDS Gels 
Densitometric scans of dried gels were obtained on a Shimadzu model CS-9000 
dual wavelength flying-spot densitometer. Intensities of the UWOV2 plasma 
membrane glycoprotein bands in the 170-kDa region of control and TFMS-
deglycosylated samples were compared. 
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2.15. Protein Estimation 
The total protein content in solubilized cells and cell lysates was estimated by 
utilizing the Bio-Rad™ protein dye-binding assay kit based on the method 
described by Bradford (1976) with bovine serum albumin as standard. 
2.16. Patient Studies 
Patients with acute myeloblastic leukaemia were selected for this study. Only cell 
samples with more than 95% viability were studied. The clinical and 
haematological data of the patients are presented in Table 2. 
3. RESULTS 
Leukaemia blast cells isolated from peripheral blood of patients with AML, and the 
human ovarian carcinoma cell line (UWOV2), were characterized for their 
expression of the 170-kDa MDR-associated Pgp by gel filtration chromatography, 
SDS-PAGE and immunohistochemical localization using Pgp-specific mAbs. 
Typical elution profiles and MW calibration curves obtained for Sephadex G-150 
(Figure 1), Bio-Gel A-0.5M (Figure 2A) and Sephadex G-200 (Figure 2B) are 
shown. The chromatographic properties of the protein MW markers eluted from 
the different gel types are summarized in Table 1. 
Bio-Gel A-0.5M filtration profiles of NaB3H4-labelled plasma membrane 
glycoproteins isolated from leukaemia blast cells prepared from peripheral blood of 
patients L24 and L100 are presented in Figures 3A and 3B, respectively. Tritiated 
plasma membrane glycoproteins prepared from both patients eluted as distinct 
peaks in the regions between 450-158 kDa and 158-44 kDa. The peaks that eluted 
beyond Vt (marked by phenol red) represent free or degraded radioactive material 
of low MW. Fractions constituting the peaks that eluted in the high MW region 
(i.e., 450-158 kDa) of the column profile were pooled, lyophilized and prepared 
for SDS-PAGE. Coomassie blue staining of the gels revealed the presence of a 
170-kDa band in samples prepared from both patients L24 and L100 (Table 2). 
This finding was confirmed in a separate experiment involving SDS-PAGE of L100 
plasma membranes solubilized directly with SDS (Figure 8). In similar 
experiments, SDS-PAGE analysis of pooled, lyophilized high MW peak fractions 
(eluted from Sephadex G150, Sephadex G-200 or Bio-Gel A-0.5M columns) or 
purified plasma membranes, resolved a 170-kDa band in samples prepared from 
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Figure 1. Molecular weight calibration of Sephadex G-150. Calibration proteins 
were solubilized and eluted at room temperature with 50 mM Tris-HCl, pH 7 .5, 
containing 0.1% SDS, 10 mM 2-mercaptoethanol, 2 mM EDTA, 2 mM PMSF and 
10 mU/ml aprotinin. Positions of protein peaks were obtained by measuring elution 
volumes and recording absorbances at 280 nm (A). A plot of log MW against the 
partition coefficients (Kav) of the standard proteins (B) shows linearity of elution. 
Vitamin B12 (cyanocobalamin) eluted anomalously (B, Kav lies outside the 95% 
confidence band indicated by the dotted line). Pharmacia column: 1.5 X 85 em; 
Pharmacia P1 peristaltic pump constant flow rate: 1 x 10 pulses; Pharmacia Frac-
100 fraction collector setting: 60 min/fraction. Run time: ~96h. 
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Figure 2. Calibration curves typically obtained for proteins separated on (A) Bio-Gel A-0.5M and (B) Sephadex G-200. See Figure 1 
for details. The partition coefficients CKavs) for standard proteins eluted from Bio-Gel A-0.5M fall within the 95% confidence limits (not 
















Table 1. Relationship Between Molecular Weight and Elution Behaviour of Various Calibration Proteins on Sephadex 
G-150 Sephadex G-200 and Bio-Gel A-0.5M Gel Filtration Columns 
Kav Values/Gel type 
Molecular weight MW (kDa) Sephadex G-150 Sephadex G-200 BioGel A-0.5M 
markers 
Blue dextran 2000 V0 (0) V0 (0) 
Thyroglobulin 669 0.220 
Apoferritin 450 0.021 
Catalase 240 0.167 
~-Amylase 200 V0 (0) 
Aldolase 158 0.229 
y-Globulin 158 0.540 
Alcohol dehydrogenase 150 0.144 
~ 
Bovine serum albumin 66 0.304 0.374 
Ovalbumin 44 0.640 0.521 
Carbonic anhydrase 29 0.682 
Chymotrypsinogen A 25 0.729 
Myoglobin 17 0.820 
Cytochrome C 12.4 Vt(l.O) 0.958 
Cyanocobalamin 1.35 
Phenol red 0.354 Vt(1.0) Vt(l.O) 
, 













Table 2. Analysis of P-Glycoprotein Expression in Human Peripheral Blood leukaemia Cells by Gel Filtration, SDS-PAGE and the P-glycoMab™ Diagnostic Kit 
Patient Gender Age Diagnosis (FAB) Course/Management Sephadex G-150*/G-200 BioGel AO.SM SDS-PAGE P-glycoMab™ reaction 
L19 M 33 AML No chemotherapy 0.052-0.224 ND + 
L21 M 22 AML, M1 VP-16, single dose ND ND 
L23 M 39 ALL Ara-C, VP-16, MTX 0.017-0.224 ND + 
L24 M 19 AML resistant to Resistant to VP-16, ND 0.009-0.138 + + treatment Ara-C, MTX 
L26 F 69 AML Paliative therapy 0.086-0.284 ND - -
L28 M 42 AML, M1 VP-16, DNR, Ara-C ND ND + -
L31 F 82 ANLL No chemotherapy ND ND + -
L42 M 31 AML Terminal care V0 -0.120* ND 
(Continued) 









Table 2. (continued) 
Patient Gender Age Diagnosis (F AB) Course/Management Sephadex G-150*/G-200 BioGel A0.5M SDS-PAGE Monoclonal antibody 
C219 Reaction 
L45 M 44 AML, M3 Ara-C, VP-16, DNR ND ND + 
L55 M 67 AML Terminal care ND 0.009-0.157 
L84 F 46 AML, M1 CTR4 induction ND ND + 
therapy 
L94 M 21 AML, M2 CTR4 induction ND ND + 
therapy 
L95 M 44 AML, M1 Palliative therapy ND ND + 
L97 M 50 AML VP-16, ADR, MTX ND ND + -
L100 M 49 Relapsed AML Ara-C, VP-16, DNR ND 0.009-0.138 + + 
Abbreviations: F AB, French-American-Bristish Co-operative Group classification of the acute leukaemias (Bennett et al., 1976; Bennett et al., 1981); VP-16, etoposide ( 4' -dimethylepipodo-
phyllotoxin 9-(4,6-0-ethylidene-~-D-glucopyranoside); Ara-C, cytosine arabinoside; MTX, methotrexate; DNR, daunorubicin; ADR, adriamycin; CTR4, cytosine arabinoside-etoposide-













samples prepared from patients L21 and L26 (Table 2 and Figure 8) and patients 
L42 and L55 (Table 2). 
The use of SDS in the solubilization of plasma membrane glycoproteins 
was evaluated in UWOV2 ovaria~ carcinoma cells. The solubilization trial was 
conducted in an attempt to optimize the extraction of cell-surface glycoproteins 
from these cells. Figure 4 illustrates the recovery of [3H]glucosamine-labelled 
glycoproteins from the 104,000g supernatant and pellet fractions as a function of 
detergent concentration. The increased recovery of radiolabel from the supernatant 
fraction was concentration-related, whereas that recovered from the pellet remained 
constant at all detergent concentrations. Optimal solubilization, relative to control 
(0% SDS), was achieved at SDS concentrations in excess of 0.1 %. The 104,000g 
supernatant fraction was taken to represent the plasma membrane fraction and an 
SDS concentration of 2% was considered sufficient to extract the majority ·of cell-
surface glycoproteins. 
Separation of cell-surface glycoproteins derived from UWOV2 cells 
metabolically labelled with [3H]glucosamine on a column of Bio-Gel A-0.5M, 
yielded high MW peak fractions in the 240-158 kDa region of the column profile 
(Figure 5), suggesting, but not confirming, the presence of a 170-kDa 
glycoprotein. This finding was corroborated by Sephadex G-200 fractionation of 
[3H]glucosamine-labelled plasma membrane glycoproteins isolated from UWOV2 
cells following 72h incubation in the absence (control) and presence (TM-treated) 
of 5 p,g/ml TM (Figure 6). High MW UWOV2 plasma membrane glycoproteins 
eluted as a broad peak in the 200- and 150 kDa range of the Sephadex G-200 
chromatographic profile (Figure 6). This peak was reduced to approximately 53% 
(obtained by integration of area under peak) of control in the presence of TM, 
indicating inhibition of glycoprotein synthesis. This presence of the purported 170-
kDa glycoprotein in UWOV2 cells (Figure 7 A and Figure 8) and its disappearance 
as a result of prolonged TM exposure (Figure 8) were confirmed by SDS-PAGE 
analysis of purified plasma membrane samples. Chemical deglycosylation of the 
170-kDa protein with TFMS for 30 min reduced its band intensity by about 5%, 
but did not alter the MW of the 170-kDa protein (Figure 7B). At later times, the 
band intensity was reduced by more than 80%, indicating cleavage of peptide 
bonds. Since the deglycosylation was not optimized, no conclusion regarding the 
contribution of oligosaccharaide moieties to the overall MW of the 170 kDa 
glycoprotein could be made. When UWOV2 plasma membranes were 
immunoprecipitated with Pgp-specific mAbs MRK16 and C219, the 170-kDa band 
was again present, although contaminating bands were also noted (Figure 8). This 
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Figure 4. Solubilization profiles for [3H]glucosamine-labelled glycoproteins 
extracted from UWOV2 ovarian carcinoma cells. Cells were metabolically labelled 
with [3H]glucosamine and lysed in hypotonic buffer. Cell lysates, from which 
nuclei and mitochondria were removed by differential centrifugation, were 
solubilized with increasing concentrations of SDS in buffer A and re-centrifuged 
for 1h at 104, OOOg at room temperature as described in "Materials and Methods". 
The supernatant and pellet fractions so obtained were equalized for protein and 
assayed for radioactivity by liquid scintillation spectrometry. 
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Figure 5. BioGel A-0.5M chromatography of UWOV2 ovarian carcinoma cell-
surface glycoproteins. Cells, metabolically labelled with [3H]glucosamine, were 
lysed in hypotonic buffer and the nuclei and mitochondria removed by differential 
centrifugation as described in "Materials and Methods". The resultant cell lysate 
was solubilized in 2% SDS/buffer A and centrifuged at 104,000g for lh at room 
temperature. The 104,000g supernatant, containing radiolabelled plasma membrane 
glycoproteins, was mixed with calibration proteins and a spatula tip (""0.5 mg) each 
of blue dextran and phenol red. The mixture was layered on top of the column and 
allowed to enter the gel prior to elution with buffer ~· The elution of calibration 
proteins was monitored by recording the absorbance at 280 nm and the elution 
volumes plotted against the respective log MWs (see Table 1 for MWs and Kav 
values). Arrows mark the elution positions of blue dextran (V~) and phenol red 
(VJ. 
-
Results: Figure 6 134 
5 ,--------~.y:-~~<-cb---------------, 5.5 
00 
p-Am \ 











Carbonic anhydrase *. 
f 
- 4.5 ~ 
\ * 2 -
• ---
\ .. ... ~ \ 
\ l'k j.., I eJ 
I \ ~--·--· 
~~~~===t~·~------JJq~~~~~~~~--:i·~ __ _j o ~.: -1.-:J) 1 cm:::m m o -cv- o o 3.5 




0 40 80 120 160 
Elution volume (ml) 
o Control • TM -treated 
Figure 6. Sephadex G-200 chromatography of UWOV2 ovarian carcinoma cell-
surface glycoproteins. Cells, metabolically labelled with [3H]glucosamine in the 
absence (control) or presence (TM-treated) of 5 11glml tunicamycin (TM), were 
lysed in hypotonic buffer and the nuclei and mitochondria removed by differential 
centrifugation as described in "Materials and Methods". For details see the legend 
to Figure 5. 
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Figure 7. Electrophoretic mobilities (A) of UWOV2 plasma membrane glycoproteins. Dotted line represents the 95% confidence 
interval of MW estimation. Relative band intensity (obtained by densitometric tracing of dried gels) and % deglycosylation (inset) of the 
170-kDa UWOV2 plasma membrane glycoprotein at various time periods after chemical deglycosylation with TFMS are shown (B). 
Protein standards§: myosin (200 kDa), a 2-macroglobulin1 (non-reduced 340 kDa, reduced 170 kDa), phosphorylase b (97.4 kDa), 
bovine serum albumin (69 kDa), ovalbumin (46 kDa), carbonic anhydrase (30 kDa), trypsin inhibitor (21.5 kDa), lysozyme (14.3 kDa). 
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Figure 8. SDS polyacrylamide gel electrophoretic profiles of samples prepared 
from patient material and the human UWOV2 ovarian carcinoma cell line. Samples 
were processed for SDS-PAGE as described in "Materials and Methods". Lane s, 
molecular weight standards: ~-macroglobulin (1 70 kDa, reduced), phosphorylase 
b (97.4 kDa), glutamate dehydrogenase (55.4 kDa), lactate dehydrogenase (36.5 
kDa), trypsin inhibitor (20.1 kDa); lanes 1 and 2, plasma membranes from patients 
L21 and L26, respectively; lanes 3 and 4, UWOV2 plasma membranes 
immunoprecipitated with mAbs MRK16 and C219, respectively; lanes 5 and 6, 
plasma membranes derived from UWOV2 cells after a 72-h incubation in the 
presence (TM-treated) and absence (control) of tunicamycin, respectively; lanes 7 
and 8, negative and positive control for mAb C219, respectively; lane 9, 104,000g 
supernatant fraction recovered after solubilization of cell Iysates prepared from 
patient LlOO. 
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is probably due to non-specific binding and/or insufficient removal of proteins that 
might have entered the Sepharose CL-4 beads during the immunoprecipitation step. 
The expression of Pgp was examined in UWOV2 cells and peripheral blood 
leukaemia blast cells prepared from a randomly selected group of patients with 
AML. The expression of mdrl gene product, Pgp, in the aforementioned cells was 
compared by means of immunocytochemistry, using the mAb C219 and the avidin-
biotin-immunoperoxidase method. The drug-sensitive human acute lymphoblastic 
leukaemia cell line, CCRF-CEM (Pgp-negative; purple) and its drug-resistant 
derivative, CEM-VLB10o (strongly Pgp-positive; dark brown) were used as 
controls (Plate 1) . Immunoperoxidase staining showed expression of C-219 reactive 
Pgp in the UWOV2 cell line (Plate 2). Two out of the 15 samples prepared from 
patients with AML that were analysed with the P-glycoCHEK™ diagnostic kit 
stained positively for Pgp (Table 2, Plate 2). Although SDS-PAGE analysis of 
some samples from AML patients , who had either received chemotherapy or not, 
showed the presence of a 170-kDa membrane protein, this could not be confirmed 
by the C219 mAb reaction using the standard exclusion criteria (Table 2) . 
4. DISCUSSION 
Effective management of ovarian carcinomas is often limited by their clinical non-
responsiveness to chemotherapy. Cell lines derived from these tumors manifest 
aspects of the MDR phenotype to various extents (Finstad et al., 1990; Sekiya et 
al., 1992; Wu et al., 1992). However, the development of resistance to drugs that 
are most active against ovarian carcinoma may occur through mechanisms other 
than the expression of Pgp (Rubin et al., 1990; Misawa et al., 1992). Despite this 
and the large variability in Pgp levels observed in patients with ovarian cancer (van 
der Zee et al. , 1991), the insensitivity of this malignancy to chemotherapy can be 
explained, in part, by the expression of the mdr1 gene product (Rutledge et al. , 
1990; Holzmayer et al., 1992; Sekiya et al ., 1992). Thus, ovarian carcinoma cell 
lines derived from clinically drug-resistant patients will facilitate in-vitro anticancer 
drug screening which may allow the identification of potentially valuable treatment 
regimens (Wu et al., 1992). The results from this study show that UWOV2 ovarian 
carcinoma cells express the 170-kDa membrane Pgp that is synthesized at reduced 
rates following TM exposure. Thus , TM may be used in vitro as a resistance 
modifier in MDR. The appearance of a 170-kDa membrane glycoprotein in the 
plasma membranes of the UWOV2 carcinoma cell line is further in agreement with 
reports of Pgp expression in human ovarian tumours and cell lines (Bourhis et al. , 
1989; Bradley et al., 1989; Volm et al., 1989). 
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Plate 1. Phase-contrast micrographs of the drug-sensitive human acute 
lymphoblastic leukaemia cell line, CCRF-CEM (P-glycoprotein-negative control 
slide, top) and its drug-resistant derivative, CEM-VLB10o (P-glycoprotein-positive 
control slide, bottom) stained with the P-glycoMab™ mAb C219 avidin-biotin-
immunoperoxidase technique. 
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Plate 2. Phase-contrast micrographs of cytocentrifuge preparations of the human 
ovarian carcinoma cell line, UWOV2 (top) and peripheral blood leukaemia blast 
cells isolated from patient L24 (bottom) exhibiting positive staining with the P-
glycoMab™ mAb C219 avidin-biotin-immunoperoxidase complex (compare with 
staining patterns of +ve and -ve controls in Plate 1). 
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Analysis of Pgp expression in patient samples using the P-glycoCHEK™ 
immunocytochemical diagnostic kit, stained positively only 2 out of 15 samples. 
The 2 samples that stained positively were obtained from patients with acute 
leukaemia in relapse and who were unresponsive to combination chemotherapy 
with cytosine arabinoside, daunorubicin and methotrexate. These data would 
suggest a significant relationship between failure of chemotherapy in these patients 
and expression of the mdrl gene product. No difference in staining patterns could 
be discerned between samples prepared from treated and untreated patients. In 
some cases, SDS-PAGE analysis of plasma membrane proteins prepared from 
AML patients who had received no prior chemotherapy as well as those who had 
received either single-dose or combination chemotherapy revealed the presence of a 
170-kDa protein. However, no clinical correlation could be made of the presence 
of this 170-kDa protein with clinical status because Pgp was not identifiable in 
these samples by immunocytochemical staining using the C219 mAb reaction. 
Samples that were diffusely positive were regarded as negative. Since the C219 
antibody cannot distinguish between the MDR1 and the MDR2 gene products 
(Georges et al., 1990a), it cannot be concluded that Pgp is not present in the 
samples that yielded a 170-kDa band by SDS-PAGE analysis. 
The low incidence of AML patients expressing Pgp was expected since the 
samples were selected at random and the progression of the condition during 
chemotherapy was not followed. Perhaps a different approach to the analysis of 
Pgp expression in AML patients would be necessary, including staging of the 
disease following chemotherapy. Presumably the variations detected in staining of 
Pgp for the various AML cells are the result of patient differences. Nevertheless, 
other studies have demonstrated that resistance to chemotherapy remains an 
important cause of treatment failure in acute leukaemias (Kuwazuru et al., 1990; 
Marie et al., 1991; List and Spier, 1992). P-glycoprotein is detected with high 
frequency in AML and in prospective studies its overexpression is an independent 
determinant of response to treatment and overall survival with conventional dose-
induction regimens (Chitnis et al., 1991; Musto et al., 1991b; Pirker et al., 1991). 
Therapeutic studies aimed at testing various MDR-reversal agents, such as 
verapamil, quinine and several others, to restore drug sensitivity will imminently 
improve treatment outcome in high-risk acute leukemias (Sonneveld and Nooter, 
1990; Marie et al., 1992b; Solary et al., 1992). 
Recently, Pieters et al. (1991) reported that in-vitro drug sensitivity assays 
(e.g., MTT assays) which measure gross cellular resistance may have prognostic 
value in relation · to initial clinical drug resistance and long-term outcome of 
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chemotherapy. Many of the differences in cell-biological and clinical characteristics 
in human cancers (e.g. , age, gender, immunological and chromosomal phenotype) 
are of prognostic value and may reflect differences in clinical response to 
chemotherapy. Therefore, the identification of common mechanisms of resistance 
(clinical and experimental) in subsets of patients is an important consideration in 
the design of effective clinical trials and treatment modalities. Long-term follow-up 
studies might also add to our understanding of the prognostic value of in vitro 
drug-sensitivity assays and analysis of Pgp expression in clinical drug resistance. 
Non-Pgp-mediated drug resistance mechanisms have been described (Estey et al., 
1987; Danks et al., 1988; Baas et al., 1990). Consequently, it will be important to 
explore further which mechanisms are responsible in cases of clinical drug 
resistance where Pgp is undetectable. Finally, models of broad-spectrum drug 
resistance (Pgp and non-Pgp-mediated MDR) and clinical trials (Millward et al., 
1992; Trumpet al., 1992; Yahanda et al., 1992) are being implemented to address 
the problems associated with MDR. 
5. SUMMARY AND CONCLUSIONS 
Human ovarian carcinoma cells (UWOV2, established from a patient refractory to 
combination chemotherapy with actinomycin D, doxorubicin, cisplatin and 
vincristine), and blast cells isolated from peripheral blood of 15 patients with acute 
myeloid leukaemia (AML), were characterized for their expression of the multidrug 
resistance (MDR)-associated 170 kDa P-glycoprotein (Pgp) by gel filtration 
chromatography, sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-
P AGE) and immunocytochemistry using Pgp-specific monoclonal antibodies 
(mAbs). Plasma membrane glycoproteins from patients L24 and L100 eluted from 
a Bio-Gel A-0.5M column as distinct peaks in the regions between 450-158 kDa 
\ 
and 158-44 kDa. Analysis of pooled lyophilized 450-158 kDa fractions from 
patients L24 and L100, respectively, by SDS-PAGE revealed a 170-kDa band, the 
presence of which was also confirmed in purified plasma membranes extracted 
directly with SDS. 
In similar experiments, high molecular weight (~150 kDa) peaks (eluted 
from Sephadex G150, Sephadex G-200 or Bio-Gel A-0.5M columns) and SDS-
solubilized plasma membranes showed a 170-kDa band in samples derived from 
patients L19, L23, L28, L31, U5, L84, L94, L95, and L97, but not in those 
obtained from patients L21, L26, L42 and L55. The expression of Pgp in 
peripheral blood leukaemia blast cells prepared from a randomly selected group of 
patients with AML was analysed by the P-glycoCHEK C219™ 
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immunohistochemical method. Only 2 of 15 samples from patients with AML 
stained positively for Pgp. This was expected since one patient (L24) was resistant 
to combination chemotherapy with etoposide, cytosine arabinoside and 
methotrexate, and the other patient (L100) presented with AML in relapse 
following chemotherapy with cytosine arabinoside, etoposide and . daunorubicin. 
SDS-PAGE analysis of samples from AML patients, who had received either 
chemotherapy or no chemotherapy, showed the presence of a 170-k:Da membrane 
protein, but this could not be confirmed by immunoperoxidase staining with the 
mAb C219. No difference in staining patterns could be discerned between cytospin 
preparations from the treated and the untreated patients in this group. Therefore, 
no clinical correlation could be made with the presence of the 170-k:Da protein 
using this technique. 
The expression of mdr1 gene product, Pgp, was also shown in UWOV2 
cells by means of immunocytochemistry, using the mAb C219 and the avidin-
biotin-peroxidase method. Separation of cell-surface glycoproteins derived from 
UWOV2 cells metabolically labelled with [3H]glucosamine on a column of Bio-Gel 
A-0.5M yielded high MW (240-158 k:Da) peak fractions, suggesting but not 
confirming the presence of a 170-k:Da glycoprotein. This was again demonstrated 
by Sephadex G-200 fractionation of [3H]glucosamine-labelled UWOV2 plasma 
membrane glycoproteins isolated after 72h incubation in the absence (control) and 
presence (TM-treated) of 5 JLg/ml tunicamycin (TM). High MW UWOV2 cell-
surface glycoproteins eluted as a broad peak in the 200-150 kDa range of the 
Sephadex G-200 chromatographic profile. This peak was reduced to approximately 
53% of control in the presence of TM, indicating inhibition of glycoprotein 
synthesis. The presence of a 170-k:Da glycoprotein in UWOV2 cells and its 
disappearance as a result of prolonged TM exposure were confirmed by SDS-
PAGE of purified plasma membranes. When UWOV2 plasma membranes were 
immunoprecipitated with Pgp-specific mAbs MRK16 and C219, the 170-k:Da band 
was again present, although contaminating bands were also noted. The results from 
this study show that UWOV2 ovarian carcinoma cells express Pgp and that TM 
exposure reduces its rate of synthesis. Thus, TM may have implications as a 
resistance modifier in in vitro studies related to the mechanisms and prevention of 
MDR. 
Chapter 6 143 
CHAPTER 6 
CONCLUSIONS AND PERSPECTIVES 
Resistance to chemotherapeutic agents represents a major clinical obstacle in the 
control of most tumours. P-glycoprotein (Pgp) confers multidrug resistance by 
functioning as an energy-dependent drug efflux pump. To fully realize the 
therapeutic potential associated with manipulation of the multidrug transporter, it 
will be necessary to understand the mechanisms of action of the transporter and its 
regulation. Recent advances have provided insights into the complexity of this 
multifunctional transport system. Chemosensitizers like verapamil modulate 
multidrug resistance by interfering with the efflux action of Pgp and thus can 
decrease drug resistance or can re-establish drug sensitivity by restoring normal 
drug accumulation and distribution within the multidrug-resistant tumour cell. 
Clinical trials using verapamil have been prompted for leukemia and ovarian 
cancer. In addition, other approaches are the subject of current preclinical 
investigations. 
If it can be demonstrated that tumours are dependent upon an increased 
expression of Pgp for resistance, the critical issues will be the regulation of such an 
expression and the mechanism by which the steady-state levels and biochemical 
characteristics of Pgp are elevated or altered in the absence and presence of drug 
selection pressure. These ideas suggest that the regulation of Pgp gene expression 
at both the transcriptional and translational levels is a promising area for future 
research. It is possible that post-translational processing such as phosphorylation 
and glycosylation may regulate the insertion and activity of Pgp in the plasma 
membrane. 
The aim of the work described in this thesis was to establish whether 
tunicamycin could be used in vitro as a chemosensitizer to reverse the MDR 
phenotype. A correlation was sought between the MDR phenotype (drug resistance 
and toxicity, drug transport and retention) and the perturbation of tumour cell-
surface glycoproteins in vitro by TM. 
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The data indicate that the rates of glycoprotein synthesis in certain MDR 
cell lines are increased compared with the corresponding parental cell lines. 
Tunicamycin inhibited the synthesis of proteins and glycoproteins in the various 
cell lines studied. No constant pattern of altered glycosyltransferases between drug-
resistant and drug-sensitive cells was observed. The lack of inhibition of any of the 
glycosyltransferases by TM observed in KB-8-5-11-MDR cells, for example, 
indicates that inhibition of N-linked oligosaccharide synthesis may not necessarily 
interfere with the surface expression of certain glycoproteins. The results obtained 
su~gest that the degree of inhibition by TM of glycosyltransferases and of total 
protein and glycoprotein synthesis in drug-sensitive and drug-resistant cells, 
respectively, may depend on their specific complement of oligosaccharide 
structures. From these considerations it may be that changes induced by TM in the 
biosynthesis of glycoproteins in drug-resistant cells are relevant in research into the 
nature of multiple drug resistance. 
Tunicamycin enhances the cytotoxicity of various anticancer agents in 
drug-resistant cell lines to a greater extent than in their corresponding parental 
cells. The extent of the potentiation of cytotoxicity of anticancer drugs by TM 
differed in the various cell lines that have been studied. These variations in 
response can perhaps be attributed to variations in cross-resistance to the anticancer 
drugs which, in turn, may be determined by differences in genetic regulation and 
biochemical mechanisms involved in the protection of cells against cytotoxic 
agents. The consistent pattern of increased drug cytotoxicity that was observed in 
all MDR cell lines suggests a common mechartism(s) of reversal of drug resistance. 
Our findings do not directly demonstrate that the enhancing effects of TM on drug 
' cytotoxicity are mediated by inhibition of Pgp, but they do establish that TM is an 
in vitro biological response modifier (chemosensitizer) in MDR. 
The uptake of vincristine (VCR) was not affected in the various cell lines 
following exposure to TM. Cellular VCR loading was significantly greater in 
certain parental (drug-sensitive) cells compared with their corresponding MDR 
cells. The decreased VCR accumulation in MDR cells can perhaps be ascribed to 
an enhanced VCR efflux, since these cells overexpress Pgp. Treatment of MDR 
cell lines with TM consistently limited VCR efflux with resultant increase in VCR 
retention. Tunicamycin did not alter drug efflux and consequently VCR retention in 
some parental cells. In other parental cells, however, TM reduced the level of VCR 
retention. Tunicamycin probably enhances VCR retention in MDR cell lines by 
inhibiting drug efflux. Drug-resistant cells were more responsive to TM 
pretreatment, possibly due to the presence of raised Pgp levels. This observation is 
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relevant in understanding the biochemical basis of MDR. Tunicamycin may exert 
its effect by the inhibition of Pgp synthesis and/or by alteration in efflux pump 
activity. Transient inhibition of both protein and glycoprotein synthesis during TM 
exposure may con~ribute to alterations in VCR efflux and retention observed in the 
MDR cell lines. Tunicamycin may modify the molecular conformation of de novo 
synthesized Pgp, and its ability to engage in intermolecular interactions such as 
drug recognition, binding and efflux. The results presented here may have 
important implications for the potential use of TM as an MDR modifier, 
particularly to study the effects of glycosylation on the properties of Pgp and its 
interaction with cytotoxic drugs. The in vivo and in vitro cytotoxic spectrum of this 
antibiotic, above all, remains to be determined. 
P-glycoprotein expression was demonstrated in UWOV2 ovarian carcinoma 
cells and in acute leukaemia blasts from patients using the P-glycoCHEK™ 
immunohistochemical diagnostic kit. It is concluded that the identification of 
common mechanisms of resistance (clinical and experimental) in subsets of patients 
is an important consideration in the design of clinical trials and treatment 
modalities. Long-term follow-up studies might also aid in the acceptance of the 
prognostic value of in vitro drug-sensitivity assays and analysis of Pgp expression 
in clinical drug resistance. It would be interesting to explore further which 
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